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THE CLINICAL PROBLEM: HYPERTROPHIC 
CARDIOMYOPATHY
Hypertrophic cardiomyopathy (HCM) is the most fequent familial heart disease 
with a prevalence of 0.2-0.5% worldwide.1 It is characterized by left ventricular (LV) 
hypertrophy mainly affecting the interventricular septum (IVS).2 This thickening of 
the IVS, in many cases (≈70%),3 leads to obstruction of the LV outflow tract (LVOT). 
Furthermore, HCM patients often show displacement of the anterior mitral valve 
leaflet in the LVOT, known as systolic anterior movement (SAM), which further 
increases LVOT obstruction. This may lead to shortness of breath, chest pain, loss of 
physical condition and even syncope. 
HCM is often referred to as a disease of the sarcomere, due to the high number of 
sarcomere gene mutations that cause the disease. High throughput sequencing 
identified mutations in 8 sarcomeric genes (MYH7, MYBPC3, TNNT2, TNNI3, MYL2, 
MYL3, ACTC1 and TPM1) which are thought to be strong disease-causing candidates.4 
Sarcomere mutations are present in up to 50-70% of HCM patients and are 
predominantly found (80% of identified mutations) in the genes encoding the thick 
filament proteins β-myosin heavy chain (MYH7 gene) and cardiac myosin binding 
protein-C (cMyBP-C; MYBPC3 gene). Mutations in genes encoding thin filament 
proteins (≈18%) include cardiac troponin T (cTnT; TNNT2 gene), cardiac troponin I 
(cTnI; TNNI3 gene), cardiac troponin C (cTnC; TNNC1 gene), cardiac tropomyosin (cTm; 
TPM1 gene) and actin (ACTC1 gene). While a large number of HCM patients do not 
carry a sarcomere gene mutation (sarcomere mutation-negative, SMN), they show 
the same clinical features as sarcomere mutation-positive (SMP) HCM patients, albeit 
disease onset is at older age and disease progression is less severe (more arrhythmias 
and end-stage heart failure in SMP)(CHAPTER FIVE).5 
Currently, there is no preventive or curative treatment for HCM patients. Family 
screening of SMP HCM patients may uncover the pathogenic mutation in family 
members, many of which are at that point still asymptomatic. Prediction of in 
whom and when symptoms will develop is currently not possible. Knowledge of 
the sequence of events that lead from sarcomere mutation to cardiac dysfunction 
and hypertrophy, and ultimately end-stage heart failure is warranted for improved 
diagnosis and timely treatment. In this thesis we report on studies in human HCM 
combining ex vivo studies in cardiac tissue samples collected during cardiac surgery, 
and in vivo echocardiographic analyses of heart function. We defined changes in 
cardiac function at early and advanced (end-stage) cardiac disease, and studied sex-
differences to gain insight in the cellular determinants of disease progression in HCM. 
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1Clinical (phenotypic) Heterogeneity of HCM The clinical presentation of HCM is very heterogeneous. While generally symptoms appear between 20 to 50 years of age, a relatively small group of mutation carriers 
remain asymptomatic during their entire life, while others develop symptoms and 
hypertrophy at a very young age, die of acute cardiac arrest or progress to end-stage 
heart failure (HF). The majority of patients live a normal life wherein symptoms can 
be managed with medicinal therapy. Olivotto et al.6,7 have described and classifi ed 
the diff erent stages of disease progression in patients with HCM (Figure 1). Mutant 
sarcomere proteins likely cause the initial defects in cardiac performance (stage I) 
before the heart remodels. Around 75% of HCM patients develop the “classic” (stage 
II) form of HCM with LV hypertrophy and diastolic dysfunction. A relatively small 
percentage (5-10%) progresses, due to adverse remodeling (stage III), to end-stage 
HCM (Stage IV). This stage is characterized by thinning of the LV myocardium, LV and 
left atrial (LA) dilation, extensive fi brosis and impaired systolic function. Ho et al.5
showed that cumulative morbidity is signifi cantly higher in patients diagnosed before 
40 years of age, and in SMP compared to SMN patients. In addition to diff erences 
based on genotype, sex diff erences have been described. Over the years the majority 
of clinical trials and cohort studies have had an underrepresentation of women, with 
the percentage of women included ranging between 26 and 45%.8,9 At the time of 
diagnosis women are on average 9 years older and show more advanced clinical 
symptoms compared to men.8,10 Knowledge of pathomechanisms underlying sex 
diff erences in HCM is warranted to improve diagnostic and treatment strategies 
(CHAPTERS 4-6). 
Figure 1. Stages of HCM disease progression.
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HCM Diagnosis
The guidelines indicate that maximal wall thickness of the LV should exceed 15 mm in 
one or more LV myocardial segments.  Patients presenting with a wall thickness of 13-
14 mm require further evaluation such as family history and abnormalities in clinical 
and laboratory tests. A patient with a 13 mm LV wall thickness will be diagnosed 
with HCM when they have a first-degree relative diagnosed with HCM.11 Our studies, 
described in CHAPTERS 4-6 indicate that the diagnostic criterion for maximal wall 
thickness may have to be corrected by body surface area. 
Current HCM Treatment
Most acute symptoms, such as syncope, are due to LVOT obstruction. Initially 
symptomatic patients are treated with non-vasodilating β-blockers (or calcium 
channel blockers) because of its negative inotropic and chronotropic effect, which 
leads to improved diastolic filling, reduced outflow gradient and improved perfusion 
of the sub-endocardium. Disopyramide is recommended in addition to a β-blocker 
(or, if this is not possible, verapamil) to improve symptoms in patients with resting 
or provoked LVOT obstruction. When rate control is not sufficient and LVOT gradient 
is ≥ 50 mmHg, invasive treatment is usually considered. There are two techniques to 
reduce the septal myocardium that causes the obstruction: 1) surgical myectomy, 
during which a part of the hypertrophied IVS is removed during open heart surgery; 
or 2) alcohol septal ablation, in which alcohol is injected in the artery supplying blood 
to the septum leading to infarction and eventually shrinkage of the IVS. The  most 
devastating complication in HCM patients is sudden cardiac death. Since 20 years 
internal cardiac defibrillators (ICD) are implanted in the high risk patients which can 
terminate potentially lethal arrhythmias.12 Current treatments are very invasive and 
do not prevent development of HCM. However, preclinical administration of diltiazem 
(a calcium channel blocker) may improve early LV remodeling in HCM.13 
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1FUNCTION AND PHYSIOLOGY OF THE HEART & CHANGES IN HCM
Anatomy and Function
The heart consists of four chambers: two ventricles and two atria. These chambers 
work together to deliver de-oxygenated blood to the lungs (small circulation) and 
oxygenated blood to the rest of the body (systemic circulation). Blood from the right 
atrium, which is depleted of oxygen by the body, fl ows into the right ventricle which 
in turn pumps blood into the pulmonary arteries and to the lungs for oxygenation. 
Oxygenated blood returns to the heart through the pulmonary veins, enters the 
left atrium (LA) and fl ows into the left ventricle (LV) (via the mitral valve) which in 
turn will pump the oxygenated blood to the rest of the body via the aorta. For the 
heart to function, it needs to relax to allow fi lling with blood (diastolic phase of the 
cardiac cycle) and it needs to contract to eject blood (systolic phase of the cardiac 
cycle). Contraction and relaxation of the cardiac muscle cells (cardiomyocytes) in the 
atria and ventricles is coordinated by proteins involved in electrical activation, and 
calcium handling and binding, i.e. excitation-contraction coupling of cardiomyocytes 
(described below). 
Structure of Cardiac Muscle – Sarcomeres
The smallest functional contractile unit of the cardiomyocyte is the sarcomere, these 
repetitive units give cardiac muscle the characteristic striated pattern. Sarcomeres 
consist of two main structures, the thick and thin fi laments which enable cardiac 
contraction. The thick fi lament mainly consists of the protein myosin, a motor protein. 
Myosin binds to the main protein of the thin fi lament, actin. Cardiac myosin binding 
protein C is another thick fi lament protein which spans between actin and myosin, 
keeping them at a favorable distance. The initiation of contraction of cardiac muscle 
is regulated by the troponin complex and by tropomyosin, both are located on the 
thin fi lament. The troponin complex consists of three subunits: cTnC the calcium 
receptor; cTnI an inhibitor of contraction and cTnT a tropomyosin binding protein. 
In the presence of Ca2+ myosin binds to actin to form a cross-bridge. Once bound to 
actin, myosin undergoes a conformational change known as the power stroke which 
displaces the thin fi lament further along the thick fi lament thereby shortening the 
sarcomere and thus the cardiomyocyte. The longest human protein is titin, it is a 
mechano-sensor and mainly regulates the viscoelasticity of cardiomyocytes. Titin can 
modulate cardiomyocyte stiff ness by the ratio of its two isoforms: a short, more stiff  
isoform N2B and a longer more compliant isoform N2BA.14     
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The Cardiac Cycle
When the mitral valve opens, blood can freely flow from the LA into the LV, this is 
called passive filing of the LV. When LV pressure reaches LA pressure, the atrium 
contracts to increase LV filling, this is called the atrial kick or active filling. During the 
filling phase the LV increases in volume while pressure remains low. After LV filling, 
ventricular contraction occurs and the mitral valve is closed due to the increase in LV 
pressure. This is where isovolumetric contraction starts: the volume remains constant 
while pressure increases due to ventricular contraction. When the rise in LV pressure 
exceeds aortic pressure, the aortic valve opens and blood is ejected into the aorta. 
During the ejection phase LV pressure remains high, while LV volume declines. At the 
end of the ejection phase pressure in the aorta exceeds LV pressure which leads to 
closure of the aortic valve. At this point pressure in the LV is high and volume is low. 
All valves are closed and this is the start of the isovolumetric relaxation phase. The LV 
relaxes and pressures begin to drop. When LV pressure drops below LA pressure the 
mitral valve will open which is the start of a new filling phase. 
Cardiac output (CO) reflects cardiac pump function and is determined by multiplying 
heart rate and stroke volume. Depending on the situation (i.e. during rest or stress/
exercise), the heart can increase or decrease the amount of blood that is pumped 
through the body. The sympathetic nervous system is activated during stress (i.e. 
during anxiety or physical exercise), while the parasympathetic nervous system 
is active at rest. The autonomic nervous system influences CO by increasing or 
decreasing heart rate. For example: adrenaline increases the rate of the sinoatrial 
node, which increases heart rate and thereby increases CO. As your heart rate can be 
tripled during exercise, the increase in heart rate is the biggest contributor to your 
elevation of CO. 
Not only heart rate but also the amount of blood that is pumped out during each 
heartbeat. (i.e. stroke volume) determines cardiac output. When the preload (venous 
return to the heart) increases, the contractility of the heart increases, based on 
the Frank-Starling mechanism. The length-dependent activation of myofilaments 
underlies the Frank-Starling mechanism (studied in CHAPTER 2). An increase in 
preload means greater filling of the LV thereby stretching the cardiomyocytes. Up to 
a certain length stretching of the myofilaments leads to a greater production of force 
by the cardiomyocytes which thereby increases stroke volume. In addition, more Ca2+ 
is released from the intracellular Ca2+ storage via an adrenaline-mediated mechanism, 
which also increases the force development of cardiomyocytes during exercise (see 
below: beta-adrenergic receptor activation). 
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1Excitation-Contraction Coupling Translating electrical stimulation of cardiomyocytes into mechanical force production occurs through a process called excitation-contraction coupling. The electrical 
activation of the heart is initiated at the sinoatrial node which consists of pacemaker 
cells and resides in the right atrium.  The electrical signal is distributed through 
the atria and transmitted to the atrioventricular node, which relays the signal from 
the atria to the ventricles, albeit with a ~100 ms delay. This ensures that each atrial 
contraction is followed by a ventricular contraction and thereby effi  cient fi lling of the 
ventricle.  
Calcium Induced Calcium Release
For cardiomyocytes to contract cytosolic Ca2+-concentrations need to increase. The 
electrical impulse (action potential) causes depolarization of the cell which induces 
the opening and closing of various ion channels. Depolarization of the cell membrane 
causes Ca2+-entry into the cell via L-type Ca2+-channels. This Ca2+-release triggers the 
release of stored Ca2+ in the sarcoplasmic reticulum (SR), via the ryanodine receptor 
(calcium-induced calcium release (C.I.C.R.)(Figure 2). 
Calcium Binding & Cross-Bridge Formation
The cytosolic Ca2+ binds to the myofi lament protein cTnC. Calcium binding to cTnC 
is the initiator of contraction, as it leads to a series of conformational changes that 
enables myosin heads to bind to actin (so-called cross-bridge formation) which 
results in cardiomyocyte contraction. At low (diastolic) [Ca2+] myosin binding to actin 
is inhibited by the tropomyosin-troponin complex which blocks myosin-binding sites 
on actin. Upon Ca2+-binding to cTnC, tropomyosin is moved, releasing the myosin-
binding sites on actin. For relaxation (diastole) to occur the formation of cross-bridges 
need to be stopped. This is achieved by lowering the cytosolic [Ca2+].15 
Calcium Re-uptake
Most of the Ca2+ is removed from the cytosol and pumped back into the SR through 
the Ca2+-ATPase pump (SERCA) and out of the cell via the sodium-calcium exchanger 
(NCX). SERCA together with phospholamban (PLN), a protein that inhibits SERCA, 
can fi ne tune the levels of cytosolic Ca2+. During exercise, an increase in heart rate 
needs to be matched by an increased release and re-uptake of Ca2+. Protein kinase A 
(PKA) is activated through adrenaline or noradrenaline binding to the β-adrenergic 
receptors on cardiomyocytes and increases the activity of SERCA by phosphorylation 
of PLN. PKA-mediated phosphorylation of PLN reduces the interaction between 
PLN and SERCA, and thereby releases the inhibitory eff ect of PLN on SERCA. This not 
only leads to a quicker removal of Ca2+ from the cytosol, but also increases the SR 
calcium concentration, thereby increasing the Ca2+ available for release at the next 
contraction. At the same time, phosphorylation of cTnI by PKA decreases myofi lament 
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Ca2+-sensitivity, and Ca2+ is released faster by the myofilament, which becomes 
available for re-uptake by SERCA in the SR. Increasing PKA  activity during sympathetic 
stimulation causes increases in contractile force and faster relaxation, which allows 
enough time for the heart to fill when heart rate is increased. 
  
Figure 2. Excitation-contraction coupling. 
Schematic diagram of a cardiac muscle cell and the events during excitation-contraction coupling. Adapted 
with permission from van der Velden and Stienen16 
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1HCM DYSFUNCTIONDiastolic dysfunction (impaired relaxation) is an important functional defect in 
patients with HCM. Even before hypertrophy occurs (stage I) changes in diastolic 
function are already measurable. Through the stages of the disease the degree of 
diastolic dysfunction progresses as well. Determinants of diastolic dysfunction include 
cellular changes caused by gene mutations, and structural remodeling (hypertrophy 
and fi brosis). The increase in LV wall thickness (due to hypertrophy) impairs blood 
supply to the myocardium. Second, due to the increased wall thickness the energy 
demand is higher. Thirdly, due to the genetic mutations the cells energy system is 
less effi  cient.17 Together this may cause relative ischemia in the myocardium due to 
an increase in demand and a decrease in supply. When ischemia becomes chronic it 
could lead to loss of cardiomyocytes and the formation of fi brosis (scar tissue). The 
increase of fi brosis (interstitial and/or replacement) decreases myocardial compliance 
and augments LV wall stress, resulting in increased LV pressure during diastole. 
One of the cellular changes that contribute to impaired relaxation in HCM is an 
increase in myofi lament Ca2+-sensitivity.18 An increase in cytosolic Ca2+-concentration 
is needed for contraction and must be decreased for relaxation to occur (as described 
earlier). When myofi laments are more sensitive to Ca2+ they will produce force even at 
low amounts of cytosolic Ca2+ during diastole and thereby limit relaxation. 
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AIM AND OUTLINE OF THESIS
The HCM patient population is very heterogeneous in clinical presentation. Ranging 
from patients in stage I of the disease that remain asymptomatic to patients that 
progress to stage IV or even die because of sudden cardiac death. The trigger 
which causes disease progression is still unknown. In this thesis we define the 
pathophysiology and secondary cardiac remodeling in patients with HCM. Therefore 
we have studied patients in different stages of the disease and with different 
underlying sarcomere mutations. In CHAPTER TWO we have focused on the Frank-
Starling mechanism and myofilament Ca2+-sensitivity in HCM patients with different 
underlying mutations to study genotype specific pathogenic effects. These were all 
patients with stage II HCM who underwent myectomy surgery due to symptomatic 
LVOT obstruction.
The last decade it has become more and more apparent that cardiac pathologies 
are affected by sex. In CHAPTER THREE we reviewed physiological and HCM related 
sex differences. One of the first clinically detectable alterations in heart function of 
HCM patients is a decrease in diastolic function. In CHAPTER FOUR we have studied 
echocardiography data, histological and cellular changes of stage II HCM patients 
undergoing myectomy because of symptomatic LVOT obstruction. This chapter 
shows the differences found in diastolic dysfunction between women and men with 
stage II HCM. In CHAPTER FIVE we provide an overview of gene- and sex-differences 
in stage II HCM patients. A small percentage of HCM patients progress to end-stage 
(stage IV) heart failure. These patients were in need of a heart transplant and during 
surgery samples of their myocardium were taken. In CHAPTER SIX we have studied 
adverse remodeling in stage IV HCM patients and compared them to the secondary 
remodeling seen in patients with stage II HCM. Here we tried to find a pathogenic 
effect which might have triggered disease progression to stage IV HCM and could 
explain the more severe cardiac remodeling in women. 
Based on the research in this thesis, we discuss the limitations of current diagnostic 
criteria in CHAPTER SEVEN. CHAPTER EIGHT provides an overview of results from 
this thesis and recent observations from the National Cardiomyopathy consortium 
Dosis. CHAPTER NINE provides a summary of the main findings of this thesis and 
future perspectives. 
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CHAPTER TWO  
Perturbed length-dependent activation in 
human hypertrophic cardiomyopathy with 
missense sarcomeric gene mutations
Published in Circulation Research 2013; 112: 1491-1505
Heart Filligree - by Vasco Sequira
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ABSTRACT
Rationale: High-myofilament Ca2+-sensitivity has been proposed as a trigger of 
disease pathogenesis in familial hypertrophic cardiomyopathy (HCM) on the basis of 
in vitro and transgenic mice studies. However, myofilament Ca2+-sensitivity depends 
on protein phosphorylation and muscle length, and at present, data in humans are 
scarce.
Objective: To investigate whether high myofilament Ca2+-sensitivity and perturbed 
length-dependent activation are characteristics for human HCM with mutations in 
thick and thin filament proteins.
Methods and Results: Cardiac samples from patients with HCM harboring 
mutations in genes encoding thick (MYH7, MYBPC3) and thin (TNNT2, TNNI3, TPM1) 
filament proteins were compared with sarcomere mutation-negative HCM and 
nonfailing donors. Cardiomyocyte force measurements showed higher myofilament 
Ca2+-sensitivity in all HCM samples and low phosphorylation of protein kinase A (PKA) 
targets compared with donors. After exogenous PKA treatment, myofilament Ca2+-
sensitivity was similar (MYBPC3mut, TPM1mut, sarcomere mutation-negative HCM), 
higher (MYH7mut, TNNT2mut), or even significantly lower (TNNI3mut) compared 
with donors. Length-dependent activation was significantly smaller in all HCM 
than in donor samples. PKA treatment increased phosphorylation of PKA-targets in 
HCM myocardium and normalized length-dependent activation to donor values in 
sarcomere mutation-negative HCM and HCM with truncating MYBPC3 mutations but 
not in HCM with missense mutations. Replacement of mutant by wild-type troponin 
in TNNT2mut and TNNI3mut corrected length-dependent activation to donor values.
Conclusions: High-myofilament Ca2+-sensitivity is a common characteristic of 
human HCM and partly reflects hypophosphorylation of PKA targets compared with 
donors. Length-dependent sarcomere activation is perturbed by missense mutations, 
possibly via posttranslational modifications other than PKA hypophosphorylation or 
altered protein–protein interactions, and represents a common pathomechanism in 
HCM.
Key words: calcium, cardiomyopathy, contractility, hypertrophy, myocardium
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• Hypertrophic cardiomyopathy (HCM) is commonly caused by mutations in genes 
encoding sarcomeric proteins.
• Previous studies demonstrated early signs of myocardial dysfunction in the 
absence of clinically detectable cardiac hypertrophy.
• In vitro and transgenic animal models expressing mutant thick- and thin-fi lament 
proteins in the heart implicate elevated myofi lament Ca2+-sensitivity as a major 
mechanism for the pathogenesis of HCM.
What is New?
• Cardiac myocytes isolated from the interventricular septal tissues of patients with 
hypertrophic obstructive cardiomyopathy show diverse and mutation-related 
changes in myofi lament Ca2+-sensitivity, which are dependent on the aff ected 
gene.
• This increase in myofi lament Ca2+-sensitivity could be in part attributable to 
hypophosphorylation of protein kinase A targets.
• Myofi lament length-dependent activation is impaired in cardiac myocytes 
isolated from patients with HCM harboring missense mutations and represents a 
mechanism underlying the development of HCM.
Data on myofi lament length-dependent activation in transgenic animal models 
harboring HCM mutations are confl icting, and studies in human HCM are scarce. 
High myofi lament Ca2+-sensitivity partly refl ects hypophosphorylation of protein 
kinase A targets, indicative of secondary disease–related alterations. Reduced length-
dependent sarcomere activation is a common feature of human HCM caused by 
mutations in genes encoding thick- and thin-fi lament proteins. Pretreatment with 
protein kinase A did not correct impaired length-dependent sarcomere activation 
in HCM samples carrying missense mutations. Mutation-induced impaired length-
dependent activation may limit the preload-mediated contractile reserve of the heart. 
Our fi ndings, in combination with clinical studies, support the notion that sarcomere 
mechanical dysfunction is central to the pathogenesis of HCM and precedes the 
development of cardiac hypertrophy.
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INTRODUCTION
Myofilament contraction is initiated by interaction between the thin actin and thick 
myosin filaments. This actin–myosin interaction (i.e., thin-filament myosin cross-bridge 
binding) and the magnitude of myofilament force generation are tightly regulated 
by muscle length, Ca2+-binding, and protein phosphorylation.1 Defective proteins 
resulting from mutations in genes encoding sarcomere proteins may directly impair 
regulation of muscle contraction and manifest themselves as phenotypic aberrations 
of the heart. Hypertrophic cardiomyopathy (HCM) reflects the pathological phenotype 
associated with sarcomeric gene mutations.2,3 Affecting 1:500 individuals worldwide, 
HCM is the most common cause of sudden death in young people.2 Genotyping 
studies have identified a disease-causing mutation in ≈70% of all patients with HCM.4 
Mutations in thick-filament–encoding genes, MYH7 (β-myosin heavy chain [β-MyHC]) 
and MYBPC3 (cardiac myosin–binding protein-C [cMyBP-C]), account for ≈80% of all 
identified sarcomere mutations, whereas ≈18% of the mutations are found in thin-
filament–encoding genes, TNNI3 (cardiac troponin I [cTnI]), TNNT2 (cardiac troponin 
T [cTnT]), TNNC1 (cardiac troponin C), TPM1 (α–tropomyosin), and ACTC1 (α-cardiac 
actin).5 The remaining 2% are attributed to incidental mutations in the thick-
filament genes, MYL3 and MYL2, encoding the regulatory and essential myosin light 
chain, and the sarcomere-associated gene TTN, which encodes titin.5 On the basis 
of the numerous sarcomeric gene mutations, HCM is referred to as a disease of the 
sarcomere.
Both animal6,7 and clinical8–10 studies have shown that carriers of HCM-causing 
mutations demonstrate early signs of cardiac dysfunction, even before a hypertrophic 
phenotype is observed. Additionally, sudden cardiac death occurs in young 
individuals in the absence of clinically detectable cardiac hypertrophy.11 This suggests 
that the initial defects in cardiac performance are triggered by mutant sarcomere 
proteins rather than remodeling of the heart. Sarcomere mutations may directly 
impair myofilament function and contractile performance of the heart3 or indirectly 
via changes in intracellular Ca2+-handling.12 Because the myofilaments represent 
a major intracellular buffer of Ca2+, any perturbation in myofilament Ca2+-sensitivity 
may provide a substrate for cardiac arrhythmias. Only recently, Knollmann’s group13 
showed that TNNT2 mutations alter intracellular Ca2+-handling via myofilament Ca2+-
sensitization in transgenic mice models, which was associated with altered action 
potential regulation and occurrence of arrhythmias. This implies that myofilament 
Ca2+-sensitivity is central in HCM pathology.
Whether or not myofilament sensitization to Ca2+ is of relevance in human HCM 
is a matter of ongoing research.14–16 Our recent studies in manifest HCM with 
MYBPC3 mutations showed higher myofilament Ca2+-sensitivity compared with 
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non-failing donor myocardium.15,16 However, high Ca2+-sensitivity coincided with 
low phosphorylation of target proteins of the β-adrenergic signaling pathway, cTnI, 
and cMyBPC and was normalized to donor values by exogenous protein kinase A 
(PKA) treatment.15 This suggests that the high myofi lament Ca2+-sensitivity observed 
in human HCM with MYBPC3 mutations is attributable to secondary disease–
related posttranslational modifi cations rather than the mutation itself. In addition 
to posttranslational protein modifi cations, muscle length represents an important 
determinant of myofi lament Ca2+-sensitivity. Recently, we observed impairment of 
length-dependent sarcomere activation evident from a blunted length-dependent 
increase in myofi lament Ca2+-sensitivity in HCM with MYBPC3 mutations.15 Under 
normal conditions, intracellular Ca2+-buff ering will increase with increased 
myofi lament Ca2+-sensitivity on myofi lament lengthening.17,18 Perturbations in length-
dependent myofi lament activation will alter Ca2+-buff ering by the sarcomeres and 
may provide a basis for altered Ca2+-handling in HCM.
In the present study, we investigated whether perturbed length-dependent activation 
rather than high myofi lament Ca2+-sensitivity is a common pathomechanism in human 
HCM with mutations in thick- and thin-fi lament genes. Measurements in sarcomere 
mutation-positive HCM were compared with sarcomere mutation–negative HCM 
(SMN) and non-failing donors. Our study shows that mutation-related changes 
in myofi lament Ca2+-sensitivity are diverse and depend on the aff ected gene. We 
observed impaired length-dependent sarcomere activation in all HCM samples. The 
blunted length dependence of sarcomeres was attributable to low phosphorylation 
of PKA targets compared with donor myocardium in patients with MYBPC3 truncating 
mutations and HCMsmn but a direct consequence of HCM missense mutations. 
Using troponin exchange in HCM cardiomyocytes with a homozygous TNNT2 and a 
heterozygous TNNI3 mutation, we provide evidence that <50% of poison peptide is 
suffi  cient to impair length-dependent activation of the sarcomeres. Because most 
patients carry a heterozygous sarcomere mutation that may result in relatively low 
levels of mutant (poison) peptide, impaired length-dependent sarcomere activation 
represents a pathomechanism in HCM.
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METHODS
An expanded version of the Methods section can be found in the online-only Data 
Supplement.
Myocardial Samples
Left ventricular septum tissue was obtained from patients with HCM harboring thick- 
and thin-filament gene mutations during myectomy surgery to relieve left ventricular 
outflow obstruction. Hypertrophic obstructive cardiomyopathy was evident from 
the high septal thickness (normal value <13 mm) and high left ventricular outflow 
tract pressure gradient (normal value <30 mm Hg). Clinical characteristics and 
mutation information of patients with HCM are listed in Table 1. Our study included 
patients carrying heterozygous mutations in MYBPC3 (n=21; MYBPC3mut), MYH7 
(n=6; MYH7mut), TNNI3 (n=2; TNNI3mut), and TPM1 (n=1; TPM1mut). The MYBPC3mut 
group consisted of patients with truncating (n=17) and missense (n=4) mutations. 
Data for these MYBPC3mut groups are presented separately. Septum tissue was also 
obtained from 1 end-stage failing patient with HCM carrying a homozygous TNNT2 
mutation (TNNT2mut). Septum myectomy tissue from 7 patients with HCM in whom 
no mutation was found after screening of 8 genes (SMN) and cardiac tissue from 12 
non-failing donors served as controls. Donors (age range, 14–65 years; mean, 39±5 
years; 9/3 male/female, respectively) had no history of cardiac abnormalities, normal 
ECG, and normal ventricular function on echocardiography within 24 hours of heart 
transplantation. Samples were obtained after written informed consent, and the 
study protocol was approved by the local ethics committees.
Isometric Force Measurements and Protein Analysis
Analysis of single cardiomyocyte force measurements and sarcomeric protein 
phosphorylation was performed as described previously.15,19,20
Exchange of Recombinant Human Troponin Complex
Expression, purification, and reconstitution of recombinant human wild-type cardiac 
troponin in single cardiomyocytes from the TNNT2mut heart and 1 of the TNNI3mut 
hearts were performed as described previously.21 Evaluation of the degree of exchange 
into cardiomyocytes was determined by labeling cTnT of wild-type recombinant 
cardiac troponin with a myc-tag to allow differentiation between endogenous and 
recombinant wild-type cTnT in Western blot analysis.
Data Analysis
Data are presented as mean±SEM of all single cardiomyocytes per patient/donor 
group. To take into account the repeated sample assessments within patient/donor 
groups, multilevel analysis was performed. Comparison between all groups was 
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performed for Ca2+-sensitivity at 2.2-μm sarcomere length and length-dependent 
activation of cardiomyocytes before and after PKA. Paired-group comparisons were 
performed for maximal developed force (Fmax) at 1.8- and 2.2-μm sarcomere length 
before and after PKA. Detailed explanation of the data analyses, signifi cance levels 
(exact P values), and 95% confi dence intervals for all comparisons are given in the 
online-only Data Supplement.
RESULTS
Myofi lament Ca2+-Sensitivity in HCM Compared With Non-failing 
Donors
To assess myofi lament Ca2+-sensitivity, force-Ca2+-relations were constructed for 
all cardiac samples at a sarcomere length of 2.2 μm. Ca2+-sensitivity for all HCM 
samples was signifi cantly higher compared with donors on the basis of their lower 
EC50 values (Figure 1A). Because the high Ca
2+-sensitivity may be attributable to low 
phosphorylation levels of PKA-target proteins, measurements were repeated after PKA 
treatment. The PKA-induced reduction in Ca2+-sensitivity (ΔEC50) was larger in all HCM 
groups compared with donors (with signifi cant changes in MYBPC3mut, MYH7mut, 
and TNNI3mut), except for TNNT2mut, which only showed a minor nonsignifi cant 
change (Figure 1B). After PKA treatment, myofi lament Ca2+-sensitivity was close to 
donor values in MYBPC3mut, TPM1mut, and SMN, whereas Ca2+-sensitivity remained 
signifi cantly higher compared with donor values in MYH7mut and TNNT2mut (Figure 
1C). Interestingly, after PKA treatment, Ca2+-sensitivity was signifi cantly lower in 
TNNI3mut compared with HCMsmn and donor values. 
Fmax at a sarcomere length of 2.2 μm was signifi cantly lower in all HCM groups 
compared with donors and was not corrected by PKA treatment (Online Table I). In 
addition, the steepness of the force-Ca2+-relation was signifi cantly lower and not 
corrected by PKA in all HCM groups compared with donors (data not shown).
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Figure 1. Myofilament Ca2+-sensitivity at a sarcomere length of 2.2 μm. 
A. Myofilament Ca2+-sensitivity (EC50) was significantly higher in all hypertrophic cardiomyopathy (HCM) 
groups compared with donors. B. The protein kinase A (PKA)–induced reduction (ΔEC50) in myofilament 
Ca2+-sensitivity was larger in HCM groups compared with donors, except in the TNNT2mut sample, in 
which PKA had no significant effect. C. Myofilament Ca2+-sensitivity was similar in MYBPC3mut, TPM1mut, 
sarcomere mutation-negative HCM (SMN), and donor after treatment with PKA, whereas it was higher than 
donor in MYH7mut and TNNT2mut. PKA-treated TNNI3mut cells showed a lower myofilament Ca2+-sensitivity 
compared with SMN and donor. Open bar represents MYBPC3 truncating mutation; solid gray bars represent 
missense mutations. *P<0.05 vs donor; §P<0.05 vs TNNT2mut; #P<0.05 vs SMN.
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Length-Dependent Myofi lament Force Characteristics
Force development was measured at various [Ca2+] and 2 sarcomere lengths to 
determine length-dependent activation of myofi laments (Figure 2A). After a 
sarcomere length increase from 1.8 to 2.2 μm at maximal Ca2+-activation, donor 
samples showed a signifi cant increase in Fmax (Table 2), which is in accordance with the 
well-known eff ects of length on force development.22 A signifi cant length-dependent 
increase in Fmax was observed in MYBPC3mut, MYH7mut, TPM1mut, and SMN heart 
samples, whereas no signifi cant increase in Fmax was found for both TNNT2mut and
TNNI3mut. As illustrated in Table 2, the ΔFmax (diff erence in Fmax between sarcomere 
lengths of 1.8 and 2.2 μm) was much lower in HCM with missense mutations compared 
with the other groups. 
To investigate the length-dependent increase in myofi lament Ca2+-sensitivity, force 
at submaximal [Ca2+] was normalized to the Fmax to obtain normalized force-Ca
2+-
relations at both sarcomere lengths (Figure 2B). For all HCM and donor groups, the 
normalized force-Ca2+-relation shifted to the left as sarcomere length increased, 
indicative of increased Ca2+-sensitivity. However, the increase in myofi lament Ca2+-
sensitivity on an increase in sarcomere length (ΔEC50) was signifi cantly lower in all 
sarcomere mutation-positive HCM and SMN samples compared with donors (Figure 
2C). 
Stimulation of the β-adrenergic receptor pathway has been shown to enhance the 
length-dependent shift in the force-Ca2+ relation, suggesting a modulating role for 
PKA-mediated protein phosphorylation in length-dependent sarcomere activation.23,24
Because previous studies showed lower phosphorylation levels of myofi lament PKA 
target proteins in HCM compared with donors,15,16 the blunted length-dependent 
activation in HCM compared with donors may be explained by a diff erence in protein 
phosphorylation level. Indeed, analysis of protein phosphorylation showed lower 
phosphorylation levels of both cTnI and cMyBP-C in all HCM groups compared with 
non-failing donors, except in TNNT2mut, in which phosphorylation of the PKA target 
proteins did not diff er from donor (Figure 3A).
To test whether the blunted length-dependent change in Fmax and myofi lament 
Ca2+-sensitivity was corrected by PKA-mediated phosphorylation of cMyBP-C and 
cTnI, force measurements were performed after pre-treatment with exogenous 
PKA in a subset of HCM and donor samples. PKA pretreated MYBPC3mut, MYH7mut, 
and SMN and donor cells showed a signifi cant increase in maximal force after a 
sarcomere length increase, similar to that observed in non-treated cardiomyocytes 
(Table 2). PKA did not restore the blunted length-dependent increase in Fmax evident 
from the signifi cantly lower ΔFmax in HCM with missense mutations compared with 
donor (Table 2). Pre-treatment with exogenous PKA signifi cantly enhanced the 
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length-dependent shift in myofilament Ca2+ sensitivity in HCM with truncating 
MYBPC3mut and SMN samples to values observed in donors but did not correct the 
blunted length-dependent change in EC50 in all other HCM mutant groups harboring 
missense mutations (Figure 2D). 
Because the MYBPC3mut and MYH7mut groups consisted of different mutations, we 
averaged functional data for each HCM mutation separately. Data are shown in Table 
II in the online-only Data Supplement).
PKA-Mediated Protein Phosphorylation
To determine whether the absence of an effect of PKA on sarcomere functional 
properties is attributable to a defect in PKA-mediated protein phosphorylation in HCM 
myocardium, phosphorylation status of PKA target proteins was analyzed in HCM 
and donor samples incubated with exogenous PKA. Figure 3B shows HCM samples 
incubated without and with PKA separated by 1-dimensional gel electrophoresis and 
stained with ProQ-Diamond and SYPRO Ruby. PKA increased phosphorylation of both 
PKA targets, cMyBP-C and cTnI, in HCM samples. Phosphorylation levels (normalized to 
untreated donor samples, which were included on the gel and set to 1; dotted line) are 
depicted in Figure 3C and show that phosphorylation of cMyBP-C after PKA was close 
to values observed in donor samples in all HCM samples. Analysis of phosphorylation 
at specific PKA sites (Ser275 and Ser284) on cMyBP-C confirmed increased PKA-
mediated phosphorylation in HCM samples (Figure 4). In addition to cMyBP-C, 
phosphorylation of cTnI increased by PKA in all HCM samples (Figure 3B), although 
values did not reach the level found in donor myocardium (Figure 3C). PKA treatment 
of donor samples increased cTnI phosphorylation by ≈25%. Similar data were obtained 
when cTnI phosphorylation was analyzed by Phos-Tag gel electrophoresis creating a 
pattern of unphosphorylated, monophosphorylated, and bisphosphorylated cTnI 
(Online Figure II). PKA-treated HCM samples showed increased bisphosphorylated 
cTnI levels, but some monophosphorylated cTnI remained. Previous Phos-Tag analysis 
of the donor samples (n=12) revealed a distribution pattern of 7% unphosphorylated, 
27% monophosphorylated, and 66% bisphosphorylated cTnI.15 On treatment of donor 
samples (n=2) with PKA, cTnI was mostly bisphosphorylated (Online Figure II).
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Figure 2. Myofi lament length–dependent activation. 
A. Tension development as a function of [Ca2+] at short (1.8 μm) and long (2.2 μm) sarcomere lengths for 
donor (left) and TPM1mut (right) heart samples. B. Normalized force-Ca2+-relationships for donor (left) and 
TPM1mut (right) heart samples. C. The length-dependent increase in myofi lament Ca2+-sensitivity was lower 
in all sarcomere mutation-positive hypertrophic cardiomyopathy (HCMmut) compared with donors before 
protein kinase A (PKA) treatment. D. PKA pretreatment restored length-dependent activation to donor in 
HCM with truncating MYBPC3mut and sarcomere mutation-negative HCM (SMN) but not in HCMmut with 
missense mutations. Open bar represents MYBPC3 truncating mutations; solid gray bars represent missense 
mutations.*P<0.05 vs donor; #P<0.05 vs HCMs








Sample 1.8 μm 2.2 μm ΔFmax N/n 1.8 μm 2.2 μm ΔFmax N/n
Truncating
MYBPC3 19.6±1.5 29.8±2.4** 10.2±1.2 14/47 27.6±1.5 37.0±2.0** 9.4±1.3 4/19
Missense
MYBPC3 13.0±1.3 15.5±1.7** 2.5±0.8* 4/12 11.4±1.0 13.9±1.5** 2.5±1.0* 4/12
MYH7 15.1±1.6 19.1±1.8** 3.9±1.0* 6/32 18.8±2.6 22.6±3.1** 3.8±1.1* 4/15
TNNT2 21.5±3.2 24.4±6.0 3.0±4.4 1/6 13.7±2.1 15.2±2.4 1.5±1.3* 1/4 
TNNI3 9.8±2.5 10.1±2.8 0.3±1.1* 2/8 8.4±1.4 9.5±1.9 0.83±0.8* 2/10
TPM1 10.7±2.1 17.0±3.0** 6.3±1.5 1/6 9.1±2.3 9.6±1.7 0.58±0.7*# 1/4
SMN 18.2±1.4 28.3±2.6** 10.1±1.7 7/31 26.8±2.3 38.7±2.7** 12.0±1.4 3/12
DONOR 26.3±2.2 35.1±3.1** 8.8±2.1 9/32 26.2±1.4 36.2±1.9** 10.0±1.6 3/12
 
Table 2. Effects of sarcomere length increase on Fmax before and after PKA.
ΔFmax indicates difference in Fmax between sarcomere lengths of 1.8 and 2.2 μm; HCM, hypertrophic 
cardiomyopathy; N, number of samples; n, number of cardiomyocytes; and PKA, protein kinase A. P<0.05 was 
considered significant; *vs donor; **1.8 vs 2.2 μm; #ΔFmax (no PKA pre-treatment) vs ΔFmax (PKA pretreatment).
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Correction of Length-Dependent Activation in HCM With Mutant 
cTnT and Mutant cTnI by Human Recombinant Wild-type Troponin
To determine whether mutant sarcomeric protein is the direct cause of the 
blunted length-dependent increase in myofi lament Ca2+-sensitivity, we performed 
troponin exchange experiments in cardiomyocytes from the TNNT2mut sample. The 
homozygous TNNT2mut necessarily results in 100% mutant cTnT and thus represents 
a unique tool to assess the level at which mutant protein perturbs sarcomere function. 
Exchange with increasing concentrations of wild-type human troponin complex (0.25, 
0.5, and 1 mg/mL in the exchange solution) resulted in 62±2%, 78±1%, and 86±1% 
troponin exchange on the basis of Western blot analyses of endogenous and myc-
tag–labeled wild-type cTnT (Figure 5A; left blot). In exchanged cells without PKA 
pre-treatment, replacement of mutant troponin with unphosphorylated recombinant 
wild-type troponin did not restore the reduced length-dependent activation to 
donor values (Figure 5B). However, replacement of endogenous mutant troponin 
by unphosphorylated recombinant troponin reduces cTnI phosphorylation in the 
TNNT2mut cells. Therefore, measurements were also performed in the troponin-
exchanged cells after PKA treatment to increase cTnI phosphorylation to donor 
levels. In cells in which 62% of mutant troponin was replaced by wild-type troponin, 
the length-dependent increase in myofi lament Ca2+-sensitivity was still signifi cantly 
lower compared with donor values, indicating that 38% of mutant protein is suffi  cient 
to impair length-dependent activation. However, the blunted length-dependent 
activation was restored to donor values in TNNT2mut-exchanged cells, harboring 22% 
and 14% endogenous mutant cTnT (Figure 5C). Similarly, exchange of mutant cTnI in 
one of the HCM samples harboring the R145W missense mutation in TNNI3 by ≈90% 
unphosphorylated wild-type troponin complex (Figure 5A; right blot) corrected 
length-dependent activation only after PKA treatment (Figure 5D and 5E). Hence, 
normalization of length-dependent activation to donor values on exchange with wild-
type cTn complex is evident only after PKA treatment of troponin-exchanged cells.
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Figure 3. Phosphorylation of protein kinase A (PKA) target proteins before and after PKA treatment. 
A. Protein phosphorylation values were corrected by the corresponding SYPRO-stained protein bands and 
normalized to the values found in donors, which were set to 1 (dotted line). Phosphorylation of cardiac 
myosin–binding protein-C (cMyBP-C; left) and cardiac troponin I (cTnI; right) was lower in all hypertrophic 
cardiomyopathy (HCM) samples compared with donors, except for the TNNT2mut sample, which showed 
relatively high phosphorylation. Open bar represents truncating MYBPC3 mutations; solid gray bars 
represent missense mutations. B. Cardiac samples before (−) and after (+) PKA treatment separated by 
1-dimensional gel electrophoresis and stained with ProQ-Diamond (phosphorylation) and SYPRO Ruby 
(total protein stain). C. Thin-filament mutations were clustered in a single group (THINmut). ProQ-stained 
protein phosphorylation values of PKA-treated samples were corrected by the corresponding SYPRO-
stained protein bands and normalized to values in nontreated donor samples, which were included on the 
gel and set to 1 (dotted line). PKA increased phosphorylation of both target proteins in all HCM groups. 
Numbers of samples included in the analyses are indicated in the bar graphs.
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DISCUSSION
Our study shows that high myofi lament Ca2+-sensitivity in human HCM myocardium is 
independent of the presence of a sarcomere mutation and at least partly explained by 
protein hypophosphorylation. Sarcomere mutations may modify Ca2+-sensitivity, but 
the direction and magnitude of the change depend on the aff ected gene. Impaired 
length-dependent activation of sarcomeres represents a common pathomechanism 
underlying HCM and could not be corrected by PKA treatment in HCM with missense 
mutations in genes encoding thick- and thin-fi lament proteins. Moreover, our 
troponin exchange experiments provide direct proof that mutant troponin impairs 
length-dependent activation. Our data indicate that mutant proteins resulting from 
missense mutations could perturb length-dependent sarcomere activation and 
underlie cardiac dysfunction observed at early stages of HCM disease development.
Myofi lament Ca2+-Sensitivity and Phosphorylation Background
Our studies in human HCM with mutations in both thick- and thin-fi lament proteins 
showed high myofi lament Ca2+-sensitivity at a sarcomere length of 2.2 μm (Figure 1A). 
This is in agreement with previous studies in transgenic mouse models and in vitro 
studies with mutant proteins, which indicate that HCM sarcomere mutations sensitize 
myofi laments to calcium.3,12,13,25 However, the higher Ca2+-sensitivity in sarcomere 
mutation-positive HCM groups compared with non-failing donors coincided with 
lower phosphorylation levels of cMyBP-C and cTnI (Figure 3A). The diff erence in 
myofi lament Ca2+-sensitivity between sarcomere mutation-positive HCM and non-
failing donor can thus be partly explained by hypophosphorylation of sarcomeric 
proteins rather than the sarcomere gene mutation itself. 
A possible explanation for the low phosphorylation levels may reside in a blunted 
β-adrenergic response in patients with HCM. A blunted response to isoproterenol, 
a β-adrenoreceptor agonist, has been reported in transgenic mice harboring TPM1
and MYH7 mutations.26,27 Moreover, reduced β-adrenoreceptor density has been 
reported in patients with HCM.28 Treatment of HCM samples with PKA increased 
phosphorylation of the PKA target proteins (Figures 3 and 4 and Online Figure II) 
and normalized myofi lament Ca2+-sensitivity in MYBPC3mut, TPM1mut, and SMN to 
values observed in non-failing donors. In contrast, after PKA, higher myofi lament Ca2+-
sensitivity was still present in MYH7mut and TNNT2mut, suggesting a Ca2+-sensitizing 
eff ect by these mutations. Interestingly, PKA treatment signifi cantly lowered Ca2+-
sensitivity of the TNNI3mut R145W compared with donor. This observation contrasts 
with transgenic animal models and reconstituted thin fi laments using recombinant 
human mutant cTnI.29–31 It has been suggested that the Ca2+-sensitizing action of 
mutations in the inhibitory region of cTnI (residues 137–148) directly impairs the 
intrinsic inhibitory activity of cTnI.29,30 A possible explanation for the contradicting 
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results compared with our TNNI3mut samples may reside in the amount of 
endogenous mutant protein expression. Using adenovirus gene transfection to 
incorporate the cTnI R145W mutant into adult rat cardiomyocytes, Davis et al32 
observed no elevation of myofilament Ca2+-sensitivity, which was attributed to poor 
incorporation (≈35%) of mutant protein into the sarcomeric structure compared with 
wild-type cTnI. In addition, the phosphorylation background of the sarcomeres may 
have been different among studies.
Overall, our data show that high Ca2+-sensitivity is not a specific characteristic of 
human sarcomere mutation-positive HCM because a similarly high myofilament Ca2+-
sensitivity was found in HCMsmn compared with donors, which may be ascribed to 
reduced β-adrenergic signaling as part of cardiomyopathy development. Although 
PKA is the archetypical kinase involved in modulating Ca2+-sensitivity through cTnI 
and cMyBP-C phosphorylation, it is by no means the only kinase that phosphorylates 
myofilament proteins. Both cTnI and cMyBP-C are targets for a whole range of 
kinases.33–37 cMyBP-C phosphorylation is thought to mainly affect cross-bridge cycling 
kinetics,38 although a role in mediating Ca2+-sensitivity of force has been suggested.39 
cTnI is considered to be the key regulator of Ca2+-sensitivity, and it is mainly through 
phosphorylation of Ser23 and Ser24 that PKA exerts its Ca2+-desensitizing effect, 
although many other phosphorylation sites have been identified.40 Phosphorylation 
is but one of many possible posttranslational modifications. Recent reports have 
hinted at the possible involvement of other posttranslational modifications in the 
regulation of sarcomere function such as oxidation and S-glutathionylation41 or 
O-GlcNAcylation.42 It would thus be an oversimplification to propose that a reduction 
in PKA phosphorylation of sarcomere proteins is solely responsible for the myofilament 
changes in HCM. However, the baseline Ca2+-sensitivity seems to be dominated by the 
relatively low phosphorylation levels of PKA myofilament target proteins compared 
with donors. Higher phosphorylation levels mimicked by exogenous PKA treatment, 
as would be induced during increased cardiac stress (eg, exercise), unveils a higher, 
similar, or even lower myofilament Ca2+-sensitivity in HCM, depending on the affected 
gene. Our findings suggest diverse mutation-induced changes in Ca2+-sensitivity, 
whereas high myofilament Ca2+-sensitivity is partly explained by secondary disease–
related changes in protein phosphorylation.
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Figure 4. Site-specifi c phosphorylation of protein kinase A (PKA) target sites of cardiac myosin-
binding protein-C (cMyBP-C).
A. Western blot analysis of cMyBP-C phosphorylation with specifi c antibodies for PKA sites Ser284 (top) and 
Ser275 (bottom) before (−) and after (+) PKA treatment (phosphorylation values were corrected for minor 
diff erences in protein loading by Ponceau-stained myosin light chain 2 [MLC2]). B. Protein phosphorylation 
values were normalized to the values found in untreated donor samples, which were included on the blot 
and set to 1 (dotted line). Thin-fi lament mutations were clustered in a single group (THINmut). Numbers 
of samples included in the analyses are indicated in the bar graphs. All samples showed an increased 
phosphorylation at both sites on PKA treatment.
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Figure 5. Replacement of endogenous mutant cardiac troponin by recombinant human wild-type 
troponin complex.
A. Quantifi cation of troponin exchange in cardiomyocytes from a TNNT2mut and a TNNI3mut heart. 
Immunoblots stained with an antibody against cardiac troponin T (cTnT) that recognizes both endogenous 
cTnT (lower band) and recombinant myc tag–labeled cTnT (cTnTmyc; top band). Left. An example of a 
suspension of cardiomyocytes from a TNNT2mut heart exchanged with increasing concentrations of wild-
type human recombinant troponin complex. Exchange with 0.25 mg/mL (lane 1), 0.5 mg/mL (lane 2), and 1 
mg/mL (lane 3) troponin complex. TNNT2mut heart without added recombinant troponin complex (lane 4). 
Right. A suspension of cardiomyocytes from a TNNI3mut heart exchanged with 1 mg/mL wild-type human 
recombinant troponin complex. Similar amounts were loaded on the blots (shown by Ponceau-stained actin) 
to allow cTnT analysis within the linear detection range. B. The length-dependent activation was signifi cantly 
lower compared with donor in all TNNT2mut cells harboring varying amounts of mutant cTnT (100% without 
exchange and 38%, 22%, and 14% in cells exchanged with increasing concentrations of unphosphorylated 
recombinant wild-type troponin). C. Measurements were also performed in exchanged cardiomyocytes, 
which were subsequently treated with protein kinase A (PKA) to normalize cTnI phosphorylation. Pre-
treatment with exogenous PKA was not able to recover the blunted length-dependent activation in 
TNNT2mut cells with 38% of mutant cTnT, but it did recover the reduced length dependence of TNNT2mut
exchanged with 78% and 86% wild-type troponin. D. The length-dependent activation was signifi cantly 
lower in TNNI3mut cells exchanged with ≈90% unphosphorylated recombinant wild-type troponin (wt-cTn) 
compared with donor cells. E. Pre-treatment with exogenous PKA restored the blunted length-dependent 
activation in TNNI3mut cells exchanged with wt-cTn complex to donor values. *P<0.05 vs donor; §P<0.05 vs 
TNNT2mut or TNNI3mut.
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Impairment of Length-Dependent Sarcomere Activation in HCM
Our data indicate that mutant sarcomeric proteins in HCM perturb length-dependent 
activation of myofilaments, which may contribute to early cardiac dysfunction 
observed in sarcomere mutation carriers. Studies in transgenic mouse models and 
troponin-exchange techniques with mouse tissue harboring HCM mutations were 
not conclusive because a reduced or normal length-dependent activation was found 
compared with controls.27,43–46 The recent study of Ford et al46 may shed some light on 
these previous observations. Those authors studied length-dependent differences in 
mice expressing TNNT2 mutations either in an α-MyHC (predominant in murines) or in 
a β-MyHC (predominant in healthy adult human hearts) background. It was observed 
that mice expressing the R92L mutation in the physiological α-MyHC background 
presented a normal length-dependent Ca2+-activation, whereas in the presence of 
the slow-cycling β-MyHC isoform, length dependence was lost.46 Defects in length-
dependent sarcomere properties were not similar in all HCM samples because the 
blunted length-dependent increase in myofilament Ca2+-sensitivity was corrected 
to donor values by exogenous PKA in truncating MYBPC3mut and SMN, whereas it 
remained defective in HCM with missense mutations in MYBPC3, MYH7, TNNT2, 
TNNI3, and TPM1. Moreover, the increase in maximal force  generating capacity on 
an increase in sarcomere length was almost entirely absent in HCM with troponin 
mutations (Table 2). Although PKA increased phosphorylation of cTnI and cMyBP-C 
and reduced myofilament Ca2+-sensitivity at 2.2 μm in all HCM samples (except in 
the homozygous TNNT2mut), it did not restore length-dependent activation in HCM 
samples with missense mutations. Intriguingly, a negative myofilament length-
dependent activation was observed after PKA in the TPM1mut sample (Figure 2D), 
suggesting that length-dependent activation is even more impaired during increased 
cardiac stress. 
The blunted length-dependent activation may be partly related to the relatively 
low phosphorylation of PKA targets and high baseline myofilament Ca2+-sensitivity. 
The suggestion that PKA-mediated myofilament protein phosphorylation has a 
modulatory role in length-dependent activation comes from studies in ferret papillary 
muscles23 in which isoprenaline, a stimulator of the β-adrenergic receptor pathway, 
enhanced the length-dependent change in the force-Ca2+-relation. Studies in cardiac 
tissue in which cTnI was replaced by skeletal TnI, which lacks the PKA target serines 
(Ser23/24), showed higher myofilament Ca2+-sensitivity but a significantly reduced 
length-dependent activation,24,47 indicating a role for cTnI phosphorylation in length-
dependent activation. A study by Cazorla et al44 in transgenic mice lacking cMyBP-C 
demonstrated lower length-dependent activation than wild-type mice that could not 
be restored by exogenous PKA treatment, which suggests that cMyBP-C is needed 
for proper length-dependent sarcomere activation. In our human samples with 
truncating MYBPC3 mutations, impaired length-dependent activation was corrected 
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to donor values by PKA. Our previous study in HCM with truncating mutations in 
MYBPC3 showed reduced expression of full-length cMyBP-C to ≈70% compared with 
donor values (i.e., haploinsuffi  ciency). Overall, our studies in human HCM with MYBPC3 
truncation mutations indicate that the presence of ≈70% of full-length cMyBP-C 
protein in the sarcomere is suffi  cient to preserve the length-dependent properties of 
the sarcomeres.15
The perturbations in length-dependent activation in HCM with mutations in thin-
fi lament genes may be explained by the 3-state model of fi lament transition in 
which the troponin–tropomyosin complex has a central regulatory role. Myofi lament 
contraction and force production are tightly regulated by the troponin–tropomyosin 
complex, which regulates the interaction between the actin and myosin fi laments. 
It is believed that the myofi laments exist in a dynamic equilibrium between three 
biochemical transitions (Figure 6) that refl ect diff erent interactions between actin 
and myosin, called the blocked (B-state), closed (C-state), and open (M-state) states 
of thin-fi lament regulation.48,49 In the B-state, Ca2+ is not bound to cardiac troponin 
C, and tropomyosin sterically blocks myosin-binding sites on F-actin (Figure 6A). 
In the C-state, Ca2+ binds to cardiac troponin C, which changes conformation of the 
troponin–tropomyosin complex, resulting in non–tension-generating cross-bridges, 
which bind weakly to F-actin (i.e., weakly bound cross-bridges; Figure 6B).49–51 The 
M-state involves strong binding of tension-generating cross-bridges, which results 
in myofi lament contraction and force development (Figure 6C).49–51 Because of the 
central roles of cTnT and cTnI in the transition from the B-state to the C-state,52–54 it is 
likely that mutation-induced irregularities in protein interactions may translate into 
thin-fi lament abnormalities. 
The C-terminal half of cTnI docks the troponin–tropomyosin complex onto the outer 
domain of F-actin at low cytoplasmic [Ca2+],58 stabilizing the formation of the B-state. 
Interestingly, ≈86% of cTnI HCM-causing mutations (dashed red circle in Figure 
6D), including the one present in our study, are found in the C-terminal half of cTnI 
(residues 137–210), a region responsible for actin binding.25,60 Indeed, disruption of 
the B-state has been suggested in HCM-causing mutations aff ecting not only cTnI61
but also cTnT.62,63 The relevance of the transition from the B- to the C-state for proper 
length-dependent activation has been shown by Smith and Fuchs,64 who were the 
fi rst to provide evidence for a length-sensitive step in the transitions of thin-fi lament 
activation. A reduction in ionic strength (<0.05 mol/L), known to shift the B-state 
equilibrium toward a stable C-state,65 coincided with impairment of length-dependent 
activation.64 The blunted length-dependent increase in myofi lament Ca2+-sensitivity 
observed in the thin-fi lament mutation groups can thus be explained by disruption 
of the B-state and an increased number of weakly bound cross-bridges in the C-state. 
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Eleven HCM mutations have been identified in α-tropomyosin.60 To the best of our 
knowledge, the present study is the first to analyze the effects of an HCM-causing 
mutation (M281T) in the overlap region of tropomyosin, which has a central role 
in cooperative activation of the thin filament.66,67 The steepness of the force-Ca2+-
relation, which is an indicator of the relative number of near-neighbor interacting 
sites, was significantly lower in TPM1mut compared with donors (1.98±0.37 and 
3.33±0.11, respectively; Figure 2B), indicative of impairment of the cooperative 
response in activating the thin filament. Palm et al68 demonstrated that tropomyosin 
overlap regions are required for proper formation of a ternary complex with the 
N-terminal tail of cTnT. Because the N-terminal region of cTnT is needed to maintain 
the thin filament in the B-state,53,54 it is likely that mutations in the overlap region of 
α-tropomyosin structurally impair formation of the B-state and thereby impair length-
dependent activation of myofilaments.
Previous studies indicated that myosin is not involved in the formation of the first two 
equilibrium states, that is, B- and C-states.49–51 However, myosin is crucial for formation 
of the M-state (myosin-induced) because strong binding of tension-generating 
cross-bridges is required for thin-filament activation and force production.49–51 
Because five of the six samples used in our study have mutations in the myosin S1 
domain, responsible for actin binding,69 it is likely that the deleterious effects of MYH7 
mutations occur via perturbation of the M-state. A recent study by Farman et al70 
highlights the essential role of the orientation of the myosin heads that precede thin-
filament activation for proper lattice spacing and length-dependent activation. Thus, 
altered myosin head orientation, as a result of mutations, may impair formation of the 
M-state and affect length-dependent activation.
The possible involvement of cMyBP-C in the modulation of thin-filament activity 
has only recently been addressed. Electron microscopy and 3-dimensional 
reconstruction of thin filaments with cMyBP-C suggest that the N-terminal extension 
of cMyBP-C could modulate the movement of tropomyosin on F-actin and interfere 
with actomyosin interactions, possibly involved in the regulation of thin-filament 
activation.71 The MYBPC3 missense mutations in our study are located along the 
N-terminal extension of cMyBP-C and may alter the tropomyosin–actin interaction 
and thereby impair length-dependent activation.
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Figure 6. Schematic drawing of the thin-fi lament functional unit. 
Seven actin monomers (gray) spanned by 1 tropomyosin dimmer (red) and 1 troponin complex: cardiac 
troponin C (cTnC; pink), cardiac troponin I (cTnI; blue), and cardiac troponin T (cTnT; orange). N and C 
indicate the N- and C-terminal protein ends, respectively. Dark-blue tropomyosin depicts near-neighbor 
tropomyosin dimmer interaction.55,56 The orientation of thin-fi lament proteins is as follows: The N-terminal 
region of cTnT points toward the pointed end (M-band), whereas the core domain of the troponin complex 
is oriented to the barbed end (Z-disk).57 Interacting sites and structural location of actin-tropomyosin-
troponin proteins are matched in accordance with available literature.25,50,51,56,58,59 Cardiac TnI residues 1 to 34 
are arbitrarily positioned. Our drawing follows the proposed mechanism for Ca2+-regulation of contraction 
proposed by Murakami et al.58 A. B-state (blocked); when ATP is present and cytoplasmic [Ca2+] is low such 
that Ca2+ is not bound to cTnC, tropomyosin sterically blocks the myosin-binding sites on F-actin. B. C-state 
(Ca2+-induced); cytoplasmic [Ca2+] rises such that Ca2+ binds to cTnC, inducing conformational changes of the 
troponin complex, resulting in an ≈25° movement of tropomyosin on the thin fi lament, thereby exposing 
most of the myosin-binding sites on F-actin. Note the movement of tropomyosin away from subdomains 
one and two of F-actin. In the C-state, the myofi lament is not yet activated because non–tension-generating 
cross-bridges bind weakly to F-actin. C. M-state (myosin induced); involves the strong binding of tension-
generating cross-bridges that induce an additional ≈10° movement of tropomyosin on F-actin, resulting 
in myofi lament activation and contraction. Note the transition of tropomyosin into subdomains three and 
four of F-actin. D. Solid arrows depict the location of mutation sites on thin-fi lament proteins present in our 
human hypertrophic cardiomyopathy samples. cTnT residues 1 to 65 are shortened to fi t the enlarged scale.
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STUDY LIMITATIONS AND CLINICAL 
IMPLICATIONS
Although we were able to study a large collection of human HCM samples with 
different mutations in thick- and thin-filament proteins, care must be taken when 
extrapolating our findings to all patients with HCM. Our HCM population consisted 
of patients with left ventricular outflow tract obstruction, and the patient with the 
homozygous TNNT2 mutation had end-stage heart failure. Our data highlight that 
mutation-induced changes in myofilament Ca2+-sensitivity and length-dependent 
sarcomere activation are diverse and depend on the affected gene, and most likely 
location and type of the mutation in the affected protein. We provide evidence that 
mutant protein may impair sarcomere function at ≈38% expression (Figure 5C), 
which emphasizes the importance of studying the mutant protein level at which 
cardiac performance is impaired. Future studies in transgenic mice models and 
human myectomy samples are warranted to extend our findings to a broader set of 
sarcomere mutations and to assess the toxic dose of mutant proteins. 
Although sarcomere mutation–negative patients are commonly used as control 
group, we cannot completely rule out the presence of rare mutations. However, 
because our cardiomyocyte analyses revealed no functional impairments (PKA-
normalized length-dependent activation in SMN), the likelihood of the presence of a 
rare mutation is low. 
Our study revealed perturbed sarcomere length-dependent activation as a common 
mechanism underlying cardiac dysfunction in HCM. Pathological hypertrophy 
presumably reflects the compensatory response of the heart to counteract impaired 
sarcomere defects such as the blunted length-dependent myofilament activation. 
The relatively low force-generating capacity of cardiomyocytes and the inability 
to increase force on an increase in sarcomere length may in part underlie cardiac 
dysfunction and initiate compensatory hypertrophy. Pak et al72 showed a blunted 
end-systolic pressure-volume relation in patients with HCM, suggesting that the 
hearts were unable to properly recruit preload to augment contractility. The latter 
observation may be explained by cardiac remodeling. However, likewise, the mutation-
induced blunted length-dependent sarcomere activation may limit preload-mediated 
contractile reserve of the heart in patients with HCM. Our study, in combination with 
others,6–10 supports the hypothesis that defective sarcomere function as a result of 
gene mutations is central to early stages of HCM disease and precedes development 
of hypertrophy. Moreover, the blunted increase in myofilament Ca2+-sensitivity on 
an increase in length may alter Ca2+-buffering in the cardiomyocytes and provide a 
substrate for arrhythmias.
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Female (N) Male (N) P value
AGE, Y 51±13 (16) 47±14 (22) 0.43
IVS, mm 21±1.0 (16) 22±1.1 (18) 0.55
LVOTO, mmHg 94±5.1 (16) 81±6.1 (18) 0.11
EC50 at SL 2.2 2.45±0.23 (15) 2.38±0.14 (21) 0.79
EC50 at SL 2.2 after PKA treatment 2.67±0.21 (4) 2.95±0.21 (14) 0.72
Delta EC50 0.54±0.59 (4) 0.74±0.18 (14) 0.66
Fmax at SL 2.2 22.41±2.74 (14) 24.28±2.77 (20) 0.65
Fmax at SL 2.2 after PKA treatment 26.61±5.29 (4) 22.62±3.41 (14) 0.58
ADDENDUM 
No Sex-Diff erences Found in Length-Dependent Activation in HCM 
Patients 
The main focus of this thesis is the infl uence of sex on disease progression in HCM 
patients. We therefore, in retrospect, have analyzed data used in CHAPTER TWO for 
sex-diff erences. Table 1 shows clinical and cellular parameters divided by sex.  
Table 1. 
Abbreviations: Y: years; IVS: interventricular septum; LVOTO: left ventricular outfl ow tract obstruction; EC50: 
Myofi lament Ca2+-sensitivity; SL: slack length; PKA: protein kinase A; Fmax: maximal force
Although not signifi cant, women on average were four years older at time of 
myectomy/heart transplantation. IVS thickness is comparable between women and 
men (not corrected for body surface area). The maximal gradient of the LVOT is 13 
mmHg higher in women compared to men, although not signifi cantly. There were 
no diff erences found in length dependent activation between women and men. The 
cardiomyocyte response to sarcomere elongation or treatment with protein kinase A 
(PKA) is not dependent on sex.  
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ABSTRACT
Differences in cardiac physiology are seen between men and women in terms of health 
and disease. Sex differences start to develop at puberty and are maintained during 
aging. The prevalence of almost all cardiovascular diseases is found to be higher in 
men than in women, and disease progression tends to be more rapid in male than 
in female patients. In cohorts of patients with hypertrophic cardiomyopathy (HCM), 
the most common autosomal inherited cardiac disease, men are over- represented, 
suggesting increased penetrance of HCM-causing mutations in male patients. Cardiac 
remodeling in patients with HCM is higher in men than in women, the same is seen in 
HCM animal models. Patients with HCM are at increased risk of sudden cardiac death 
(SCD) and developing rhythm disorders. There seems to be no sex effect on the risk 
of SCD or arrhythmias in patients with HCM; however, animal studies suggest that 
certain mutations predispose men to SCD.
Keywords: hypertrophic cardiomyopathy, arrhythmias, pathophysiology, atrial 
fibrillation, sex, sudden cardiac death
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INTRODUCTION
The incidence of most cardiovascular diseases diff ers greatly between men and 
women. The prevalence of coronary artery disease and heart failure is markedly 
lower in women than in men, especially at a younger age.1 Sex diff erences in cardiac 
rhythm disorders are also seen, with some forms being more prevalent in men (e.g., 
atrial fi brillation [AF]2) and others in women (e.g., atrioventricular nodal reentrant 
tachycardia3). A plethora of factors are thought to contribute to these diff erences, 
including eff ects of sex hormones and diff erent risk factor profi les. Intriguingly, sex 
diff erences are found even in autosomal dominant inherited cardiomyopathies. Men 
and women carrying the same disease-causing mutation can still have diff erent 
disease penetrance and prognosis. The most common inherited cardiomyopathy is 
hypertrophic cardiomyopathy (HCM). 
Although sex diff erences are studied, diagnosis of cardiac disease is mostly based on 
symptoms found in men. Most therapies for cardiac disease are based on research 
in male patients and control groups, while pathophysiology of cardiac disease has 
distinct sex diff erences. Surprisingly, women are still under represented in clinical 
trials. The American Heart Association reported that of all patients with heart failure 
in 2010, 47% were women4; however, large clinical trials showed that the percentages 
of male patients enrolled ranged from 70% to 83%.5–7 This phenomenon is not a relic 
of the past, as the three largest clinical trials of 2013 studying cardiac disease used 
patient cohorts consisting of 77%–83% male patients.8–10 Women show diff erences 
in symptoms and cellular pathomechanisms compared with men and therefore 
may react diff erently on treatment. Sex diff erences in disease onset and progression 
emphasize the need to study patho-physiological mechanisms in both men and 
women. Sex diff erences in HCM disease presentation and HCM-related arrhythmias 
are the subject of this review. As sex is a  purely biological description of being male 
or female, it is used in this review rather than the more culturally loaded term “gender.”
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PHYSIOLOGY OF THE HEART
Sex Difference in Healthy Hearts
Sex differences not only manifest themselves in cardiac disease but are already 
present in healthy hearts. However, differences between men and women do not 
arise until puberty. The number and size of cardiomyocytes are initially equal in boys 
and girls,11 which is reflected in almost equal heart weights in prepubescent children 
of either sex.12 Because cardiomyocytes become post mitotic after birth, the growth of 
the heart after this period is the result of the growth of individual heart muscle cells.
During puberty, changes between male and female hearts become apparent. The 
ability to predict left ventricular (LV) weight on the basis of age alone decreases; 
however, growth remains proportional to body size.13,14 The rate of growth of heart 
weight remains constant in young women but is significantly higher in young men.12 
As a consequence, the absolute cardiac mass after puberty is15%–30% higher in men 
than in women.14 Further differences between male and female hearts arise during 
adulthood.
The aging process of the heart has notable dissimilarities between sexes. There 
are conflicting reports on the changes in LV weight between men and women 
during aging. In a small necropsy-based study, the average number of ventricular 
cardiomyocytes in men and women younger than 45 years was determined to be 
approximately 8 billion ((5.9 ± 1.4) x 109 and (2.1 ± 0.4) x 109 in the LV and the right 
ventricle, respectively), which in women did not change appreciably until death.15 In 
men, the number of cardiomyocytes decreased by 64 million myocytes/y till the age 
of 45,15 which was partly compensated by cardiomyocyte hypertrophy. This cell death 
is likely due to increased cardiomyocyte apoptosis, which is higher in men than in 
women.16 Some studies suggest a reduction in ventricular weight during aging only in 
men,14,15 although a large recent study in the Framingham study population showed 
loss of ventricular weight in both sexes.17
Sex-specific changes in cardiac function are observed during aging. It seems that 
systolic function (if expressed as the related term ejection fraction or fractional 
shortening) either does not change18 or actually increases17,19 with age in both sexes. 
This increase in fractional shortening is more pronounced in women.19 However, this 
is at least in part explained by a reduction in LV volumes (both diastolic and systolic), 
which results in a lower stroke volume and cardiac output in older men and women.17
Diastolic function decreases with age,18 leading to filling impairments. In both sexes, 
there is a progressive slowing of cardiac relaxation with age.14 In general, deterioration 
of diastolic function with age is more pronounced in women than in men.20,21 
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This diff erence is mainly attributed to the exacerbated diastolic stiff ness of the LV 
observed in aging women.21 This would also contribute to the reduced diastolic long-
axis and radial velocities observed in older women compared with older men and 
younger women.22 The decrease in diastolic function with age has been suggested to 
make women more susceptible to developing heart failure with preserved ejection 
fraction.23
Sex diff erences in healthy hearts are not only confi ned to cardiac morphology but also 
seen in the pacemaker and conduction system. Diff erences in heart rates between 
men and women mirror the changes seen in heart size. No diff erences in heart rates 
between female and male fetuses are seen in utero.24 From puberty to menopause, 
women have higher heart rates than do men,24 and this diff erence decreases after 
menopause.25 Again, sex diff erences in electrocardiograms arise only after puberty. 
For example, the QT interval, which represents ventricular depolarization and 
repolarization, of adolescent boys shortens to the duration measured in adult men, 
while this interval does not change in women.24 Thus, adult men have shorter QT 
intervals than do women.26 This is likely caused by testosterone that is thought to 
shorten ventricular repolarization, as the QT interval was longer in castrated men than 
in control subjects.27
Calcium and Cardiomyocyte Contractility
Both diastolic and systolic function of the heart are the macroscopic eff ects of the 
behavior of individual cardiomyocytes. Cardiac contraction is initiated by Ca2+-induced 
Ca2+-release, which follows membrane depolarization. In short, depolarization leads to 
Ca2+-infl ux through L-type Ca2+-channels (LTCCs). This small and localized Ca2+-infl ux 
leads to activation of ryanodine receptors on the sarcoplasmic reticulum, resulting 
in a large Ca2+-release into the cytosol and allowing cardiac contraction to occur. 
After contraction, the cytosolic Ca2+-concentration is lowered by active sarcoplasmic 
reticulum Ca2+-ATPase and by Na+/Ca2+-exchanger (NCX) in the sarcolemma.
An important modulator of Ca2+-homeostasis and thus contraction is protein kinase 
A (PKA). Noradrenaline released as a result of sympathetic stimulation binds to β1- 
adrenergic receptors on cardiomyocytes, leading (indirectly) to PKA activation. PKA 
phosphorylates proteins involved in excitation-contraction coupling, such as LTCCs, 
ryanodine receptors, and phospholamban, which together lead to a positive inotropic 
and lusitropic response.28
Both male and female sex hormones have modulatory eff ects on Ca2+-handling. 
Estrogen seems to attenuate Ca2+ transients in rats, as ovariectomy increases Ca2+-
transients, which could be normalized by estrogen replacement.29 This eff ect was 
ascribed to estrogen-reducing PKA activity rather than a direct eff ect on Ca2+-handling 
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proteins.29,30 Chu et al31 found that estrogen deprivation in rats does affect protein 
levels of Ca2+-handling proteins, as levels of NCX were decreased and LTCCs levels 
were increased in ovariectomized rats. This resulted in a higher diastolic Ca2+-
concentration because of the decreased NCX protein levels, and again, these changes 
were normalized by estrogen replacement.31 In contrast, testosterone increased 
expression of both LTCCs and NCX in isolated rat cardiomyocytes.32 In orchiectomized 
rats, no effect of testosterone deprivation was seen on basal contractile function; 
however, the inotropic response to noradrenaline was blunted.33
REMODELING IN HCM: A CLINICAL OVERVIEW
Sex differences not only manifest themselves in the healthy heart but are seen in 
cardiac pathologies, where they can have a profound effect on pathophysiology 
(Table 1). For instance, sex effects are seen in patients with HCM and have clinical 
implications as discussed later in this section. HCM is the most prevalent monogenic 
inherited cardiac disease, with a prevalence of 200 per 100,000 individuals.34 
HCM is defined as “a disease of the heart muscle characterized by unexplained LV 
hypertrophy associated with non-dilated ventricular chambers in the absence of 
another cardiac or systemic disease that itself would be capable of producing the 
magnitude of hypertrophy present in a patient.”35 HCM is the most frequent cause 
of sudden cardiac death (SCD) at a young age. LV hypertrophy is often asymmetric, 
caused by selective thickening of the interventricular septum (IVS). Clinically, other 
features such as diastolic dysfunction and LV outflow tract obstruction together 
with histopathological signs such as increased interstitial fibrosis and cardiomyocyte 
hypertrophy and/or disarray are seen.36
There is a wide variety in the clinical course of HCM, ranging from an asymptomatic 
status to progressive heart failure. Severe IVS hypertrophy can lead to LV outflow 
tract obstruction, thereby impairing cardiac output in particular during stress (i.e., 
hypertrophic obstructive cardiomyopathy [HOCM]). To restore cardiac output in 
patients with HOCM, part of the IVS is removed during myectomy surgery or alcohol 
septal ablation (ASA). Only a small number of patients with HCM progress to end-
stage heart failure (1%–2% of patients with HCM per year). 
In approximately 65% of patients with HCM, a causative mutation can be identified.37 
Mutations that cause HCM are almost exclusively located in genes encoding 
sarcomeric proteins. At present, more than 1400 HCM-causing38 mutations are 
identified, which contribute to the heterogeneity of this disease.39 Approximately 80% 
of identified mutations are found in the genes encoding the thick filament proteins, 
cardiac myosin binding protein C (cMyBP-C;gene: MYBPC3) and β-myosin heavy 
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chain (β-MyHC; gene: MYH7).40 Approximately 6.5% of mutations are found in cardiac 
troponin T (gene TNNT2), with other sarcomere genes found only sporadically.40
Although sarcomere gene mutations are identifi ed as the underlying cause of HCM, 
the exact molecular pathophysiological mechanisms underlying the transition from 
mutation carrier to a manifest patient with HCM and, in some cases, end-stage heart 
failure are currently unknown.
SEX DIFFERENCES IN PATIENTS WITH HCM
Since HCM is an autosomal dominant disorder, an equal representation would be 
expected between male and female patients with HCM. However, published patient 
cohorts show over representation (ranging from 55% to 74%) of men, suggesting 
higher penetrance of HCM-causing mutations in male patients.41,42 Moreover, at 
the time of diagnosis, women were on average 9 years older than men.41 This age 
diff erence could be an explanation for the fact that women had more advanced 
disease than did men at initial evaluation.41 In a recent study in Chinese patients with 
HCM, female sex (in patients younger than 50 years) was associated with decreased 
survival.43
Sex diff erences are seen in the extent of ventricular remodeling in patients with 
HCM (see Table 1). Schulz-Menger et al44 found a lower remodeling index in HCM 
women than in HCM men. This index is based on the relation between LV weight and 
LV volumes and has been proposed  to quantify LV remodeling. The exacerbated LV 
remodeling in male patients might be caused by increased fi brosis, as replacement 
fi brosis is thought to be a potentiating element of LV remodeling in HCM.45 Indeed, 
fi brosis, assessed either at necropsy46 or noninvasively with late gadolinium 
enhancement magnetic resonance imaging,47 is present at a higher level in male 
patients.
HCM AND ARRHYTHMIAS
In addition to the contractile defi cits seen in patients with HCM, the structural and 
physiological changes in the myocardium make patients with HCM more susceptible 
to rhythm disorders. Patients with HCM have a 4–6 times increased risk of developing 
atrial and ventricular arrhythmias.48 Atrioventricular blocks are the most common and 
mostly occur after septal reduction therapies.49




Clinical studies Animal model studies Reference 
HCM Women on average 9 years older 
than men at diagnosis
Higher penetrance of HCM-
causing mutations in men
41,77
LV remodeling Eccentric hypertrophy in men 
with LV dilation, and concentric 
hypertrophy in women without 
dilation
Lower remodeling index in women
Male mice show LV dilation 
while female mice do not 
Stronger induction of 
pathological markers in male 
mice 
11,78,79,44,70,73,66
Fibrosis Higher in men than in women Higher in male mice than in 
female mice
45–47,68,71
SCD No sex difference All male mice died after 
adrenergic stimulation
SCD is mutation dependent
41,51,77,66,35,75
AF No sex difference in contrast to the 
general population where men 
have a higher prevalence of AF
No sex difference
AF is mutation dependent
41,60–63,49,53,60
Ca2+-sensitivity Increased Ca2+-sensitivity in patients 
with HCM
No sex difference
Sex difference is mutation 
dependent
72,69,71,73
Table 1. Summary of sex-related differences in HCM disease presentation.
AF = atrial fibrillation; HCM = hypertrophic cardiomyopathy; LV = left ventricular ;SCD = sudden cardiac 
death.
SCD 
Patients with HCM have an increased risk of SCD, with an SCD rate of approximately 
1%/y.35 If risk factors for SCD are present, this risk can be markedly higher.50 Risk factors 
for SCD in patients with HCM are (1) personal experience of ventricular fibrillation or 
SCD event, (2) family history of SCD events, (3) unexplained syncope, (4) non sustained 
ventricular tachycardia, (5) LV wall thickness ≥30 mm, and (6) impaired blood flow 
response to exercise.35 The fact that the risk factor system is not perfect was reported 
in a recent study in patients with HCM free of risk factors. Even in this low-risk group 
of patients, the rate of SCD was 0.6%/y.51 In patients with HCM, sex does not seem to 
affect SCD. Rates of SCD were similar in men and women in a large study in patients 
from Italy and the United States.41,51
Atrial Fibrillation
In patients with HCM, the incidence of AF is approximately 2%/y, with a prevalence 
of approximately 20%–25%, which increases with age and develops most frequently 
after the age of 60 years.52 AF is an independent risk factor for mortality in patients 
with HCM.53 AF increases the risk of HCM-related deaths four times, with mortality 
being 3%/y.52 This increased mortality is driven by the higher occurrence of heart 
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failure and stroke-related death.52 Risk factors for AF54 (all of which are more common 
in patients with HCM than in the general population) include left atrial enlargement,55 
sleep-disordered breathing,56 in homogeneous atrial conduction,57 and ventricular 
myocardial fi brosis.58 Furthermore, there are genetic mutations that predispose to AF; 
47% of patients carrying the Arg663His missense mutation in the MYH7 gene develop 
AF.59
Sex Diff erences  
In patients without HCM, age and sex are the two most powerful predictors of the 
incidence of AF.60 In the general population, male sex is associated with a 1.5-fold 
increased risk of developing AF. Large clinical trials conducted in patients with AF 
showed that 56%–62% are men.59,68 Surprisingly, in patients with HCM the incidence 
of AF is equal in men and women (19%–29% in men; 18%–26% in women).41,62,63 This 
could be due to the fact that women are diagnosed later than men.41
Iatrogenic Rhythm Disorders 
Iatrogenic rhythm disorders are also common in patients with HCM. Septal reduction 
therapies are aimed at reducing LV outfl ow tract obstruction, but can increase the 
risk of arrhythmias. The reduction in LV outfl ow tract obstruction can be achieved 
through 2 procedures. One procedure is ASA, in which a small amount of ethanol 
is administered through the coronary artery supplying the septum. This results in 
infarction of part of the septum. The infarct region may contain the right bundle 
branch; therefore, 36% of patients who underwent ASA develop right bundle 
branch block. In 12%, the left bundle branch is also involved, developing complete 
heart block.49 The other procedure used is surgical septal myectomy (SSM), which 
involves removal of septal tissue from the anterior portion of the IVS. 40% of patients 
undergoing SSM develop left bundle branch block, and 3% develop complete heart 
block.
In addition to bundle branch block, the two procedures have diff erent outcomes 
with regard to more detrimental arrhythmias. As ASA does not need open heart 
surgery, this procedure was considered to be of lower risk to patients than SSM. 
However, short-term mortality rates between the two procedures are comparable.64
Also, during long-term follow-up, no diff erences in mortality were seen.64 However, 
as ASA results in infarction, the scar can become an arrhythmogenic substrate. This is 
indeed the case, as patients who underwent ASA are more likely to need implantable 
cardioverter-defi brillator implantation65 and have more appropriate implantable 
cardioverter-defi brillator discharge. Therefore, SSM is the fi rst consideration for 
patients with HCM with drug-refractory HOCM.35 To our knowledge, no sex diff erences 
are found in iatrogenic rhythm disorders in patients with HCM.
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MOLECULAR BASIS FOR SEX DIFFERENCES IN 
HCM: LESSONS FROM ANIMAL MODELS
Studies in animal models of HCM-associated mutations have provided valuable insight 
into disease pathology and have given some initial insights into sex differences. 
Studies in mice have shown that the male sex predisposes to an earlier disease onset, 
which is consistent with clinical data.66,67 Male mice develop myocardial fibrosis more 
frequently, earlier, and more pronounced than their female counterparts.68 Although 
numerous animal models of HCM have been studied, only few have analyzed sex 
differences, which are discussed below (see Table 1).
MYH7
As mice predominantly express α-MyHC (encoded by MYH6), as opposed to β-MyHC 
(encoded by MYH7) expressed in humans, mouse models of HCM-associated MYH7 
mutations mutate the MYH6 gene (α-MyHC and β-MyHC are 93% identical in amino 
acid sequence). Sex differences in the hypertrophic response were observed in 
different HCM-associated MYH6 mutant mouse models. In a transgenic (TG) mouse 
model expressing MYH6 with both a R403Q mutation and a deletion in the actin-
binding site, the extent of hypertrophy was greater in female TG mice than in male 
mice, especially at older age.67,69,70 Although the increase in heart weight was greater 
in female mice, only male mice showed LV dilation.70 In line with patients with HCM, 
diastolic function was impaired in TG mice, but the dysfunction was more pronounced 
in male mice.67
However, these differences seemed model-dependent, as in a heterozygous mouse 
model carrying only the R403Q mutation, male mice showed more hypertrophy,68,71 
fibrosis, and disarray than did female mice.68
An increased Ca2+-sensitivity of the force development of myofilaments is a common 
finding in patients with HCM.72 Also, here sex differences are seen: 10–12-month-old 
female mice carrying the dual MYH6 mutation indeed showed a higher myofilament 
Ca2+-sensitivity, while male R403Q mice did not show a difference.69 The increased Ca2+-
sensitivity in female mice was in line with lower cardiac troponin I phosphorylation, 
which was not seen in male mice.69 In the heterozygous R403Q model, these findings 
were not reproduced, as no difference in Ca2+-sensitivity between the R403Q mice and 
the wild-type (WT) mice of either sex was found.71 However, male mice showed higher 
myofilament Ca2+-sensitivity than did female mice—both the R403Q and WT mice.71
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MYBPC3
In a recent study by Najafi  et al,73 a MYBPC3-targeted knock-in mouse model 
(heterozygous point mutation on exon six [HET]) was used to study sex diff erences. 
Male HET mice had higher end-systolic and end-diastolic lumens, higher LV and 
right ventricular weights, and a reduced maximal force-generating capacity of their 
cardiomyocytes as compared with female TG mice. Myofi lament Ca2+-sensitivity did 
not diff er between sexes.73 The cardiac response to exercise also diff ered between 
male and female HET mice. While female mice developed hypertrophy following 
the exercise protocol, male mice did not. The maximum force development of 
cardiomyocytes was increased only in male mice, while only female mice showed an 
increased Ca2+ -sensitivity of force development.
TNNT2
In an elegant study, Maass et al66 compared sex diff erences in two HCM-related TNNT2
mutations: a mouse model expressing a truncated cardiac troponin T (cTnT-trunc) and 
a TG model carrying a missense mutation (cTnT-R92Q).
As in HCM patients with TNNT2 mutations,74 mice with TNNT2 mutations showed 
no hypertrophy.75,76 A comparison of these two models revealed that sex modifi es 
LV remodeling depending on the mutation. In male and female cTnT-trunc mice, 
myocardial remodeling was similar, with reduced heart weight and low amounts 
of fi brosis.66 Marked modifying sex eff ects were seen in cTnT-R92Q mice. Female 
TG hearts had weights similar to those of female WT hearts, while male TG hearts 
were smaller. Male cTnT-R92Q mice showed a stronger induction of pathological 
hypertrophy markers and had more fi brosis.66
The cTnT-trunc and cTnT-R92Q TG mouse models discussed above implicate a sex 
eff ect on cardiac arrhythmias.66 HCM-associated TNNT2 mutations are known to 
increase susceptibility to SCD.74 Interestingly, in both TNNT2 mutation mouse models, 
male mice who received long-term adrenergic stimulation all died of SCD, while none 
of the female mice died.66 As female cTnT-R92Q TG mice did not show remodeling, but 
female cTnT-trunc mice did, the susceptibility to SCD does not seem to be mediated 
by the a priori presence of LV remodeling.
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CONCLUSIONS AND IMPLICATIONS FOR FUTURE 
RESEARCH
Sex plays an important role in cardiac pathophysiology. Differences in cardiac 
physiology between men and women start to develop at puberty and are maintained 
during aging. Sex differences are also observed in patients with HCM. Men are over 
represented in HCM patient cohorts, suggesting increased penetrance of HCM-
causing mutations in men; however, even though men show increased cardiac 
remodeling and fibrosis, diagnosed women tend to fare worse than men. There are 
only minor sex differences in the incidence of arrhythmias in patients with HCM.
Studies in mice models of HCM-associated mutations have shown that the male sex 
predisposes to an earlier onset of disease. Furthermore, development of myocardial 
fibrosis in male mice is more pronounced, has an earlier onset, and occurs more 
frequently than in their female counterparts.
In various clinical and animal studies, sex differences have been reported with 
regard to the physiology of the heart, HCM disease onset and severity, and cardiac 
arrhythmias. However, the underlying pathophysiological mechanisms are still not 
fully understood.
What is the effect of sex hormones on cardiac function in cardiomyocytes carrying 
HCM mutations? How come there is a greater extent of cardiac remodeling in HCM 
men while they seem to fare better? There seems to be no sex difference in SCD in 
patients with HCM, while sex hormones do affect depolarization and repolarization of 
the ventricles.
Answering these questions would be a vital step forward in understanding HCM 
disease pathophysiology and would provide a rationale for designing therapeutic 
options that would benefit both male and female patients with HCM.
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ABSTRACT
Background: One of the first clinically detectable alterations in heart function 
in hypertrophic cardiomyopathy (HCM) is a decline in diastolic function. Diastolic 
dysfunction is caused by changes in intrinsic properties of cardiomyocytes or an 
increase in fibrosis. We investigated whether clinical and cellular parameters of 
diastolic function are different between male and female patients with HCM at the 
time of myectomy.
Methods and Results: Cardiac tissue from the interventricular septum of patients 
with HCM (27 women and 44 men) was obtained during myectomy preceded by 
echocardiography. At myectomy, female patients were 7 years older than male 
patients and showed more advanced diastolic dysfunction than men evident from 
significantly higher values for E/e’ ratio, left ventricular filling pattern, tricuspid 
regurgitation velocity, and left atrial diameter indexed for body surface. Whereas 
most male patients (56%) showed mild (grade I) diastolic dysfunction, 50% of female 
patients showed grade III diastolic dysfunction. Passive tension in HCM cardiomyocytes 
was comparable with controls, and myofilament calcium sensitivity was higher in 
HCM compared with controls, but no sex differences were observed in myofilament 
function. In female patients with HCM, titin was more compliant, and more fibrosis was 
present compared with men. Differences between female and male patients with HCM 
remained significant after correction for age.
Conclusions: Female patients with HCM are older at the time of myectomy and 
show greater impairment of diastolic function. Furthermore, left ventricular and left 
atrial remodeling is increased in women when corrected for body surface area. At a 
cellular level, HCM women showed increased compliant titin and a larger degree of 
interstitial fibrosis.
Keywords: body surface area, cardiomyopathy, hypertrophic, diastole, humans, sex
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CLINICAL PERSPECTIVES AND RELEVANCE
What is New?
This study shows sex diff erences in patients with hypertrophic cardiomyopathy (HCM) 
at the time of myectomy with respect to diastolic (dys)function and parameters 
infl uencing passive stiff ness on a cellular level. 
• Female patients with HCM showed a higher degree of diastolic dysfunction 
(measured by echocardiography) at the time of myectomy.
• At a cellular level, female patients with HCM showed a higher amount of fi brosis 
and more compliant titin compared with male patients with HCM.
• One of the diagnostic criteria for HCM is a septal thickness of >15 mm, which is 
independent of sex. However, when corrected for body mass index, we found a 
higher indexed interventricular septum thickness in female compared with male 
patients with HCM.
What are the Clinical Implications?
• The higher indexed interventricular septum thickness in women implies a more 
progressed state of HCM in women than in men at time of surgery.
• The degree of diastolic dysfunction and sex-related cellular diff erences may 
be explained by the progression of the disease. Future research is needed to 
investigate whether sex-specifi c diagnostic protocols (indexed for body mass) are 
warranted.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular 
(LV) hypertrophy.1 It is the most prevalent monogenetic inherited cardiac disease, with 
a prevalence of 200 to ≤500 per 100.000 individuals.2 In ≈65% of patients with HCM, a 
causative mutation is identified, which is inherited in an autosomal dominant fashion.3 
Approximately, 80% of identified mutations are located in 2 genes that encode the 
thick filament proteins, cMyBP-C (cardiac myosin binding protein C; gene MYBPC3) 
and β-MyHC (β-myosin heavy chain; gene MYH7).4 Despite increased knowledge of 
the HCM-causing mutations, the exact path from genetic defect to cardiomyopathy is 
still largely unknown.
LV hypertrophy in patients with HCM is often asymmetrical and mainly affects the 
interventricular septum (IVS), which causes LV outflow tract (LVOT) obstruction. HCM is 
defined by a wall thickness ≥15 mm, although a cutoff value of 13 mm applies to first-
degree relatives.1 The hypertrophied myocardium is characterized by cardiomyocyte 
and myofilament disarray, reduced myofibrillar density, increased interstitial fibrosis, 
and vascular abnormalities.5,6 Although these structural changes are part of the 
more advanced (hypertrophied) stage of the disease, impaired relaxation is present 
at an early disease stage in mutation carriers without evident cardiac hypertrophy.7–9 
Interestingly, female patients with HCM have been described to show less ventricular 
remodeling compared with male patients,10,11 whereas several studies reported more 
severe diastolic dysfunction in women than in men with HCM.12,13 Within the latest 
cohort studies, women represent a minority of patients with HCM, with percentages 
ranging from 26% to 45%, suggesting lower disease penetrance in women.14,15 
Moreover, women are on average 9 years older than men at the time of HCM 
diagnosis.14,16 To better understand sex differences in HCM pathology, we studied 
tissue properties of cardiac samples obtained during surgical myectomy from a 
clinically well characterized group of female and male patients with HCM carrying a 
thick filament (MYH7 or MYBPC3) mutation. A comparison was made between female 
and male patients with HCM at the time of cardiac surgery.
Our study shows that women are on average 7 years older than men at the time of 
surgery. Greater diastolic dysfunction was present in female compared with male 
patients with HCM evident by diastolic grading. The sex difference in diastolic function 
was not explained by intrinsic properties of the sarcomeres because similar increases 
in myofilament Ca2+-sensitivity and no changes in passive stiffness were observed in 
single cardiomyocytes isolated from female and male HCM hearts compared with 
non-failing controls. A higher level of fibrosis in women compared with men may 
underlie the more severe impaired diastolic function in women, which was associated 
with an apparent compensatory shift toward more compliant titin isoform expression 
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in female HCM hearts. Overall, we see more severe changes in diastolic properties of 
the heart in female patients with HCM compared with male patients with HCM at the 
time of myectomy. Because the diagnostic criteria of LV wall thickness ≥15 mm does 
not take into account body surface area, disease severity might be underestimated in 
female patients with HCM and warrants future research.
MATERIALS AND METHODS
Myocardial Samples
Our study included patients carrying mutations in MYH7 (n=17) and MYBPC3 (n=54), 
of which 38% were women (mean age, 50±13 ranging from 6–72). Cardiac tissue 
from the IVS was obtained during myectomy surgery to relieve LVOT obstruction. LV 
tissue from 37 non-failing donors without a history of cardiac abnormalities was used 
as control (51% women; mean age of 41±14 ranging from 14–65). All samples were 
immediately frozen and stored in liquid nitrogen. Not all samples were suffi  ciently 
large to perform all analysis. Clinical cutoff  values are indicated by dotted lines in 
Figure 1. The average values of control cardiac samples are indicated by the dotted 
lines in Figures 2 through 5; data for male and female control samples are shown in 
Figure I in the Data Supplement. The study protocol was approved by the local ethics 
committees, and written consent was obtained.
Echocardiographic Measurements
Echocardiographic studies were done with commercially available systems and 
analyzed according to the American Society of Echocardiography guidelines.17
Maximal wall thickness, left atrial diameter (LAD), LV end-diastolic diameter, and LVOT 
obstrustion gradient were measured. LVOT obstruction was defi ned as a gradient ≥30 
mmHg at rest or during provocation. Mitral valve infl ow was recorded using pulsed 
wave Doppler from the apical four-chamber view. Mitral E and A velocity (cm/s) and 
deceleration time (ms) were measured. Pulsed wave tissue Doppler imaging was used 
to measure septal e’ velocity (cm/s). Continuous wave Doppler in the parasternal and 
apical four chamber was used to measure tricuspid regurgitation (TR) velocity (m/s).
Diastolic dysfunction was graded as follows: grade I when E/A ratio was ≤0.8 and E 
peak velocity ≤50 cm/s; grade III when E/A ratio ≥2. In patients with E/A ratio ≤0.8 
and E peak velocity >50 cm/s or E/A ratio >0.8 but <2, the E/e’ ratio (>14), indexed 
LAD (LADi; >24), and TR velocity (>2.8 m/s) were used to further diff erentiate diastolic 
function. When ≥2 of 3 variables were abnormal, left atrium (LA) pressure was elevated 
and grade II diastolic dysfunction was present. When 1 of 3 variables was abnormal, 
grade I diastolic dysfunction was present.18
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Figure 1. Influence of sex on echocardiographic parameters.
A. Wall thickness of the interventricular septum (IVS) was independent of sex (n=25 women/44 men). B. 
Female patients showed a higher E/e’ ratio compared with men (P<0.0001; n=13 women/29 men). C. Left 
ventricular (LV) filling pattern determined by the E/A ratio was more abnormal in female patients with 
hypertrophic cardiomyopathy (HCM) (P<0.05; n=15 women/33 men). D. Tricuspid regurgitation (TR) velocity 
was higher in female than in male patients with HCM (P<0.05; n=11 women/18 men). E. Indexed left atrial 
diameter (LADi) was higher in female compared with male patients with HCM (P<0.001; n=17 women/28 
men). F. Diastolic dysfunction graded per patient: female patients show greater impairment compared with 
men (P<0.0001; n=15 women/30 men). HCM values are illustrated relative to published values in the general 
population (i.e., normal values, indicated by dotted lines and marked areas).1,18,29 #Significant sex differences.
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Figure 2. Myofi lament passive tension.
A. Passive tension (Fpass) measured at diff erent sarcomere lengths in female (n=9) and male (n=10) 
hypertrophic cardiomyopathy (HCM) samples. B. Passive tension was measured at a sarcomere length of 2.2 
μm in a larger group of samples (15 female and 20 male HCM samples; 15 controls). No sex diff erences were 
observed in Fpass. C and D. Representative electron microscopy pictures of female and male HCM samples. 
E. Myofi bril density (MFD) was decreased in patients with HCM (n=9 women/15 men) in comparison with 
controls (n=9; P<0.0001). F. Passive tension at a sarcomere length of 2.2 μm corrected for MFD showed a 
trend toward an increase in patients with HCM in comparison with controls (P=0.0623) but no sex diff erence. 
Each data point refl ects a mean of cardiomyocytes/electron microscopy pictures measured per patient. 
*Signifi cant diff erences between HCM and controls.
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Isometric Force Measurements
Force measurements were performed in mechanically isolated single membrane-
permeabilized cardiomyocytes as described previously.19 In short, we measured 
passive tension at four sarcomere lengths ranging from 1.8 to 2.4 μm. All passive 
forces were normalized to cross-sectional area (i.e., cross-sectional area = width × 
depth × π / 4). To determine myofilament calcium sensitivity (pCa50), active tension 
was measured at sarcomere length of 2.2 μm, with different calcium concentrations.
Protein Analyses
Titin isoform gel electrophoresis was performed on patient samples as described 
previously.20 Samples were measured in triplicate, of which the mean was used. 
Phosphorylation of titin was assessed as described previously.21 Proteins were 
transferred to polyvinylidene difluoride membrane (Roth), and these were blocked 
with 3% BSA (Sigma). For assessment of titin phosphorylation, site-specific antibodies 
directed to Serine 4010 (N2 Bunique sequence domain; PKA [protein kinase A] and 
ERK2 [extracellular signal-regulated kinase 2] target) and Serine 11878 (PEVK [Pro-Glu- 
Val-Lys] domain; PKC [protein kinase C] and CaMKIId [Ca2+/ calmodulin dependent 
protein kinase II] target) were used (Eurogentec Belgium), visualized with enhanced 
chemiluminescence detection kit (Amersham) and scanned with Amersham Imager 
600. After stripping (Restore Western Blot Stripping Buffer; Thermo Scientific) and 
blocking in 3% BSA, membranes were incubated with an antibody directed to total 
titin (Eurogentec, Belgium), visualized with enhanced chemiluminescence detection 
kit (Amersham) and scanned with Amersham Imager 600.
To determine cMyBP-C protein level, proteins were separated on 4% to 15% precast 
Tris-HCl gels (BioRad) and stained with SYPRO Ruby. The level of cMyBP-C was 
expressed relative to α-actinin. The same gels were stained with ProQ Diamond to 
determine phosphorylation of cMyBPC.22 The phosphorylation level of cMyBP-C was 
normalized to cMyBP-C expression and values given as a fraction of controls, which 
were set to 1. Phosphorylation of PKA sites in cTnI (cardiac troponin I) was analyzed 
using a specific antibody directed against serine 23 and 24 (Cell Signaling). The 
distribution of phosphorylated forms of cTnI was analyzed using Phos-tag acrylamide 
gels.23
Expression levels of Ca2+-handling proteins PLN (phospholamban; Abcam) and SERCA2 
(sarcoplasmic reticulum Ca2+-ATPase 2) were determined by Western blot analysis 
using specific antibodies and normalized to actin.
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Histomorphometrical Analysis
Histomorphological analysis was performed on 5-μm cryosections. Tissue was stained 
using Picrosirius red staining to determine the extent of interstitial and replacement 
fi brosis, expressed as collagen volume fraction (%). Cardiomyocyte  myofi bril density 
(MFD) was determined in a subset of patients of all groups using electron microscopy 
as described previously.24 The sum of myofi bril area relative to cardiomyocyte area 
was expressed as a percentage.24,25
Data Analysis
Data in fi gures are presented as mean±SEM per group. Data in tables are presented 
as mean±SD per group. If data were normally distributed, means were compared 
with a Student t test; a Mann–Whitney U test was used when data were not 
normally distributed. To test sex diff erences in abnormality of clinical data, a χ2 test 
was performed. Correlations were tested by means of linear regression. P<0.05 was 
considered signifi cant, sex diff erences are indicated by a hashtag (#), and diff erences 
in comparison with controls are indicated by an asterisk (*). Because female patients 
with HCM are on average older than male patients with HCM, additional analyses 
were performed in which we corrected for age at myectomy. For this, we used a linear 
regression model with sex and age at myectomy as independent variables. Normality 
of residuals was checked. In case residuals were not normally distributed, a log 
transformation was used for the dependent variable. The data and analytic methods 
are available to other researchers on request for purposes of reproducing the results 
or replicating the procedure.
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RESULTS
Female Patients With HCM Are on Average 7 Years Older at the Time 
of Myectomy
Echocardiographic analysis was performed to study sex differences in cardiac diastolic 
parameters (Table 1). Detailed characteristics and parameters per patient are provided 
in Table I in the Data Supplement. Female patients with HCM were on average 7 years 
older than their male counterparts at the time of surgery (50±13 versus 43±13 years; 
P<0.05). IVS thickness was increased in all patients, meeting the wall thickness criteria 
of ≥15 mm, with a mean of 23±7 mm (Figure 1A). No difference was seen in absolute 
IVS thickness between women and men. LV end-diastolic diameter in our patient 
population was within normal range26 and showed no sex difference (Table 1). LAD 
was increased compared with control values26 but did not show a sex difference.
Greater Impairment of In Vivo Diastolic Function in Female Patients 
With HCM at the Time of Myectomy
Because diastolic impairment is one of the hallmarks of HCM, we looked for sex 
differences in in vivo diastolic function assessed by echocardiography at the time of 
myectomy. Echocardiographic measurements of diastolic function included E/e’ ratio, 
E/A ratio, and TR velocity (Table 1; Figure 1).18,27 E/e’ ratio is the ratio between early peak 
diastolic mitral valve flow (E in cm/s) and the movement of the mitral valve annulus 
during early diastole (e’ in cm/s). This ratio is a good indicator of LV filling pressure.28 
An E/e’ ratio <8 implies normal filling pressure, whereas an E/e’ ratio >15 indicates 
increased filling pressure.29 In 42 patients with HCM, E/e’ ratio was determined, of 
which 26 showed an increased E/e’ ratio (92% of women and 48% of men; P<0.01). The 
average E/e’ ratio was also significantly higher in the female HCM group compared 
with male (Figure 1B; 23.8±7.8 versus 14.8±3.4, respectively; P<0.0001). The normal 
range of LV filling pattern (E/A ratio) is between 0.8 and 2, and only 33% of our female 
patients fit within this range compared with 67% of our male patients (Figure 1C; 
P=0.10). TR velocity showed higher values in female compared with male patients 
with HCM (Figure 1D; 2.61±0.54 versus 2.15±0.54, respectively; P<0.05). Overall, LV 
filling pressure, LV filling pattern, and TR velocity were more abnormal in HCM women 
than in men (Figure 1). The differences in diastolic cardiac properties between female 
and male patients with HCM remained even after correction for age (Table 1; P values 
corrected for age).
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Sex diff erences in cardiac remodeling may be obscured by body size. IVS, LV end-
diastolic diameter, and LAD were, therefore, corrected for body surface area. After 
correction for body surface area, indexed IVS thickness (IVSi) was signifi cantly greater 
in HCM women compared with men with a diff erence of 2.8mm/m2 (Table 2). This 
might imply a more severe phenotype in our female HCM group. Correction of LV 
end-diastolic diameter for body surface area did not reveal a sex diff erence, whereas 
LA remodeling was aff ected more in female patients than in male patients evident 
from a signifi cantly higher LADi (Table 2). Longstanding diastolic dysfunction leads to 
enlargement of the LA, with an LADi ≥24 considered to be abnormal.26 An LADi above 
this cutoff  value was seen in 44% of our HCM patient cohort who were predominantly 
women (65%; P<0.01). The average LADi of male patients (22±3 mm/m2) falls within 
the normal range (15–24 mm/m2), whereas we observed a signifi cantly larger average 
LADi in women (Figure 1E; 26±3 mm/m2; P<0.001). After correction for age and IVSi, 
LADi values were still signifi cantly higher in female compared with male patients with 
HCM (Table 2; P values corrected for age).
Diastolic dysfunction can be graded into three groups: abnormal (grade I), pseudo 
normal (grade II), and restrictive relaxation (grade III). We graded our patients and 
found a signifi cant diff erence in distribution between female (n=15) and male (n=30) 
patients with HCM (Figure 1F; P<0.0001). Fifty percent of our female patients showed 
grade III diastolic dysfunction, whereas 56% of our male patients showed grade I 
diastolic dysfunction. Taken together, the echocardiographic data indicate a higher 
degree of diastolic dysfunction in HCM women at the time of myectomy.
Cardiomyocyte Stiff ness is Independent of Sex
Impaired relaxation may be caused by mutation-mediated changes in the intrinsic 
properties of cardiomyocytes, hypertrophy, or an increase in fi brosis.8,30 At the cellular 
level, diastolic function can be infl uenced by passive tension of sarcomeres, which 
was assessed by single cardiomyocyte measurements. Data were compared with 
non-failing donor tissue to determine whether the observed parameters deviate from 
control levels. Figure 2A demonstrates similar length dependency of passive tension 
in female and male samples. Passive tension was not diff erent between women 
(1.95±0.16 kN/m2) and men (1.91±0.10 kN/m2; Figure 2B). Moreover, the HCM group 
did not signifi cantly diff er from control values (2.15±0.32 kN/m2).
The number of myofi brils determine cellular passive tension and may be decreased 
as a result of hypertrophy.31 Therefore, passive tension was corrected for MFD. Figure 
2C and 2D show representative electron microscopy images of HCM tissue used to 
determine MFD. In line with our previous study,31 we found a signifi cant decrease 
in MFD in patients with HCM compared with controls (Figure 2E; 49±1% versus 
65±2%; P<0.0001). No sex diff erence in MFD was found in the HCM patient group. To 
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test the hypothesis that the normal passive tension observed in patients with HCM 
is caused by fewer but stiffer myofibrils, passive tension was corrected for MFD in a 
subset of patients (Figure 2F). Corrected passive tension was higher in patients with 
HCM compared with controls, although not significantly (3.73±0.23 versus 2.88±0.42, 
respectively). Hence, passive tension of cardiomyocytes cannot explain the sex 
difference in the degree of diastolic dysfunction.
Absence of Sex Difference in Myofilament Calcium Sensitivity
Apart from high passive tension, high calcium sensitivity may underlie impaired 
cellular relaxation.32 From previous studies, it is known that calcium sensitivity is 
increased in cardiomyocytes from patients with HCM.33 Consistent with previous 
studies, an increase in myofilament calcium sensitivity was observed in the HCM 
patient group compared with controls (Figure 3A and 3B; P<0.0001), but no influence 
of sex on calcium sensitivity was found.
Disease-related changes in myofilament protein composition and phosphorylation 
may underlie altered myofilament function. Mutations in MYBPC3 were associated with 
reduced cMyBP-C expression (i.e., haplo-insufficiency).34,35 Accordingly, in the present 
study, we observed cMyBP-C haplo-insufficiency in patients with HCM carrying 
MYBPC3 mutations, which was independent of sex (women, 0.55±0.02, and men, 
0.55±0.03, versus controls, 0.81±0.03; P<0.0001). PKA-mediated phosphorylation, via 
activation of the ß-adrenergic receptor pathway, is downregulated in HCM.36 cMyBP-C 
and cTnI are sarcomeric proteins that are phosphorylated by PKA and thereby may 
influence myofilament function (i.e., reduction in myofilament calcium sensitivity). In 
line with reduced PKA-mediated phosphorylation, phosphorylation levels of cMyBP-C 
were decreased in patients with HCM (women, 0.81±0.07, and men, 0.60±0.07) 
compared with controls (1.00±0.04; P<0.001). The sex difference in overall cMyBP-C 
phosphorylation may be explained by site-specific phosphorylation differences 
between women and men because cMyBP-C is phosphorylated at multiple sites, 
which are target for different kinases.37 The decrease was the largest in male patients 
(Figure 3C). A decrease was also found in cTnI phosphorylation in patients with HCM 
compared with controls (Figure 3D; women, 0.35±0.06, and men, 0.47±0.09, versus 
controls, 2.38±0.49; P<0.0001). No sex difference was found on cTnI phosphorylation. 
Accordingly, Phos-tag analyses of the different forms of cTnI phosphorylation 
(unphosphorylated, monophosphorylated, and bisphosphorylated) showed a similar 
pattern in women and men (Figure 3E).
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Men (n=44) N P Value Distribution P Value corrected 
for age
Age at 
myectomy, y  
50±13 (27) 43±13 (44) 71 <0.05 Normal
IVS, mm 23±9 (26) 22±6 (40) 66 0.65 Not normal 0.33*
LVOTO, mmHg  66±31 (23) 58±32 (39) 62 0.34 Normal 0.39
LVEDD, mm   43±5 (22) 43±6 (37) 59 0.81 Normal 0.77
LAD, mm 48±7 (20) 45±7 (33) 53 0.26 Normal 0.10
E, cm/s   95±35 (18) 74±21 (38) 56 <0.01 Normal 0.071
E/A ratio 1.8±1.0 (15) 1.3±0.5 (33) 48 0.10 Normal <0.05
E/e’ ratio 23.8±7.8 (13) 14.8±3.4 (29) 42 <0.0001 Normal <0.0001
TR velocity, cm/s 2.61±0.54 (11) 2.15±0.54 (18) 29 <0.05 Normal <0.05
Table 1. Patient characteristics and echo parameters of diastolic function.
This table shows the patient characteristics and echocardiographic parameters refl ecting diastolic function 
grouped by sex as mean±SD. Detailed characteristics and parameters per patient are shown in Tables I, II, 
and III in the Data Supplement. E indicates mitral E velocity; IVS, interventricular septum; LAD, left atrial 
diameter; LVEDD, left ventricular end-diastolic diameter; LVOTO, left ventricular outfl ow tract obstruction; 
and TR, tricuspid regurgitation. *Linear regression on log(IVS). Residuals were normally distributed.
Women Men N P Value Distribution P Value corrected 
for age
BSA, m2 1.8±0.3 (19) 2.0±0.1 (34) 53 <0.001 Normal
IVSi, mm/m2 13.3±5.3 (19) 10.5±1.8 (32) 51 <0.05 Not normal <0.01*
LVEDDI, mm/m2 23±3 (16) 21±3 (32) 48 0.12 Normal 0.10
LADi, mm/m2 26±3 (17) 22±3 (28) 45 <0.001 Normal <0.01
Table 2. LV and LA Dimensions Indexed for BSA.
Indexed LV and LA dimension as mean±SD. Detailed characteristics and parameters per patient are shown 
in Tables I, II, and III in the Data Supplement. BSA indicates body surface area; IVSi, indexed interventricular 
septum thickness; LADi, indexed left atrial diameter; LV, left ventricle; and LVEDDi, indexed left ventricular 
end-diastolic diameter. *Linear regression on IVSi. Residuals were normally distributed.
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Figure 3. Myofi lament calcium sensitivity.
A. Calcium–force relationships at a sarcomere length of 2.2 μm of female (n=11) and male (n=15) hypertrophic 
cardiomyopathy (HCM) samples are shifted to the left in comparison with controls (n=7). B. Myofi lament 
calcium sensitivity (pCa50) was signifi cantly higher in patients with HCM (P<0.0001; n=13 women/18 men) 
compared with controls (n=13), whereas no sex diff erence was observed. Each data point refl ects a mean 
of cardiomyocytes measured per patient. C. MyBP-C (myosin binding protein C) phosphorylation (P<0.001) 
was decreased in patients with HCM (n=10 women/19 men) compared with controls (n=12). D and E.
In comparison with controls (n=17), phosphorylation of cTnI was decreased in patients with HCM (n=15 
women/18 men), with an even distribution in (un)phosphorylated cTnI (cardiac troponin I) forms between 
women and men. F. PLN (phospholamban) expression was lower in female (n=16) than in male (n=30) 
patients with HCM. G. SERCA2 (sarcoplasmic reticulum Ca2+-ATPase 2) expression was lower in patients with 
HCM compared with controls (P<0.0001; n=11) with an even larger decrease in female than in male patients 
(P<0.05; n=16 women/28 men). H. The PLN/SERCA2 ratio was higher in patients with HCM compared with 
controls (P<0.05). *Signifi cant diff erences between HCM and controls. #Signifi cant sex diff erences.
Lower Expression of Ca2+-handling Proteins in Myectomy Samples 
From Female Compared With Male Patients With HCM
PLN and SERCA2 are key regulators of myocardial relaxation during diastole. PLN
expression levels did not diff er between patients with HCM and controls (4.45±0.66). 
There was, however, a lower expression of PLN in female compared with male patients 
with HCM (Figure 3F; 3.38±0.31 versus 4.44±0.33; P<0.05). SERCA2 expression was 
considerably lower in patients with HCM (women, 1.46±0.08, and men, 1.79±0.12) 
compared with controls (Figure 3G; 3.34±0.24; P<0.0001). SERCA2 also showed a 
sex diff erence with lower expression levels in female compared with male patients 
with HCM (P<0.05). PLN/SERCA2 ratio was higher in patients with HCM compared 
with controls (Figure 3G; women, 2.47±0.29, and men, 2.70±0.31, versus controls, 
1.32±0.18) but did not show a sex diff erence. When corrected for age, no signifi cant 
sex diff erence was present for the Ca2+-handling proteins SERCA2 and PLN.
More Compliant Titin in Female Patients With HCM
Another important contributor to diastolic function is titin.38,39 Titin functions as a 
molecular spring thereby modulating passive stiff ness of cardiomyocytes and has 
been shown to regulate passive stiff ness in an isoform dependent manner.39 In cardiac 
muscle, two major isoforms are identifi ed: a short, more stiff  isoform (N2B) and a long, 
more compliant isoform (N2BA). Both isoforms are co-expressed within the human 
heart and can be displayed in a N2BA/N2B ratio to describe titin-based passive 
stiff ness.
A representative titin gel is depicted in Figure 4A. Sex had a profound eff ect on titin 
isoform composition in patients with HCM because women showed more compliant 
titin compared with men (Figure 4B; P<0.05). This sex eff ect on titin composition was 
not seen in controls (0.58±0.06 [women] versus 0.70±0.09 [men]; mean value: controls, 
0.63±0.20). The male HCM group (0.74±0.04) showed no diff erence compared with 
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controls, but female patients with HCM had more compliant titin isoform (1.00±0.10) 
compared with controls (P<0.01). The titin N2BA/N2B ratio significantly correlates 
with diastolic dysfunction (Figure 4C; P<0.01; R2=0.29).
Phosphorylation of titin also influences passive stiffness of the cardiomyocytes. 
PKA-mediated phosphorylation at serine 4010 decreases passive tension, whereas 
PKC-mediated phosphorylation at serine 11878 increases passive tension.40,41 
Representative blots of both phosphorylation sites are shown in Figure 4D. PKA 
phosphorylation did not show sex differences (Figure 4E; women [n=10], 0.95±0.05, 
versus men [n=13], 0.96±0.07). In addition, no difference was observed in PKC 
phosphorylation of titin (Figure 4F; women [n=5], 1.07±0.19, versus men [n=6], 
1.21±0.31).
Our data show that titin isoform changed in a sex-dependent manner with a 
shift toward a more compliant isoform in women, whereas no sex differences in 
phosphorylation are present. The increase in compliant titin isoform seems to be 
related with the degree of diastolic dysfunction.
More Fibrosis in Female Patients With HCM
Stiffness of the cardiomyocyte is dependent on the cellular components mentioned 
above. However, changes in the extracellular matrix can influence cardiac stiffness as 
well. Both replacement and interstitial fibrosis are known to increase in patients with 
HCM during remodeling and negatively influence cardiac compliance.42,43 Figure 5A 
shows representative images of Picrosirius red stainings, from which collagen volume 
fraction was determined. As expected, our controls showed little fibrosis (1.21±0.23%), 
and no differences were found between women and men. Collagen volume fraction 
in patients with HCM was significantly increased compared with control values 
(P<0.0001), with a significantly larger increase in female patients with HCM compared 
with men (Figure 5B; 6.42±0.95% versus 4.18±0.66%; P<0.05).
Sex differences in titin isoform composition and fibrosis in the HCM patient group 
remained after correction for age (Table 3).
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Figure 4. Increased compliant titin isoform in female patients with hypertrophic cardiomyopathy 
(HCM).
A. Representative titin gel showing N2BA and N2B titin isoforms of patients with HCM. B. N2BA/N2B ratio was 
increased in female (n=18) patients with HCM in comparison with controls (P<0.01; n=15) and signifi cantly 
higher than in male (n=20) patients with HCM (P<0.05). C. Scatterplot showing a signifi cant correlation 
(linear regression) between N2BA/N2B ratio and the grade of diastolic dysfunction (P<0.01; R2=0.29). D.
Representative titin phosphorylation blots of PKA (protein kinase A) and PKC (protein kinase C) sites on 
titin. E and F. Phosphorylation of both the PKA (serine 4010) and PKC (serine 11878) site did not show sex 
diff erences. Each data point refl ects a mean titin ratio measured per HCM patient and control. *Signifi cant 
diff erences between HCM and controls. #Signifi cant sex diff erences.
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Figure 5. Higher amounts of fibrosis in hypertrophic cardiomyopathy (HCM) women.
A. Representative Picrosirius red staining on a female (11.9%) and male (5.5%) HCM sample. The deep red 
staining depicts fibrosis. B. Fibrosis was higher in female compared with male patients with HCM (P<0.05). 
Furthermore, the HCM group in total showed more fibrosis compared with controls (P<0.0001). Each data 
point reflects a mean collagen volume fraction (CVF) measured per HCM patient. F indicates female; and M, 
male. *Significant differences between HCM and controls. #Significant sex differences.
DISCUSSION
Here, we investigated whether changes in diastolic characteristics of the heart in 
patients with HCM at the time of cardiac surgery are sex dependent. Main findings 
of the study are that women with HCM have greater diastolic dysfunction than 
men at the time of surgery, apparent from the increased LV filling pressures, altered 
filling pattern, greater TR velocities, and more pronounced LA remodeling. Factors 
contributing to impaired relaxation in HCM are increased calcium sensitivity and 
fibrosis, with fibrosis being higher in women. Furthermore, the compliant titin 
isoform is increased in female patients with HCM, suggesting a sex difference in the 
compensatory response to the progression of diastolic dysfunction.
In this study, female patients with HCM who underwent myectomy were on average 
7 years older at time of surgery than men. Olivotto et al14 found an age difference of 
9 years at time of diagnosis and initial evaluation, with more advanced symptoms in 
female patients with HCM. Several other studies have confirmed these findings.15,44,45 
Women are underrepresented in the patient population in the present (38%) 
and multiple previous HCM studies (≈40%).10,14–16,43–48 We found greater diastolic 
dysfunction in our female patients with HCM, which is in line with a previous study.12 
The preload-independent measure for diastolic function (E/e’ ratio) was in the 
pathological range in 92% of our female HCM patient group compared with 48% of 
the male group. Increases in LAD reflect the chronic burden of increased diastolic 
pressures on the LA.46 In most of our HCM population, LAD was increased, confirming 
previous studies.49,50 We did not find a sex difference in the absolute values of LAD, 
but after indexing LAD for body surface area, LADi was significantly higher in women 
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than in men. LADi values in our female HCM group range from moderately to severely 
abnormal, whereas in our male group, values range from normal to mildly abnormal.26
LV wall thickness of ≥15 mm is currently the diagnostic criteria for HCM, without 
adjustment for body surface area or sex.1 In line with earlier published data, absolute 
IVS thickness is independent of sex.47,48 However, when we indexed IVS thickness 
for body surface area, female patients showed a greater IVSi compared with male 
patients. The increases of LADi and IVSi in our female patients could simply be because 
of the more advanced age. However, there was no correlation between age and IVSi 
and only a weak positive correlation between age and LADi (P<0.01; R2=0.20). There 
were only two parameters that signifi cantly correlated with age: LV fi lling pressure 
(E/e’) increases with age, whereas PLN expression decreases with age in both men 
and women (Figure II in the Data Supplement). In addition, after correction for age, in 
vivo echocardiographic parameters of diastolic dysfunction and cardiac remodeling 
(IVS and LADi) remained signifi cantly diff erent between female and male patients 
with HCM (Tables 1 and 2). Overall, our data show a more severe stage of cardiac 
dysfunction and remodeling in women than in men at the time of myectomy. 
The ratio between N2BA/N2B titin isoforms is an important contributor to 
cardiomyocyte stiff ness and thereby diastolic function. Specifi cally the ratio between 
the stiff er N2B isoform and the more compliant N2BA isoform.51,52 Our group of non-
failing control samples had a titin isoform ratio of 0.63±0.20, which is comparable with 
previously published data.53–55 We showed for the fi rst time a higher N2BA/N2B ratio 
in female compared with male patients with HCM. However, titin phosphorylation 
by PKA and PKC did not show sex diff erences. Because no sex diff erence in passive 
tension was observed, other post-translational modifi cations of titin (e.g., induced by 
oxidative stress)56 may counterbalance the higher level of compliant titin isoform in 
women. A correlation, independent of sex, was found between diastolic dysfunction 
and titin composition, which implies that the switch to longer titin isoforms is an 
attempt to compensate for the impaired relaxation. Despite the titin isoform change, 
women still show more severe diastolic dysfunction. A rat study showed that under 
metabolic stress, female rats show an increase of the compliant titin isoform.38
Furthermore, ovariectomized rats show an even greater increase, suggesting an 
infl uence of female hormones on titin isoform switch during stress. Estrogen does not 
seem to have a direct eff ect on titin isoform expression but could, during stress, act as 
a modulator enabling isoform switch.38 The increase in titin compliance could also be a 
reaction to the increase in interstitial fi brosis seen in patients with HCM; a correlation, 
however, was not found. Previous clinical studies in patients with HCM showed more 
fi brosis in men,10,57 except for Chen et al12 who showed no sex diff erence. These studies 
have measured fi brosis through late gadolinium enhancement. Measuring interstitial 
fi brosis with the latter technology is not possible and might explain the contrast to 
our results. 
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Although more compliant titin isoform was observed in female compared with male 
patients with HCM, we did not observe a sex difference in cardiomyocyte passive 
tension. Moreover, HCM values did not differ from control values. In line with our 
results, Hoskins et al58 did not find a difference in passive tension between HCM 
cardiomyocytes and controls. Correction for MFD also did not reveal a significant sex 
difference in passive tension. The increase in myofilament calcium sensitivity in HCM 
cardiomyocytes could partly explain the diastolic dysfunction, although our data 
suggest that sex is not an influencing factor regarding calcium sensitivity. The lower 
expression of PLN and SERCA2 in female compared with male patients with HCM may 
underlie the sex difference in diastolic dysfunction, although the PLN/SERCA2 ratio did 
not differ between female and male patients.





















Table 3. Protein analyses: differences between men and women before and after correction for age.
PLN indicates phospholamban; and SERCA2, sarcoplasmic reticulum Ca2+-ATPase 2.
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LIMITATIONS AND CLINICAL IMPLICATIONS 
Our study focused on patients who underwent myectomy, whereas many patients 
with HCM receive alcohol septal ablation (ASA) to relieve LVOT obstruction. Because 
age and disease severity may diff er between ASA and myectomy patients, the sex 
diff erence observed in the present study may not apply to the ASA group. Most HCM 
patient samples included in our study came from the Erasmus Medical Center. In a 
20-year period (1996– 2016), 23% of patients received ASA at the Erasmus Medical 
Center. There was no age diff erence between the ASA and myectomy group (52±16 
versus 52±15 years), and in both groups, 60% were men. Previous single-center 
and multicenter studies, which compared outcome in ASA and myectomy patients, 
showed that the age at the time of intervention was slightly higher in the ASA than in 
the myectomy group, but no diff erences were present in baseline functional/anatomic 
characteristics of the heart (similar maximal wall thickness, LV outfl ow tract gradient, 
and systolic and diastolic dysfunction).59–61 Thus, currently, there are no indications 
that disease severity is diff erent between ASA and myectomy patients.
The number of MYBPC3 mutations in our study is high compared with the previously 
reported average MYBPC3 mutation frequency (≈20%).62 In the Netherlands, HCM 
is dominated by three MYBPC3 founder mutations,63 which is why the percentage 
of MYBPC3 compared with MYH7 is relatively high. This may limit the translation of 
our observations to the general HCM population because of diff erences in disease 
onset and progression between mutation groups. However, no diff erence was found 
in disease penetrance between MYBPC3 founder mutations and other MYBPC3
mutations.63 A recent meta-analysis by Sedaghat-Hamedani et al62 reported an average 
mutation frequency of 20% in MYBPC3 and 14% in MYH7. The meta-analysis showed 
a lower mean age of onset in MYH7 (35 years) compared with MYBPC3 (39 years) and 
a higher risk of ventricular tachycardia in MYH7 compared with MYBPC3, whereas no 
diff erences were observed in mean IVS thickness and LVOT obstruction. The age of 
onset showed large heterogeneity in all mutation groups, which is characteristic for 
HCM. Nannenberg et al64 showed increased mortality risk in specifi c age categories 
(ranging from 10–19 years to 50–59 years) in HCM families with MYBPC3 mutations. 
These studies show that disease onset and progression are highly variable in all 
mutation groups. In our patient group, no diff erence was observed in age of onset, 
LVOT obstruction, and IVS thickness between MYH7 and MYBPC3 mutation groups, 
indicating that the clinical indications for myectomy were similar in both groups. 
Moreover, both mutation groups had a similar percentage of women, respectively 
41% in the MYH7 mutation group (7 of 17) and 37% in the MYBPC3 mutation group 
(20 of 54). The average age distribution was also comparable in both mutation groups 
(mean age: MYH7 group, 49 years in women and 44 years in men; MYBPC3 group, 48 
years in women and 44 years in men).
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To conclude, our clinical data show that women are older at time of operation and 
have more advanced diastolic dysfunction, even after correction for age. We found 
increased titin compliance, lower PLN and SERCA2 expression, and more interstitial 
fibrosis in female compared with male patients with HCM. Data from our HCM patient 
group suggest that disease severity may be underestimated in women with a similar 
IVS but higher IVSi compared with men.
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ABSTRACT
Background: Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited 
cardiac disease, with a prevalence of 1 in up to 200. In about 40% of patients no 
mutation is identified (sarcomere mutation negative, SMN) while mutations in 
different genes encoding sarcomere proteins account for most genotype-positive 
patients (sarcomere mutation positive, SMP). In a previous study (CHAPTER FOUR), 
we observed more diastolic dysfunction at the time of myectomy in female compared 
to male HCM patients with tick filament gene mutations. Here we define if sex-
differences in diastolic dysfunction and cardiac remodeling are dependent on the 
underlying genotype.
Methods and Results: Cardiac tissue from the interventricular septum of HCM 
patients was obtained during myectomy surgery to relieve LV outflow tract obstruction. 
Echocardiographic measurements were obtained and analysis were performed to 
determine capillary density, fibrosis and titin isoform composition. Our study included 
patients carrying the following mutations: MYH7 (n=17) and MYBPC3 (n=53) (THICK 
filament mutations; 28 women and 42 men), TNNI3 (n=4), TNNT2 (n=3) and TPM1 (n=1) 
(THIN filament mutations; 4 women and 5 men); additionally 48 SMN patients were 
included (22 women and 26 men). The SMN group shows less cardiac remodeling 
which coincided with less severe diastolic dysfunction compared to the SMP groups. 
Female patients showed more severe cardiac remodeling (higher septal thickness and 
left atrial dimension) and diastolic dysfunction compared to male patients, which was 
independent of genotype.
In the SMP group women show significantly higher fibrosis compared to men, this 
difference was not found in the SMN group. Titin was more compliant in women of 
the THICK filament group compared to men. This sex-difference was not found in 
THIN filament group and SMN group, while a lower capillary density was observed in 
female compared to male patients in all groups.  
Conclusion: Overall, diastolic dysfunction and cellular remodeling are greater in 
the SMP groups compared to the SMN group while SMN patients are older at time 
of myectomy. Women show greater diastolic dysfunction in all patient groups which 
coincided with a lower capillary density.  
Keywords: hypertrophic cardiomyopathy, sex-differences, mutation, remodeling, 
diastolic dysfunction
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INTRODUCTION
With a prevalence of 1 in up to 200, hypertrophic cardiomyopathy (HCM) is the most 
prevalent inherited cardiac disease.1,2 The mutations are most frequently found in 
genes encoding sarcomere proteins, predominantly the thick fi lament proteins 
β-myosin heavy chain (MYH7) and cardiac myosin-binding protein C (MYBPC3).3
Approximately 9%4 of all mutations are found in genes encoding thin fi lament 
proteins including cardiac troponin T (TNNT2), cardiac troponin I (TNNI3) and cardiac 
tropomyosin (TPM1). In about 40% of patients no pathogenic gene variant is found. 
The latter group is referred to as sarcomere mutation-negative (SMN) HCM.5 The SMN 
patient group shares the same phenotype as HCM sarcomere mutation-positive (SMP) 
patients including left ventricular (LV) hypertrophy, interstitial and/or replacement 
fi brosis and myocyte disarray and malalignment,6 although diff erences in pathological 
and clinical parameters have been reported as well. 
In general, SMP patients present at earlier age and have a higher prevalence of family 
history of HCM.7–9 LV thickening in SMN patients is more uniform in contrast to the 
asymmetric thickening in SMP patients.10 Moreover, in vivo microvascular dysfunction 
was more severe in SMP than in SMN,11 and more extracellular volume and higher 
extent of late gadolinium enhancement, indicative for more fi brosis, was observed in 
SMP than in SMN.12 One of the fi rst clinical signs of HCM is diastolic dysfunction which 
may be the result of mutation-mediated changes in the heart muscle.13,14 Furthermore, 
SMP in contrast to SMN show a two-fold increased risk for adverse clinical outcomes, 
such as heart failure, sudden cardiac death, atrial fi brillation and transplant or the 
need of a ventricular assist device.9   
Recently we have found sex-diff erences in diastolic dysfunction and cardiomyocyte 
and extracellular matrix properties in a SMP HCM patient group carrying thick 
fi lament gene mutations.15,16 Our study showed more severe diastolic dysfunction 
and more cellular remodeling at the time of myectomy in women compared to men 
with mutations in the thick fi lament genes MYH7 and MYBPC3. It is unknown if this 
sex-diff erence also holds true for patients with thin fi lament mutations or SMN HCM 
patients. Here we investigated if these sex-diff erences are specifi c for thick fi lament 
mutations, or an independent characteristic of HCM. We thereto compared our 
previously reported data in HCM patients with thick fi lament mutations (CHAPTER 
FOUR and SIX) to HCM patients carrying thin fi lament mutations (TNNT2, TNNI3, TPM1
(THIN fi lament)) and SMN patients.  




Cardiac tissue from the interventricular septum (IVS) of HCM patients was obtained 
during myectomy surgery to relieve LV outfl ow tract (LVOT) obstruction. Our study 
included patients carrying the following mutations: THICK fi lament mutations: 
MYH7 (n=17; 7 women and 10 men), MYBPC3 (n=53; 21 women and 32 men); THIN 
fi lament mutations: TNNI3 (n=4; 2 women and 2 men), TNNT2 (n=3; 1 woman and 2 
men) and TPM1 (n=1; 1 men)). Additionally 48 SMN (22 women and 26 men) patients 
were included who tested negative for  ≥ 8 pathogenic sarcomere genes (Figure 
1). All myocardial samples were immediately frozen and stored in liquid nitrogen. 
The local Ethics Committees have approved the study protocol and written consent 
was obtained. Note that data from the THICK fi lament group have been reported 
previously. 15,16
Figure 1. Overview of sarcomere mutations in this study.
Our study consist of 126 HCM patients with mutations in fi ve genes which are defi ned as disease-causing 
gene variants. 62% of patients are sarcomere mutation positive (SMP), with a small group carrying a 
mutation in genes encoding thin fi lament proteins (THIN fi lament; 6%). Abbreviations: MYBPC3 (gene 
encoding myosin binding protein-C); MYH7 (gene encoding myosin heavy chain); TNNI3 (gene encoding 
cardiac troponin I); TNNT2 (gene encoding cardiac troponin T); TPM1 (gene encoding cardiac tropomyosin); 
SMN (sarcomere mutation negative); SMP (sarcomere mutation positive; THICK fi lament: patients carrying a 
MYBPC3 or MYH7 mutation.
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Echocardiographic Measurements
Maximal wall thickness, left atrial diameter (LAD), LV end-diastolic diameter (LVEDD), 
and LVOT obstruction gradient were measured. Mitral valve infl ow was recorded using 
pulsed wave Doppler from the apical four chamber view. Mitral E and A velocity (cm/s) 
were measured. Pulsed wave tissue Doppler imaging was used to measure septal 
e’ velocity (cm/s), and continuous wave Doppler in the parasternal and apical four 
chamber to measure tricuspid regurgitation (TR) velocity (m/s). Diastolic dysfunction 
was graded as follows: grade I when E/A ratio ≤ 0.8 and E peak velocity ≤ 50 cm/s; 
grade III when E/A ratio ≥ 2. In patients with E/A ratio ≤ 0.8 and E peak velocity > 50 
cm/s or E/A ratio > 0.8 but < 2, the E/e’ ratio (>14), LAD corrected for body mass index 
(LADi) (>24) and TR velocity (> 2.8 m/s) were used to further defi ne diastolic function.17
Protein Analyses
Titin isoform gel electrophoresis was performed on patient samples as previously 
described.18 
Histomorphometrical Analysis
Histomorphological analysis was performed on 15% gelatin fi xed myocardial tissue 
sectioned at 5 µm. Tissue was stained with Picrosirius Red to determine the extent 
of interstitial fi brosis. Capillary density was determined by the number of capillaries 
per mm2. Cryosections were incubated with a primary antibody (Monoclonal 
Mouse anti-Human CD31, Endothelial cell; Clone JC70A; DAKO; REF M0823) and 
secondary antibody (EnVision HRP α-mouse/rabbit (undiluted; DAKO). Staining was 
visualized using 3.3’-diaminobenzidine (0.1 mg/mL, 0.02% H2O2), the sections were 
subsequently counterstained with hematoxylin.
Data Analysis
Data was presented as mean±SEM per group, two-way ANOVA tests were performed. 
P<0.05 was considered signifi cant. 
149460_THESIS.indb   107 8-3-2021   14:34:15
G
enotype- and Sex-specific D
ifferences                     109
108
RESULTS 
Clinical and Cardiac Characteristics
In our patient group there is a striking genotype difference in age at time of myectomy, 
the THIN filament and SMN group are on average 10 years older (56±6 and 56±2) 
compared to the THICK filament group (46±2; p<0.01; Table 1). Recently, we have 
published that women are 7 years older at time of myectomy in HCM patients carrying 
a MYBPC3 or a MYH7 mutation.15 Here we have expanded our study population to 
include THIN and SMN patients. On average, female HCM patients were 5 years older 
compared to male HCM patients at time of myectomy (p<0.05; Table 2). In the THICK 
filament and SMN groups, women were respectively 5 and  6 years older compared to 
men, while in the THIN filament group women were 10 years younger. 
HCM is characterized by asymmetric ventricular hypertrophy, most frequently of the 
interventricular septal wall. One of the current diagnostic criteria for HCM is a maximal 
LV wall thickness of ≥15 mm.5 Here we found a significant difference in IVS thickness 
at the time of myectomy between the different mutation groups. IVS thickness was 
significantly smaller in the THIN filament (19±1 mm) and SMN (19±1 mm) group versus 
23±1mm in the THICK filament group (Table 1). When indexed for BSA, this genotype 
difference was still present (Table 1). In all groups women had a significantly greater 
IVSi compared to men (p<0.05; Figure 2A and Table 2). 
LVOT obstruction (measured at rest) was similar in all genotype groups (Table 1), but 
showed a sex difference in the overall HCM group with a greater LVOT obstruction in 
women compared to men (p<0.05; Table 2). As part of LV hypertrophic remodeling, 
HCM disease evolution includes a reduction in left ventricular end diastolic diameter 
(LVEDD). No significant difference was present in LVEDD between the different HCM 
groups (Table 1), and there was no overall sex-specific difference found in LVEDD 
(Table 2). However, within the THIN filament and SMN group LVEDD is smaller in 
women compared to men (p<0.05; Table 2). This sex-specific difference in LVEDD 
disappeared when LVEDD was corrected for BSA (LVEDDi). There was a significant 
genotype-specific difference in left ventricular end systolic diameter (LVESD; p<0.01; 
Table 1), with a higher diameter in the SMN patient group compared to the SMP 
patient groups which remained when corrected for BSA. There was no overall sex-
difference in LVESD (Table 2) but within the THICK filament group women showed 
significantly smaller LVESD compared to men. When LVESD was corrected for BSA 
(LVESDi) sex-differences were observed in the overall HCM group (p<0.05; Table 2). 
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Figure 2. Clinical and cardiac characteristics
A. IVSi is higher in THICK vs THIN and SMN HCM patients (p<0.05) and in HCM women compared to men 
(p<0.01). B. LV fi lling pressures are higher in HCM women compared to men irrespective of genotype 
(p<0.001). C. Overall LADi does not show genotype- or sex-diff erences. However within the THICK fi lament 
and SMN groups LADi is higher in women compared to men (p<0.001). Abbreviations: IVSi: interventricular 
septum thickness indexed by body surface area; THICK fi lament: HCM patients carrying a MYBPC3 or MYH7
mutation; THIN fi lament: HCM patients carrying a TNNT2, TNNI3 or TPM1 mutation; SMN: sarcomere mutation 























Figure 3. Diastolic dysfunction.
A. Grading of diastolic dysfunction by genotype. Diastolic dysfunction is less impaired in the SMN patient 
group with only 7% of patients in grade III dysfunction compared to 30% and 25% in the THICK and THIN 
fi lament groups, respectively. B. Diastolic dysfunction is worse in HCM women compared to men with 74% 
in grade II and III diastolic disfunction compared to 45% in men. 
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Diff erences in Diastolic Dysfunction 
Shortly before the time of myectomy in-vivo diastolic function was assessed by 
echocardiography. A good indicator for LV fi lling pressure is the E/e’ ratio19 which 
is comparable between the genotype groups (Figure 2B). LV fi lling pressures are 
signifi cantly higher in women compared to men, irrespective of genotype (p<0.0001). 
When diastolic dysfunction is present for longer periods the left atrium will dilate 
due to diastolic volume and pressure overload.20 LAD showed no genotype or sex-
diff erence (Table 1 and 2). When LAD was indexed for BSA (LADi) we found a higher 
LADi in the overall female HCM group compared to the male group (p<0.001; Figure 
2C and Table 2). LADi values in our female HCM group range from mildly (24-26 
mm/m2) to moderately (27-29 mm/m2) abnormal (lower to upper 95% CI of mean: 
24.7-27.3 mm/m2), while in our male group values range from normal (<24 mm/m2) 
to mildly abnormal (lower to upper 95% CI of mean: 22.2-24.2 mm/m2).21 Within the 
THICK fi lament and SMN group women had greater LADi compared to men (p<0.001). 
This sex-diff erence was not seen in the THIN fi lament group. 
Based on several cardiac parameters (i.e. E/A ratio, E/e’ ratio, TR velocity and 
LADi),  diastolic dysfunction can be graded into three groups: abnormal, pseudo 
normal and restrictive relaxation.17,19  When we combine all the above mentioned 
echocardiographic parameters we graded diastolic dysfunction per patient (Figure 
3 and Table 3). The SMN patients have less diastolic dysfunction at the time of 
myectomy to the SMP patients, illustrated by the lower percentage of grade III 
diastolic dysfunction compared to the SMP group (Figure 3A). Female HCM patients 
show worse diastolic dysfunction compared to male HCM patients, which holds true 
for all genotype groups (Figure 3B). Overall, 26% of HCM women showed grade I 
diastolic dysfunction compared to 55% of HCM men, while the percentage of women 
with grade III diastolic dysfunction was larger compared to the percentage seen in the 
male HCM group.  
In conclusion, at the time of myectomy the SMP patient groups show a more severe 
stage of cardiac remodeling and diastolic dysfunction compared to the SMN patient 
group, and female HCM patients show greater impairment of diastolic dysfunction 
compared to male HCM patients in all genotype groups.   




















THICK filament group (16 women and 31 men)
HCM 5 MYBPC3 F 41 3.8 1.1 12.5 26.6 - 3
HCM 12 MYBPC3 M 37 2.0 1.0 15.0 20.2 - 3
HCM 16 MYH7 M 55 2.0 0.8 18.6 27.8 1.2 3
HCM 19 MYBPC3 M 69 1.2 0.7 17.5 24.6 - 2
HCM 24 MYBPC3 F 62 2.6 1.3 37.1 24.6 3.1 3
HCM 26 MYBPC3 F 57 0.7 0.4 13.3 27.9 - 1
HCM 32 MYH7 M 43 1.0 0.6 10.7 20.7 - 1
HCM 34 MYBPC3 F 47 2.0 0.9 18.3 23.0 3.0 3
HCM 36 MYBPC3 M 22 0.7 0.4 16.0 - - 1
HCM 42 MYBPC3 M 32 1.0 0.7 14.2 26.1 - 2
HCM 42B MYH7 F 46 3.4 0.8 20.3 24.1 2.6 3
HCM 43 MYBPC3 M 60 2.0 0.8 14.5 - - 3
HCM 47 MYBPC3 M 55 1.6 1.1 21.0 - 2.9 2
HCM 52 MYBPC3 F 24 1.1 0.9 18.9 25.5 2.5 2
HCM 58 MYBPC3 M 37 1.1 0.7 16.3 23.1 - 1
HCM 60 MYBPC3 F 45 0.7 0.6 16.9 23.6 1.9 1
HCM 62 MYBPC3 M 36 2.4 1.1 19.5 22.3 1.8 3
HCM 67 MYBPC3 M 33 1.2 0.5 16.8 23.4 - 1
HCM 71 MYBPC3 M 49 0.8 0.5 10.2 21.7 2.3 1
HCM 73 MBYPC3 M 60 1.3 1.0 15.2 - - 1,2 (high LAD 2)
HCM 80 MYH7 M 34 1.5 0.9 14.3 - 1.4 1
HCM 82 MYBPC3 M 71 0.9 0.7 16.1 29.4 2.2 2
HCM 101 MYBPC3 M 20 1.3 0.5 11 18.7 - 1
HCM 103 MYBPC3 M 26 1.3 0.7 13.8 21.7 1.4 1
HCM 104 MYBPC3 M 33 1.1 0.6 8.9 17.8 - 1
HCM 106 MYH7 M 35 0.9 0.8 11.5 - 2.1 1
HCM 110 MYBPC3 M 39 2.5 0.8 8.5 - 2.4 3
HCM 113 MYBPC3 F 21 1.3 0.7 23.1 26.3 2.3 2
HCM 114 MYH7 M 69 0.6 0.6 12.9 - 2.1 1
HCM 119 MYH7 M 41 1.3 1.1 20.4 25.7 1.4 2
HCM 120 MYBPC3 M 27 1.4 0.8 14 20.5 2.3 1
HCM 121 MYBPC3 F 54 0.9 1.0 19.8 20.5 1.5 1
HCM 122 MYBPC3 M 50 0.7 0.7 18.8 - 2.5 1
HCM 123 MYBPC3 F 59 1.2 1.4 32.9 - - 1,2 (high LAD 2)
HCM 124 MYBPC3 M 53 0.6 0.5 13.5 21.0 2.2 1
HCM 130 MYH7 M 72 2.6 1.3 18.6 20.8 3.3 3
HCM 133 MYBPC3 M 58 0.9 0.6 12.5 20.8 2.4 1
HCM 145 MYH7 M 28 1.5 0.6 - - - 1,2 (small LAD  1)
HCM 148 MYBPC3 F 51 1.0 0.7 17.3 25.7 - 2
HCM 150 MYBPC3 F 57 2.5 1.3 25 25.0 - 3
HCM 157 MYH7 F 65 2.4 1.9 33.9 27.3 3.3 3
HCM 159 MYBPC3 M 40 1.0 0.7 17.9 22.9 2.5 1
HCM 166 MYH7 F 66 0.8 1.1 32.4 - - 1,2 (high LAD 2)
HCM 169 MBYPC3 M 52 0.9 0.7 15.9 - 2.3 1
HCM 180 MYBPC3 F 51 2.25 0.9 - - - 3
HCM 185 MYBPC3 M 53 0.9 0.6 15.5 19.6 - 2
FL 1009 MYBPC3 F 67 U U U U U 3
THIN filament group (3 women and 5 men)
HCM 54 TPM1 M 65 1.9 1.3 22.4 19.0 2.7 1
HCM 55 TNNI3 M 46 1.1 0.7 26.7 31.2 - 2
HCM 59 TNNI3 M 66 0.6 0.4 13.1 21.8 - 1
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HCM 132 TNNT2 F 15 2.3 0.8 17.5 25.3 2.0 3
HCM 163 TNNI3 F 64 0.5 0.4 16.3 22.5 - 1
HCM 170 TNNI3 F 69 0.8 0.7 36.8 24.1 2.0 2
HCM 173 TNNT2 M 58 2.0 1.0 16.6 28.4 2.7 3
HCM 175 TNNT2 M 61 0.8 0.6 12.5 21.6 2.3 1
Sarcomere mutation negative HCM patients (19 women and 21 men)
HCM 13 SMN M 46 1.2 1.1 - 22.9 - 1
HCM 14 SMN M 38 0.9 0.6 - 22.1 - 1
HCM 15 SMN F 72 1.0 1.4 16.8 35.1 - 2 
HCM 20 SMN M 57 0.7 0.7 18.2 30.3 - 2
HCM 21 SMN F 75 0.7 0.5 16.1 23.9 - 1
HCM 22 SMN M 52 1.0 0.9 11.5 23.6 - 1
HCM 23 SMN F 73 0.8 1.1 32.4 35.1 2.4 2
HCM 25 SMN M 58 1.0 1.0 21.2 26.7 - 2
HCM 30 SMN F 72 1.6 1.3 - 27.7 2.8 2
HCM 39 SMN M 49 1.0 0.5 11.3 21.0 - 1
HCM 41 SMN M 46 2.9 1.0 15.3 28.3 - 3
HCM 45 SMN M 52 0.9 0.6 22.9 26.0 - 2
HCM 46 SMN F 53 0.8 0.8 17.9 22.6 - 1
HCM 56 SMN M 68 1.1 0.9 22.3 28.6 3.0 2
HCM 61 SMN F 73 1.4 1.2 18.4 24.7 3.5 2
HCM 74 SMN F 46 0.9 0.6 18.8 21.5 - 1
HCM 76 SMN F 56 0.8 0.7 18.0 22.9 2.5 1
HCM 81 SMN F 60 0.9 0.7 22.2 24.6 - 2
HCM 84 SMN M 52 3.7 1.1 - 23.6 - 3
HCM 87 SMN F 53 1.0 1.0 38.0 25.5 2.0 2
HCM 89 SMN M 59 1.1 1.3 27.2 21.5 - 1
HCM 90 SMN M 53 1.0 0.8 - 21.7 - 1
HCM 91 SMN M 26 1.6 0.8 17.8 19.3 2.0 1
HCM 96 SMN M 74 1.0 0.7 18 27.1 2.5 2
HCM 98 SMN M 63 1.3 1.2 19.4 21.6 3.0 2
HCM 102 SMN F 69 1.1 0.9 22.2 24.7 - 2
HCM 105 SMN M 65 1.1 1.1 22.9 24.3 2.6 2
HCM 111 SMN F 65 1.0 0.7 18.9 - 2.5 1,2 (high LAD 2)
HCM 112 SMN F 74 0.6 0.6 29.5 - - 1
HCM 115 SMN F 21 1.3 0.8 16.0 - 2.7 1,2 (high LAD 2)
HCM 117 SMN F 50 0.8 1.0 24.7 30.0 2.9 2
HCM 125 SMN M 66 2.7 0.9 15.2 23.7 3.1 3
HCM 156 SMN F 54 0.8 1.0 33.3 19.7 - 2
HCM 162 SMN F 56 0.7 0.7 28.2 20.7 - 1
HCM 167 SMN F 68 0.8 0.6 21.5 - - 1,2 (high LAD 2)
HCM 168 SMN M 46 1.0 1.0 20.4 22.4 - 1
HCM 171 SMN M 44 1.0 0.8 17.8 24.2 - 2
HCM 172 SMN M 57 0.7 0.6 16.2 - - 1
HCM 176 SMN M 65 0.6 0.5 10 22.1 - 1
HCM 179 SMN F 62 0.9 1.2 26.8 24.0 - 2
Table 3. Diastolic function parameters per patient.
MYBPC3: gene encoding cardiac myosin-binding protein; MYH7: gene encoding myosin heavy chain; TPM1: gene 
encoding cardiac tropomyosin; TNNI3: gene encoding cardiac troponin I; TNNT2: gene encoding cardiac troponin 
T; SMN: sarcomere mutation negative patients; F: female patients; M: male patients; y: year; E/A ratio: ratio between 
early and late fi lling of the left ventricle; E wave: early fi lling of the left ventricle; E/e’ ratio: ratio between early fi lling 
and mitral movement; LADi: left atrial diameter indexed by body surface area; TR velocity: velocity over the tricuspid 
valve; U: unknown; LAD: left atrial diameter. 
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Differences in Cellular Remodeling
Diastolic dysfunction may be explained by cardiac remodeling including hypertrophy 
and expansion of the extracellular matrix. During remodeling both replacement 
and interstitial fibrosis are known to increase and negatively influence myocardial 
compliance.22,23 Figure 4A shows the amount of fibrosis per mutation group and 
sex. There is a significant genotype-specific difference with the lowest amount of 
fibrosis in the SMN group compared to the highest amounts in the THICK filament 
group (p<0.01). Our previous studies showed a higher amount of fibrosis in female 
compared to male HCM patients with THICK filament mutations.15,16 Accordingly, in 
the present HCM patient group women show higher amounts of fibrosis compared to 
men (5.1±0.7 vs 3.0±0.3; p<0.01). However, within the SMN group this sex-difference 
is not apparent. 
A common phenomenon in HCM patients is microvascular dysfunction, which may 
contribute to an increase in fibrosis and disease progression.11,24,25 Capillary density is 
decreased in HCM patients compared to controls and decreases even further when 
the disease progresses (CHAPTER SIX).16 All HCM groups show a significant sex-
difference, with a lower capillary density in women compared to men (Figure 4B; 
p<0.01). 
Titin is another important factor that contributes to myocardial compliance and 
thereby to diastolic function.26,27 The increase of compliant titin (N2BA) relative to the 
stiff (N2B) isoform showed a genotype difference (Figure 4C; p<0.05) with a greater 
increase in the SMP groups compared to the SMN group (0.9±0.05 vs 0.7±0.04; 
p<0.05). We previously found a larger increase in the compliant titin isoform in female 
than male HCM patients compared to controls.15,16 Here we found the same sex-
difference in titin isoform composition in the THICK filament and SMN group, while no 
sex difference was observed in the THIN filament group. 
To conclude, cellular remodeling is less apparent in the SMN group compared to the 
SMP groups, with less fibrosis and a lower N2BA/N2B ratio. Overall, we found profound 
sex-differences in cellular remodeling in HCM patients independent of genotype.   
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Figure 4. Diff erences in cellular remodeling.
A. Fibrosis is genotype- and sex-specifi c with higher amounts of fi brosis in SMP vs SMN (p<0.01) and women 
vs men (p<0.001). However, the sex-eff ect is not seen in the SMN patient group. B. There is a signifi cant 
genotype-diff erence in titin composition (p<0.05). C. Capillary density is lower in HCM women compared 
to men (p<0.01). Abbreviations: SMP: sarcomere mutation positive HCM patients; SMN: sarcomere mutation 
negative HCM patients; THICK fi lament: HCM patients carrying a MYBPC3 or MYH7 mutation; THIN fi lament: 
HCM patients carrying a TNNT2, TNNI3 or TPM1 mutation. 
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DISCUSSION
We have included 126 HCM patients in this study with different genotypes. Only a 
limited number of patients (8) carry a THIN filament mutation. Therefore, this genotype 
group is significantly smaller than the SMP (70) and SMN groups (48). However, the 
distribution of gene mutations in this study is comparable to the reported HCM 
population.5 Our study included 53 women compared to 73 men (42% women), which 
is also in line with previous reports showing that women are underrepresented in 
HCM populations.15,28,29 
At the time of myectomy SMN patients are on average 10 years older than SMP 
patients, which is in line with previous studies showing an age difference of 8 years 
between MYH7 patients and THIN filament/SMN patients.7,8,30 We found an age 
difference of 5 years, i.e. women are older than men, which is in line with our previous 
study (CHAPTER FOUR) with an age difference of 7 years. Interestingly, the THIN 
filament group shows an opposite sex-effect: women are on average 10 years younger 
than men, though this is explained by the inclusion of a young female patient (15 
years, Table 3). When we exclude her, the two women within the THIN filament group 
are on average 8 years older than the men in this group (67±3 versus 59±4 years). 
We showed a significantly smaller IVS thickness and IVSi in the THIN filament and 
SMN groups versus the THICK filament group, which is consistent with previous 
studies.10,31–33
Diastolic dysfunction measured by echo cardiography is less severe in SMN compared 
to SMP HCM patients at the time of myectomy as illustrated in Figure 3A. Left 
ventricular stiffness seems comparable between al groups with a LV filling pressure 
that shows no genotype effect, as goes for LVEDD(i). However, especially in women, 
LVESD(i) is greater in the SMN group compared to the SMP groups. This might be 
explained by a smaller IVS(i) in the SMN versus the SMP group. The fact that there is 
less pronounced diastolic dysfunction in this group might explain the age difference 
with the SMP groups. 
Women show greater impairment of diastolic function irrespective of genotype, with 
higher LV filling pressures, and more advanced cardiac remodeling illustrated by 
higher IVSi and LADi values compared to men. However, the sex-differences may be 
explained by the fact that female patients are older at time of myectomy compared to 
male patients, though in our previous study in patients with thick filament mutations 
the sex-specific differences in diastolic function and cardiac remodeling were still 
present after correction for age. Nevertheless, worsening of symptoms due to LVOT 
obstruction and the need for cardiac surgery occurs at an older age in women than in 
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men. The older age in female HCM patients at time of myectomy may be explained by 
compensating mechanisms which postpone clinical manifestations. 
One of these compensating mechanisms might be the isoform change of titin from 
the stiff  to more compliant isoform, which is larger in female than in male HCM 
patients. In our recent study we found a correlation between titin composition 
and diastolic dysfunction, implying that the isoform switch might be an attempt to 
compensate for the impaired relaxation.16 This might explain the minimal changes in 
titin isoform switch in the SMN patient group. Compared to the SMP HCM patients, the 
SMN patient group shows less diastolic dysfunction, lower IVSi and their myocardium 
contains lower levels of  fi brosis. However, in the THIN fi lament and SMN patient 
groups, opposite to our fi ndings in patients with THICK fi lament mutations, we do not 
fi nd a clear correlation between titin isoform composition and fi brosis. 
In our study we have measured the amount of fi brosis but did not make a distinction 
between interstitial and replacement fi brosis, both are known to decrease cardiac 
compliance.22,23 It might be possible that the increase in compliant titin isoform is 
linked to the specifi c increase of either interstitial or replacement fi brosis. There is 
also the possibility that fi brosis and titin are both correlated to diastolic dysfunction16 
but not to each other. In patients with aortic stenosis and diastolic dysfunction, due 
to concentric hypertrophy, increased levels of fi brosis and compliant titin are found 
without a correlation between the two.34
A correlation was found between diastolic dysfunction and myocardial blood fl ow 
in women, and it is known that microvascular density is negatively associated with 
parameters of diastolic dysfunction.35,36 A consistent sex-specifi c diff erence was 
observed in all HCM patient groups, with a signifi cantly lower capillary density in 
female compared to male patients. As we have shown that capillary density further 
decreased with disease progression (CHAPTER SIX), research is warranted to defi ne 
the pathomechanisms underlying capillary rarefaction. 
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CONCLUSION
Both genotype and sex have a profound effect on diastolic dysfunction in HCM 
patients at the time of myectomy. 
SMP patients show greater impairment of diastolic dysfunction and cardiac remodeling 
on echocardiography and are younger at the time of myectomy. Furthermore, factors 
contributing to myocardial stiffness and thus diastolic dysfunction are more impaired 
in SMP compared to SMN HCM patients. Irrespective of genotype, diastolic function, 
cardiac remodeling and secondary cellular changes are more pronounced in female 
HCM patients compared to male HCM patients. 
Acknowledgements
Funding:
This work was supported by the Netherlands Cardiovascular Research Initiative, 
an initiative with support of the Dutch Heart Foundation, CVON2011-11 ARENA, 
CVON2014-40 DOSIS and VICI.
Conflict of interest 
None declared
 
149460_THESIS.indb   118 8-3-2021   14:34:16
Genotype- and Sex-specifi c Diff erences                     119
5
REFERENCES 
1. Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New Perspectives on the Prevalence of Hypertrophic 
Cardiomyopathy. J. Am. Coll. Cardiol. 65, 1249–1254 (2015).
2. Baudhuin, L. M., Kotzer, K. E., Kluge, M. L. & Maleszewski, J. J. What Is the True Prevalence of Hypertrophic 
Cardiomyopathy? J. Am. Coll. Cardiol. 66, 1845–1846 (2015).
3. Marsiglia, J. D. C. & Pereira, A. C. Hypertrophic Cardiomyopathy: How do Mutations Lead to Disease? Arq. 
Bras. Cardiol. 102, 295–304 (2014).
4. Ho Carolyn Y. et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. Circulation 
138, 1387–1398 (2018).
5. Authors/Task Force members et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic 
cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the 
European Society of Cardiology (ESC). Eur. Heart J. 35, 2733–2779 (2014).
6. Sen-Chowdhry, S., Jacoby, D., Moon, J. C. & McKenna, W. J. Update on hypertrophic cardiomyopathy and a 
guide to the guidelines. Nat. Rev. Cardiol. 13, 651–675 (2016).
7. Lopes, L. R. et al. Genetic complexity in hypertrophic cardiomyopathy revealed by high-throughput 
sequencing. J. Med. Genet. (2013) doi:10.1136/jmedgenet-2012-101270.
8. Olivotto, I. et al. Myofi lament Protein Gene Mutation Screening and Outcome of Patients With Hypertrophic 
Cardiomyopathy. Mayo Clin. Proc. 83, 630–638 (2008).
9. Ho, C. Y. et al. Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from 
the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 138, 1387–1398 (2018).
10. Bos, J. M. et al. Relationship between sex, shape, and substrate in hypertrophic cardiomyopathy. Am. 
Heart J. 155, 1128–1134 (2008).
11. Olivotto, I. et al. Microvascular function is selectively impaired in patients with hypertrophic 
cardiomyopathy and sarcomere myofi lament gene mutations. J. Am. Coll. Cardiol. 58, 839–848 (2011).
12. Ho, C. Y. et al. T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy 
Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy. Circ. Cardiovasc. Imaging 6, 
415–422 (2013).
13. Germans, T. et al. How do hypertrophic cardiomyopathy mutations aff ect myocardial function in carriers 
with normal wall thickness? Assessment with cardiovascular magnetic resonance. J. Cardiovasc. Magn. 
Reson. 12, 13 (2010).
14. Zile, M. R. & Brutsaert, D. L. New Concepts in Diastolic Dysfunction and Diastolic Heart Failure: Part II 
Causal Mechanisms and Treatment. Circulation 105, 1503–1508 (2002).
15. Nijenkamp, L. L. A. M. et al. Sex Diff erences at the Time of Myectomy in Hypertrophic Cardiomyopathy. 
Circ. Heart Fail. 11, e004133 (2018).
16. Nijenkamp, L. L. A. M. et al. Sex-specifi c cardiac remodeling in early and advanced stages of hypertrophic 
cardiomyopathy. PloS One 15, e0232427 (2020).
17. Nagueh, S. F., Smiseth, O. A. & Appleton, C. P. Recommendations for the Evaluation of Left Ventricular 
Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and 
the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016, 277–314.
18. Warren, C. M., Krzesinski, P. R. & Greaser, M. L. Vertical agarose gel electrophoresis and electroblotting of 
high-molecular-weight proteins. Electrophoresis 24, 1695–1702 (2003).
19. Nagueh, S. F. et al. Doppler Estimation of Left Ventricular Filling Pressures in Patients With Hypertrophic 
149460_THESIS.indb   119 8-3-2021   14:34:17
120
Cardiomyopathy. Circulation 99, 254–261 (1999).
20. Yang, H. et al. Enlarged left atrial volume in hypertrophic cardiomyopathy: a marker for disease severity. 
J. Am. Soc. Echocardiogr. Off. Publ. Am. Soc. Echocardiogr. 18, 1074–1082 (2005).
21. Lang, R. M. et al. Recommendations for chamber quantification. Eur. Heart J. - Cardiovasc. Imaging 7, 
79–108 (2006).
22. Noureldin, R. A. et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic 
resonance. J. Cardiovasc. Magn. Reson. 14, 17 (2012).
23.Kitamura, M. et al. Collagen remodeling and cardiac dysfunction in patients with hypertrophic 
cardiomyopathy: The significance of type III and VI collagens. Clin. Cardiol. 24, 325–329 (2001).
24. Maron, M. S. et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 
54, 866–875 (2009).
25. Knaapen, P. et al. Determinants of coronary microvascular dysfunction in symptomatic hypertrophic 
cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 294, H986-993 (2008).
26. Bupha-Intr, T., Oo, Y. W. & Wattanapermpool, J. Increased myocardial stiffness with maintenance of 
length-dependent calcium activation by female sex hormones in diabetic rats. Am. J. Physiol. Heart Circ. 
Physiol. 300, H1661-1668 (2011).
27. Opitz, C. A., Leake, M. C., Makarenko, I., Benes, V. & Linke, W. A. Developmentally regulated switching of 
titin size alters myofibrillar stiffness in the perinatal heart. Circ. Res. 94, 967–975 (2004).
28. Olivotto, I. et al. Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic 
Cardiomyopathy. J. Am. Coll. Cardiol. 46, 480–487 (2005).
29. Kubo, T. et al. Gender-specific differences in the clinical features of hypertrophic cardiomyopathy in a 
community-based Japanese population: results from Kochi RYOMA study. J. Cardiol. 56, 314–319 (2010).
30. Sedaghat-Hamedani, F. et al. Clinical outcomes associated with sarcomere mutations in hypertrophic 
cardiomyopathy: a meta-analysis on 7675 individuals. Clin. Res. Cardiol. Off. J. Ger. Card. Soc. (2017) 
doi:10.1007/s00392-017-1155-5.
31. Witjas-Paalberends, E. R. et al. Mutations in MYH7 reduce the force generating capacity of sarcomeres in 
human familial hypertrophic cardiomyopathy. Cardiovasc. Res. 99, 432–441 (2013).
32. Coppini, R. et al. Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-
filament gene mutations. J. Am. Coll. Cardiol. 64, 2589–2600 (2014).
33. Sedaghat-Hamedani, F. et al. Clinical outcomes associated with sarcomere mutations in hypertrophic 
cardiomyopathy: a meta-analysis on 7675 individuals. Clin. Res. Cardiol. 107, 30–41 (2018).
34. Gotzmann, M. et al. Alterations in Titin Properties and Myocardial Fibrosis Correlate With Clinical 
Phenotypes in Hemodynamic Subgroups of Severe Aortic Stenosis. JACC Basic Transl. Sci. 3, 335–346 (2018).
35. Mohammed, S. F. et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with 
preserved ejection fraction. Circulation 131, 550–559 (2015).
36. Haas, A. V. et al. Sex Differences in Coronary Microvascular Function in Individuals with Type 2 Diabetes 
Mellitus. Diabetes (2018) doi:10.2337/db18-0650.
149460_THESIS.indb   120 8-3-2021   14:34:17
Genotype- and Sex-specifi c Diff erences                     121
5
149460_THESIS.indb   121 8-3-2021   14:34:17
Louise L.A.M. Nijenkamp1, Ilse A.E. Bollen1, Hans W.M. Niessen2, Cris G. dos Remedios3, 
Michelle Michels4,  Corrado Poggesi5, Carolyn Y. Ho6, Diederik W.D. Kuster1,7, Jolanda 
van der Velden1,7
1Physiology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular Sciences, The 
Netherlands;
2Pathology and Cardiac Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Cardiovascular 
Sciences, The Netherlands; 
3Muscle Research Unit, Bosch Institute, University Sydney, Sydney, Australia; 
4Department of Cardiology, Erasmus Medical Center, The Netherlands; 
5Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Firenze, Italy; 
6Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; 
7Netherlands Heart Institute, Utrecht, the Netherlands
149460_THESIS.indb   122 8-3-2021   14:34:17
CHAPTER SIX  
Sex-specific cardiac remodeling in early 
and advanced stages of hypertrophic 
cardiomyopathy
Published in 
PLOS ONE 2020; 15(5): e0232427
FeMale - by Louise Nijenkamp
149460_THESIS.indb   123 8-3-2021   14:34:17
124
ABSTRACT
Hypertrophic cardiomyopathy (HCM) is the most frequent genetic cardiac disease 
with a prevalence of 1:500 to 1:200. While most patients show obstructive HCM and 
a relatively stable clinical phenotype (stage II), a small group of patients progresses 
to end-stage HCM (stage IV) within a relatively brief period. Previous research has 
shown sex-differences in stage II HCM with more diastolic dysfunction in female than 
in male patients. Moreover, female patients more often show progression to heart 
failure. Here we investigated if differences in functional and structural properties of 
the heart may underlie sex-differences in disease progression from stage II to stage 
IV HCM. Cardiac tissue from stage II and IV patients was obtained during myectomy 
(n=54) and heart transplantation (n=10), respectively. Isometric force was measured in 
membrane-permeabilized cardiomyocytes to define active and passive myofilament 
force development. Titin isoform composition was assessed using gel electrophoresis, 
and the amount of fibrosis and capillary density were determined with histology. In 
accordance with disease stage-dependent adverse cardiac remodeling end-stage 
patients showed a thinner interventricular septal wall and larger left ventricular and 
atrial diameters compared to stage II patients. Cardiomyocyte contractile properties 
and fibrosis were comparable between stage II and IV, while capillary density was 
significantly lower in stage IV compared to stage II. Women showed more adverse 
cellular remodeling compared to men at stage II, evident from more compliant titin, 
more fibrosis and lower capillary density. However, the disease stage-dependent 
reduction in capillary density was largest in men. In conclusion, the more severe 
cellular remodeling in female compared to male stage II patients suggests a more 
advanced disease stage at the time of myectomy in women. Changes in cardiomyocyte 
contractile properties do not explain the progression of stage II to stage IV, while 
reduced capillary density may underlie disease progression to end-stage heart failure.
Keywords: hypertrophic cardiomyopathy, capillary density, disease stage, 
sex-differences
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CLINICAL PERSPECTIVES AND RELEVANCE
What is New? 
Since no diff erences were observed in cardiomyocyte contractile properties between 
early and advanced stage of HCM, our study points to microvascular ischemia and 
fi brosis as main mechanisms of disease progression rather than cardiomyocyte 
dysfunction. This suggests that similar molecular therapeutic targets may be at play 
in all phases of HCM within the myocardium, and that the diff erent clinical profi les are 
mostly due to extra-cardiomyocyte variations.
What are the Clinical Implications? 
Analyses of coronary perfusion may be warranted in HCM patients who show a 
reduction in IVS during regular clinical check-ups to identify HCM patients at risk to 
develop end-stage heart failure.   
Translational Outlook
Capillary density is only one component of microvascular dysfunction, together with 
loss of small vessel vasodilatory function and vessel compression due to increased 
wall stress. Future research could focus on evidence of ischemia and clinical research 
regarding small vessel function. 
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INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic cardiac disease 
occurring in 2-5 per 1000 individuals, and is caused by mutations in genes encoding 
sarcomeric proteins.1–3 The defining feature of HCM is unexplained left ventricular 
(LV) hypertrophy that mainly affects the interventricular septum (IVS). In addition 
to hypertrophy, the diseased myocardium is characterized by increased interstitial 
fibrosis, myofibrillar and cardiomyocyte disarray and vascular abnormalities.4,5 Clinical 
symptoms generally appear between 20-50 years of age and can range from shortness 
of breath to atrial fibrillation. In the majority of patients, these symptoms can be 
managed with therapy, and individuals have a normal life expectancy.6 However, a 
subset of patients suffers from life-threatening complications such as sudden cardiac 
arrest at a young age or progresses to end-stage heart failure.6 
To classify the different forms of HCM, Olivotto et al.7 described different stages in 
cardiac disease progression ranging from unaffected mutation carriers to end-stage 
failing HCM patients.8 The majority of HCM patients develop a ‘classic’ (stage II) form of 
HCM with the characteristic septal thickening, LV outflow tract (LVOT) obstruction and 
diastolic dysfunction. Approximately 5-10% of all HCM patients progress to the severe 
end-stage of HCM (stage IV), which is characterized by thinning of the IVS and LV wall, 
and left atrial dilation, extensive fibrosis and impaired systolic function. These patients 
show a decrease in NYHA classification and are often diagnosed with or develop atrial 
fibrillation.9 The progression from the ‘classic’ stage of HCM, via adverse remodeling 
(stage III) to stage IV shows a relatively short clinical course of approximately 6.5 
years.10 It is unclear which factors underlie the transition from a stable stage II to stage 
IV of HCM in a relatively small but severely ill group of patients. 
Notably, the lifetime risk of heart failure is higher in women than in men.11 At first 
evaluation, female HCM patients are older and present more often with symptoms.12,13 
Moreover, women show a higher risk of progression to heart failure (stage IV).12,14 We 
recently showed more severe diastolic dysfunction in female compared to male HCM 
patients at the time of myectomy (stage II), which coincided with more advanced 
tissue remodeling in women compared to men.15 Here we investigated if differences 
in functional and structural properties of the heart may underlie sex-differences in 
disease progression from stage II to IV of HCM. Functional measurements in single 
cardiomyocytes were combined with analyses of protein expression, fibrosis and 
capillary density. 
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Cardiac samples were collected from 54 patients with obstructive HCM (stage II) 
(44% female) carrying a MYH7 (myosin heavy chain; n=14) or a MYBPC3 (myosin-
binding protein-C; n=40) mutation (stage II) and 10 end-stage (stage IV) patients 
(40% female) carrying a MYH7 (n=6), a MYBPC3 (n=3) or a TNNT2 (troponin T; n=1) 
mutation. Figure 1A illustrates the diff erent gene mutations and Figure 1B shows 
where mutations are located in the protein. Table 1 provides an overview of the 
gene mutations of all patients. Patient samples were compared with non-failing 
control samples (n=30; 40±14 years; 43% female; S1 Table) without a history of cardiac 
abnormalities. IVS tissue from the stage II HCM group was collected during myectomy 
to relieve LVOT obstruction. Cardiac tissue from stage IV HCM was obtained during 
heart transplantation surgery and consisted of IVS (n=6) and LV tissue (n=4). Control 
samples included IVS (n=3) and LV (n=27) tissue. All samples were immediately frozen 
and stored in liquid nitrogen. This study was approved by the local ethics board of 
the Erasmus Medical Center (protocol number MEC-2010-40) and written informed 
consent of patients was obtained. Non-failing donor samples were acquired from 
the University of Sydney, Australia, with the ethical approval of the Human Research 
Ethics Committee (#2012/2814).  
We acknowledge the uneven distribution between patient numbers and mutations 
and tissue locations  (IVS and LV). However, our tissue characterization was dependent 
on available cardiac tissue and clinical parameters. Due to limited tissue availability, 
not all analyses could be performed in all patient/control samples. 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1. Patient information and gene mutations. 
Abbreviations: F, female; M, male; sarcomere genes MYBPC3, MYH7 and TNNT2 encoding myosin-binding 
protein-C, myosin heavy chain and cardiac troponin T, respectively. Domain & info: DF: Dutch founder 
mutation; Fam I: patient samples part of one family. Domain locations of the mutations (also illustrated in 
Figure 1B): MM: cMyBP-C motif (in Figure 1B depicted as yellow stripes between C1-C2); PA: Pro-Ala rich 
region (in Figure 1B depicted as grey stripes between C0-C1); MT: Myosin tail (in Figure 1B the dark green 
line); MH: Myosin head; Hinge: hinge region of myosin (in Figure 1B depicted as the curled green line); 
IVS, interventricular septum; IVSi, IVS indexed by body surface area (BSA); LAD, left atrial diameter; LADi, 
LAD  indexed by BSA; LVEDD, left ventricular end-diastolic diameter; LVEDDi indexed by BSA; LVOTO, left 
ventricular outflow tract obstruction; E/A ratio, ratio of mitral valve early (E) and late (A) velocity; E wave, 
mitral valve early velocity (cm/s); TR velocity, tricuspid regurgitation velocity (m/s); bb, betablocker; ccb, 
calcium channel blocker; ACE, ACE-inhibitor; (N)OAC, (novel) oral anticoagulant; ASA, antiplatelet therapy 
(acetylsalicylic acid). 
Echocardiographic Measurements
Echocardiographic studies were done with commercially available systems and 
analyzed according to the American Society of Echocardiography guidelines.16 
Maximal wall thickness, left atrial diameter (LAD), LV end-diastolic diameter (LVEDD), 
and LVOT obstruction gradient were measured. LVOT obstruction was defined as a 
gradient ≥ 30 mmHg at rest or during provocation. Mitral valve inflow was recorded 
using pulsed wave Doppler from the apical four chamber view. Mitral E and A velocity 
(cm/s) and deceleration time (ms) were measured. Pulsed wave tissue Doppler 
imaging was used to measure septal e’ velocity (cm/s). Continuous wave Doppler in 
the parasternal and apical four chamber was used to measure tricuspid regurgitation 
(TR) velocity (m/s). Echocardiographic data and medication are shown in Table 1. 
For the end-stage HCM group, a limited set of echocardiographic data was obtained, 
and not all parameters were obtained for stage II patients. Diastolic dysfunction was 
graded as follows: grade I when E/A ratio ≤ 0.8 and E peak velocity ≤ 50 cm/s; grade III 
when E/A ratio ≥ 2. In patients with E/A ratio ≤ 0.8 and E peak velocity > 50 cm/s or E/A 
ratio > 0.8 but < 2, the E/e’ ratio (>14), LADi (>24) and TR velocity (> 2.8 m/s) were used 
to further differentiate diastolic function. When ≥ 2 out of 3 variables  were abnormal, 
LA pressure was elevated and grade II diastolic dysfunction was present. When 1 out 
of 3 variables was abnormal, grade I diastolic dysfunction was present.17 
Isometric Force Measurements
Force measurements were performed in mechanically isolated single, membrane-
permeabilized, cardiomyocytes as described previously.18,19 In short, we measured 
passive tension at a range of sarcomere lengths (SL)(1.8-2.4 µm). All passive forces 
were normalized to cardiomyocyte cross-sectional area (CSA) (i.e. CSA = width x depth 
x π/4). Active tension (maximal force) was measured at SL 2.2 µm, and we determined 
myofilament calcium sensitivity (EC50) by activating cardiomyocytes in solutions with 
different calcium concentrations. 
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Protein Analyses 
Titin isoform gel electrophoresis was performed as previously described.19,20 Samples 
were measured in triplicate, of which the mean was used. 
Histomorphometrical Analyses
Cardiomyocyte myofi bril density (MFD) was measured using Electron Microscopy (EM) 
as described previously.21 MFD was calculated by the sum of myofi bril area relative 
to the total cardiomyocyte area and expressed as a percentage.21,22 To determine the 
extent of interstitial and replacement fi brosis, cryosections were stained using Picro-
Sirius Red, and fi brosis was expressed as collagen volume fraction (CVF%). Capillary 
density was determined by the number of capillaries per mm2 and per cardiomyocyte. 
Cryosections were incubated with a primary antibody (Monoclonal Mouse anti-
Human CD31, Endothelial cell; Clone JC70A; DAKO; REF M0823) and secondary 
antibody (EnVision HRP α-mouse/rabbit (DAKO). Staining was visualized using 
3.3’-diaminobenzidine (0.1 mg/mL, 0.02% H2O2), the sections were subsequently 
counterstained with hematoxylin. 
Data Analyses
Data in fi gures are presented as mean±standard error of the mean per group, data 
in tables is presented as mean±standard deviation. If data was normally distributed 
means were compared with a student’s T-test, a Mann-Whitney test was used when 
data was not normally distributed. Sex-diff erences were tested with a 2-way ANOVA. 
P<0.05 was considered signifi cant, diff erences to controls are indicated by an asterisk 
(*), sex-diff erences are indicated by a hashtag (#). 
stage II stage IV P
N (% female) 54 (44%) 10 (40%)
Age (years) 43.4±14.7 44.5±11.3 0.83
IVS (mm) 22.9±6.3 17.3±1.2 <0.05
LVOTO (mmHG) 59.2±30.4 8.3±2.9 <0.001
LAD (mm) 46.5±6.9 55.3±10.0 <0.05
LVEDD (mm) 43.1±5.0 56.8±8.2 <0.0001
Table 2. Clinical characteristics of HCM stage II and IV patient groups.
Abbreviations: IVS (interventricular septum); LAD (left atrial dimension); LVEDD (left ventricular end-diastolic 
dimension); LVOTO (left ventricular outfl ow tract obstruction).
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RESULTS 
A MYBPC3 gene mutation was present in 43 patients (40 stage II and 3 stage IV), 
of which 18 were founder mutations.  Most MYH7 mutations were located in the 
myosin head (60%) (Figure 1B and Table 1). Average values for echocardiographic 
characteristics of HCM stage II and IV patients are shown in Table 2. HCM stage II and IV 
patients have a similar average age and male patients are dominant in both groups. All 
patients meet the diagnostic criteria of an IVS thickness > 15 mm (Table 1), however, 
the HCM stage II patients show significantly greater septal thickness than the HCM 
stage IV patients. This is in line with a higher LVOT obstruction in the stage II compared 
to stage IV HCM. LAD and LVEDD were significantly higher in stage IV compared to 
stage II HCM.23  All stage IV patients were given grade III diastolic dysfunction, while 
stage II patients included 29% with grade III, 29% with grade II and 42% with grade I 
diastolic dysfunction. Female stage II patients show more severe diastolic dysfunction 
compared to male patients: 86% grade II or III diastolic dysfunction in women 
compared to 42% grade II or III in men. Drug regimen was different between female 
and male stage II HCM patients: 80% of the men received betablockers in contrast 
to 58% of the women. Calcium channel blockers were prescribed more frequently to 
women compared to men (58% versus 27%, respectively; Table 1). Unfortunately we 
could only retrieve drug regimen of one of our stage IV patients. 
Maximal force generating capacity (Fmax) of cardiomyocytes was significantly lower 
in stage II and IV HCM compared to controls (21.8±1.7 and 19.6±2.3 versus 32.8±2.9 
KN/m2 respectively; p<0.01), but did not differ between patient groups or sex (Figure 
2A). Passive tension (Fpass) was lower in both stage II and IV HCM compared to controls 
(Figure 2B; p<0.0001). No sex-differences in passive tension were observed. Figure 
2C shows representative images of myofibril density analyses by EM (stage II and IV 
HCM patient samples). Both HCM groups showed a similar decrease in MFD compared 
to controls (p<0.0001), while no sex-difference was observed (Figure 2D). Compared 
to controls, a significantly higher myofilament calcium-sensitivity was found in both 
stage II and IV HCM (EC50: 2.2±0.1 µmol/L and 3.0±0.2 versus 2.0±0.1 respectively; 
p<0.001), with no difference between the HCM groups or sex (Figure 2E). 
The N2BA/N2B titin isoform ratio was significantly higher in both HCM groups 
compared to controls, without a difference between stage II and IV HCM (0.84±0.05 
versus 0.81±0.12). At both HCM disease stages women show a higher N2BA/N2B ratio 
compared to men (Figure 3A).  Analysis of fibrosis showed increased fibrosis in stage 
II and IV HCM patients compared to controls (4.6±0.5 and 5.5±0.9 versus 1.2±0.2% 
respectively; p<0.001). Representative Picro-Sirius red staining images of stage II and 
IV HCM are shown in Figure 3C. There was no difference between the HCM groups, 
however, in both disease stages women showed significantly more fibrosis than 
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men (Figure 3B). We found signifi cant correlations between the degree of diastolic 
dysfunction and titin isoform composition (Figure 3D; R2: 0.13; p<0.05) and the 
amount of fi brosis (Figure 3E; R2: 0.31; p<0.01).
Figure 4A shows images of capillary staining in a stage II and IV HCM sample. Capillary 
density is depicted as capillaries per mm2 (Figure 4B) as well as per cardiomyocyte 
(Figure 4C). Capillary density is signifi cantly lower in stage II and IV HCM patients 
compared to controls (Figure 4B and C; p<0.0001). Furthermore, both methods 
showed a lower capillary density in stage IV compared to stage II HCM patients 
(p<0.05). Capillary density in stage II HCM is signifi cantly lower in women compared to 
men (p<0.05).  Interestingly, the reduction in capillary density from stage II to stage IV 
is attributed to the reduction of capillary density in male to a similar level as observed 
in female HCM patients. 
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Figure 2. Cardiomyocyte properties – No differences between stage II and IV HCM patients. 
A) Maximal force development is lower in stage II (n=26) and stage IV (n=8) patients in comparison to 
controls (p<0.0001) and no sex-differences were found. B) Passive tension is lower in stage II (n=19) and stage 
IV (n=8) patients in comparison to controls (p<0.0001, no sex-differences were found). C and D) Electron 
Microscopy (EM) imaging was performed and showed reduced myofibril density in stage II and IV HCM 
patient samples compared to controls. No sex-difference was present in myofibril density. E) Myofilament 
calcium-sensitivity is depicted as EC50 (the amount of calcium needed to reach 50% of maximal force). EC50 is 
significantly lower in stage II and IV HCM patients compared to controls (p<0.001). No sex-differences were 
found. Controls used for passive tension: 1, 12-13, 20; maximal force development: 5-8, 11-12, 15-16, 18-19, 
23, 26; myofilament calcium-sensitivity: 5-8, 11-12, 15-16, 18-19, 23.
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Fig 3. Titin and fi brosis – Female patients show more compliant titin isoform and fi brosis than male 
patients.
A) HCM (n=42) show an increase in titin N2BA/N2B ratio compared to controls (p<0.05). The diff erence 
in titin composition is mainly attributed to the female patients, who show an increase in compliant titin 
compared to male patients (p<0.05) and compared to controls (p<0.01)(no sex-diff erence in N2BA/N2B ratio 
was present in the control group). B) Representative Picro-Sirius red stainings of HCM stage II and IV patient 
samples. C) The amount of fi brosis is depicted as collagen volume fraction (CVF). In comparison to controls, 
fi brosis is increased in HCM (stage II (n=29) and stage IV HCM (n=8), p<0.001). Female patients show higher 
levels of fi brosis compared to male patients (p<0.05). Signifi cant correlations were found between the N2BA/
N2B ratio and grade of diastolic dysfunction (p<0.05; panel E), and fi brosis and diastolic function (p<0.05; 
panel F). Blue dots and squares depict stage IV HCM patients. Controls used for titin isoform analysis: 1-3, 
5-6, 8, 10, 13-14, 16, 20, 22, 24, 26-27. Controls used for the amount of fi brosis: 4, 8-10, 21, 23, 26, 29-30.
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Figure 4. Capillary density – Decreased capillary density in HCM patients.
A) Representative CD31 staining of HCM stage II and IV samples are shown. B) Capillary density is depicted 
as the number of capillaries per mm2. Capillary density is decreased in HCM stage II (n= 22) and stage IV (n=8) 
compared to controls (p<0.0001). The change in capillary density is sex-dependent. Female patients show 
lower capillary density compared to male patients (p<0.05). C) Capillary density is depicted as the number of 
capillaries per cardiomyocyte. Capillary density is decreased in HCM patients compared to controls (p<0.05). 
Capillary density is significantly decreased in stage IV compared to stage II male patients (p<0.05). Blue dots 
and squares represent stage IV HCM patients. Controls used for capillary density: 8-9, 21, 23, 25-26, 29-30.
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DISCUSSION
We investigated if cardiac tissue properties were more severely aff ected at stage IV 
(end-stage) than stage II of HCM, and whether these properties change in a  sex-
specifi c manner. The main fi ndings of our study are: 1) Changes in (functional) 
myofi lament properties of cardiomyocytes are similar in stage II and stage IV HCM; 
2) A similar increase in fi brosis compared to controls is present at stage II and IV HCM; 
3) Capillary density is signifi cantly lower at stage IV compared to stage II HCM; 4) 
Sex-specifi c diff erences in HCM are marked by higher levels of fi brosis, a larger shift 
to compliant titin isoform and a lower capillary density in female compared to male 
patients; 5) The disease-stage specifi c decrease in capillary density is largely explained 
by the lower capillary density in men at stage IV compared to stage II. Overall, our 
study indicates that loss of capillary density may be a factor underlying disease 
progression from stage II to IV in HCM. 
Age at time of operation (myectomy or heart transplantation) did not diff er between 
the two HCM groups and is in line with previous studies.10,24,25 HCM onset at a young 
age is one of the risk factors for developing stage IV HCM. Furthermore, HCM patients 
that progress to stage IV more often experience atrial fi brillation, mitral valve 
regurgitation, more symptom progression and less LVOT obstruction.24,26 Many stage 
IV patients did not have surgical myectomy before heart transplantation, probably 
due to the lower frequency of LVOT obstruction in these patients.24 Because stage IV 
patients reach phase II of HCM at a younger age and progress faster, their age at heart 
transplantation is similar to HCM patients who undergo surgical myectomy. 
As expected, cardiac remodeling was diff erent between stage II and IV HCM patients 
(Table 2). Stage IV patients show less hypertrophy of the IVS and increased dimensions 
of both LV and left atrium.8 Both our patient groups showed a predominance of the 
male sex (stage II: 56% and stage IV: 60%) which is in line with earlier research (ranging 
from 55-72% in end-stage HCM).25–30 As for stage II HCM patients, based on our recent 
study, we have proposed that women may be diagnosed too late because the cut-
off  value for IVS is not corrected by body surface area.15 The latter may partly explain 
the predominance of male patients in our HCM groups. Interestingly we did fi nd a 
diff erence in drug regimen between stage II women and men. The most prescribed 
drugs in both genders were betablockers, calcium channel blockers or a combination 
of both. Men were commonly prescribed betablockers (80% in men versus 58% in 
women), while women were more frequently prescribed calcium channel blockers 
(58% versus 27%) and dual therapy (38% versus 20%). 
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The main difference identified between early and end-stage HCM patient groups 
was the larger reduction in capillary density in stage IV compared to stage II. It 
is known that myocardial blood flow is decreased in HCM patients, with greatest 
impairments seen during hyperemic circumstances.31 The IVS and sub-endocardial 
layers are particularly hypo perfused.32,33 Importantly, reduced myocardial blood flow 
has been associated with fibrotic areas of the myocardium.32 Chronic exposure to 
ischemia, whether due to coronary occlusion or the inability to properly vascularize 
the hypertrophied myocardium (decreased capillary density),5,34 leads to necrosis, 
massive fibrosis and eventually wall thinning.26,35 Microvascular dysfunction in HCM 
patients was associated with a higher incidence of end-stage heart failure.32,36 The 
lower capillary density in stage IV compared to stage II HCM patients indicates that 
reduced coronary perfusion plays a role in disease progression from HCM to end-
stage heart failure. 
We are the first to report a sex-difference in capillary density in stage II HCM patients, 
where women have lower capillary density compared to men. Previous reports that 
analyzed capillary density have found no influence of sex but were not performed in 
HCM patients.37–41 A recent study showed a correlation between microvascular density 
and fibrosis, in which a decrease in capillary density was correlated with an increase in 
fibrosis.37 Furthermore, parameters of diastolic dysfunction were negatively associated 
with microvascular density.37 Interestingly, a significant decrease in capillary density 
was found only in male patients between HCM stage II and IV. Capillary density in men 
with stage IV HCM decreased to the level of women with HCM. It has been reported 
that myocardial blood flow in women at rest is higher compared to men, while the 
flow reserve (ie. increase in myocardial blood flow between rest and stress) is lower 
in women.42–44 In addition, a correlation was found between myocardial blood flow 
and diastolic dysfunction in women.42 Furthermore, endothelial cell response may be 
impaired and contribute to HCM disease progression. Future studies are warranted 
to define the cellular components which underlie perturbations in myocardial blood 
flow during HCM disease progression. 
Titin is known to modulate passive stiffness of the cardiomyocyte in an isoform-
dependent manner as it functions as a molecular spring.32 The heart consists of two 
isoforms, a short and stiff N2B isoform and a longer more compliant N2BA isoform. 
Titin-based stiffness can therefore be displayed as the N2BA/N2B isoform ratio. Our 
previous study15 showed a larger shift to more compliant titin isoform in female 
compared to male stage II HCM patients, which coincided with a higher level of 
fibrosis. This is in line with the suggestion that the increased titin compliance might 
be an attempt to compensate for the increased fibrosis and diastolic dysfunction. 
Our current study shows that titin isoform composition is not altered during disease 
progression as a similar pattern is seen at stage IV HCM (Figure 3A). In accordance, 
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the passive force measurement curves of both HCM groups clearly overlap (Figure 
2B), indicating that passive properties of myofi laments are not altered during HCM 
disease progression.
All of our patients that underwent myectomy were labeled as stage II HCM. Our 
previous and current study indicate that tissue remodeling is more advanced in 
women than in men at an earlier (stage II) disease stage, i.e. more fi brosis, a change 
in titin isoform composition and a reduction in capillary density. Based on our 
observations, our HCM stage II women may actually be at a more advanced disease 
stage and may be in need of a more aggressive treatment. 
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ABSTRACT
Purpose of review: Hypertrophic cardiomyopathy (HCM) is the most common 
genetic cardiomyopathy, diagnosed by left ventricular hypertrophy of ≥15mm 
maximal wall thickness (MWT). Recent studies reported a sex-difference in clinical 
presentation, progression and outcome of HCM. This review provides an overview of 
recent studies into sex-differences in HCM.
Recent findings: A higher number of men (55-65% of total HCM patient group) with 
manifest HCM has been observed, while female patients are older at first evaluation 
and diagnosis, present more frequently with symptoms, and have worse survival. 
Additionally, women have relatively smaller hearts even when corrected for body 
surface area (BSA), but female HCM patients have a higher interventricular septum 
thickness after correction for BSA.
Summary: Female HCM patients are possibly in a more advanced stage of disease 
at time of diagnosis because they require relatively more hypertrophy to reach the 
diagnostic threshold of ≥15mm MWT. Additional studies are warranted to explore sex-
specific diagnostic criteria for HCM.
Key words: Hypertrophic cardiomyopathy, sex differences
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KEY POINTS
• Numerous studies have observed male predominance in HCM patients, female 
HCM patients are older at fi rst evaluation and diagnosis, and present more 
frequently with symptoms
• Female HCM patients have lower 5- and 10-year survival estimates than male 
HCM patients
• HCM mutation carriers with a smaller heart (mostly women) require relatively 
more hypertrophy to reach the diagnostic criterion of MWT≥15mm
• Women could be in a more advanced stage of disease at the time of HCM 
diagnosis. Additional studies are warranted to investigate the need for sex-
specifi c diagnostic HCM criteria
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a genetic heart disease which is diagnosed 
by left ventricular (LV) hypertrophy in the absence of loading conditions such as 
aortic valve stenosis or hypertension.1,2 The diagnostic criterion for HCM diagnosis is 
a maximal wall thickness (MWT) ≥15mm (≥13mm in first degree relatives) assessed 
by cardiac imaging. The prevalence of HCM is estimated to range between 1:500 and 
1:200, which makes it the most common genetic cardiomyopathy.3 Over 1400 different 
mutations (mostly missense mutations) have been identified in 11 genes encoding for 
various components of the sarcomere, such as the thick and thin filaments and the 
Z-disc.4-9 The most commonly mutated genes are β-myosin heavy chain (MYH7) and 
myosin-binding protein C (MYBPC3), accounting for 70% of the mutations that cause 
HCM.4 However, HCM mutations are incompletely penetrant as the genotype does not 
accurately predict severity of the disease. There is a large phenotypic heterogeneity 
in people who carry HCM associated mutations; the clinical course of HCM includes 
normal life expectancy without or with mild symptoms, sudden cardiac death (SCD), 
atrial arrhythmias and progressive heart failure. Additionally, family members with the 
same mutation do not necessarily have the same symptoms or disease progression, 
and age of disease onset varies significantly.5,10 Contributing to the phenotypic 
heterogeneity of HCM is a sex-difference in clinical presentation, progression and 
outcome of the disease. Compared to other cardiac conditions, the description of sex-
differences in HCM is still in an early stage. This review provides an overview of recent 
studies on sex-differences in HCM, which are schematically illustrated in Figure 1.
CLINICAL PRESENTATION, DIAGNOSIS, 
TREATMENT AND PROGNOSIS
Clinicians may suspect HCM when a patient presents with cardiac-related symptoms 
like dyspnea, chest pain, palpitations and syncope, or asymptomatic signs like a heart 
murmur or an abnormal electrocardiogram (ECG), especially when found during 
screening of first-degree relatives. Non-invasive cardiac imaging (echocardiography 
and/ or Cardiac magnetic resonance (CMR)) leads to the diagnosis of HCM when a 
MWT of ≥15mm is measured. Genetic screening is recommended to confirm the 
diagnosis when patients exhibit signs and symptoms of disease suggestive of specific 
causes of HCM, and when it enables cascade genetic screening of family members.1 
When an HCM mutation is identified in the patient and certain family members, these 
family members will undergo regular screening with ECG and echocardiography 
to monitor presence or progression of disease.11 Presentation of HCM, either by 
symptoms or through screening of the mutation carriers, differs between sexes. 
A higher number of men (55-65% of total HCM patient group) with manifest HCM 
has been observed in several large patient cohorts,12-17 while female patients are 
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older at fi rst evaluation and diagnosis, and present more frequently with symptoms 
(Figure 1).15,18,19 It remains to be determined whether the sex-related age-diff erence 
in diagnosis is caused by inadequate clinical recognition in women, slower disease 
progression due to protective sex hormones,20,21 or a lack of sex-specifi c diagnostic 
criteria. Female HCM patients are more likely to exhibit left-ventricular outfl ow 
tract (LVOT) obstruction at rest and have higher gradients both at rest and during 
provocation.18,19 At time of LV septal reduction therapy to reduce LVOT obstruction 
gradients, women are on average 4-7 years older.18,22 A survival analysis in 3569 HCM 
patients found that women have worse survival; fi ve- and ten-year survival estimates 
were signifi cantly lower than survival estimates in men, even when corrected for 
age.18 Lower survival rates in women were not found in other studies,15,19,23 which 
can be explained by the fact that these studies had smaller cohorts with a relatively 
healthier patient population.18
Figure 1. Schematic overview of reported sex-diff erences in hypertrophic cardiomyopathy.
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CARDIAC FUNCTION
The clinical course of HCM is characterized by subtle asymptomatic impairments in 
diastolic function in mutation carriers,24,25 which in some people progresses into 
diastolic dysfunction with normal or supernormal systolic function (LV Ejection 
Fraction (LVEF) > 65%). As the disease progresses, diastolic function decreases further 
accompanied by a decline in systolic function back to normal or reduced LVEF.11
Female HCM patients showed more severe diastolic dysfunction than male HCM 
patients evident from higher E/e’ and E/A ratios, which are indicators for LV fi lling 
pressure.18,22 In addition, a higher degree of systolic impairment was found in female 
compared to male HCM patients in a recent study.19 These sex-diff erences in cardiac 
function are in line with reports of decreased exercise capacity and higher NYHA 
classifi cations in female compared to male HCM patients.15,18,26
Figure 2. Sex diff erences in cardiac dimensions of HCM mutation carriers assessed by CMR imaging. 
A. Women have lower end-diastolic volume (EDV), B. end-systolic volume (ESV), C. and LV mass after 
correction for body surface area (BSA). * p<0.05; ** p<0.005. Individuals with MYH7 and MYBPC3 mutations 
are indicated with black and gray symbols, respectively.
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CARDIAC DIMENSIONS
Cardiac remodeling in HCM is characterized by asymmetric thickening of the LV wall, 
which most frequently aff ects the interventricular septum (IVS). IVS thickness may 
increase during progression of the disease, with a diagnostic criterion of MWT ≥15 
mm and ≥13 mm for fi rst-degree relatives of HCM patients. Our CMR studies of LV 
dimensions show sex-diff erences in asymptomatic mutation carriers. Recurrent CMR 
scans were performed in 29 HCM mutation carriers (16 MYBPC3, 13 MYH7 mutations) 
to measure LV end-diastolic volume (EDV), LV end-systolic volume (ESV) and LV mass. 
Data analysis was performed by a mixed model analysis with correction for repeated 
measures. After correction for body surface area (BSA), female mutation carriers on 
average have a 10.4 ml/m2 smaller EDV (p=0.01; Figure 2A), a 6.2 ml/m2 smaller ESV 
(p=0.007; Figure 2B) and a 9.6 g/m2 lower LV mass (p<0.001; Figure 2C) than men. This 
analysis shows that the female heart is smaller than the male heart when normalized 
to BSA. These fi ndings are in line with earlier studies that used CMR to analyze cardiac 
dimensions of healthy people, and found that the female heart is signifi cantly smaller 
after correction for BSA or height.27-31 Echocardiography performed in 51 manifest 
HCM patients (40 MYBPC3, 11 MYH7 mutations) at the time of cardiac surgery showed 
that women have a signifi cantly higher IVS after correction for BSA (Figure 3). These 
cardiac imaging studies indicate that HCM mutation carriers with a smaller heart 
(mostly women) require relatively more hypertrophy to reach the diagnostic criterion 
of MWT ≥15mm  (Figure 4). Because this diagnostic criterion does not account for the 
relatively smaller female hearts, females could be in a more advanced stage of disease 
at time of diagnosis, causing a delay in treatment.
CELLULAR AND MOLECULAR CHANGES
The most recent report of the working group of myocardial function of the European 
Society of Cardiology describes that ineffi  cient sarcomere contraction sets in motion a 
cascade of cellular changes which can ultimately lead to HCM.32 Ineffi  cient sarcomere 
contraction has been proposed to lead to cellular energy depletion, impairing 
calcium homeostasis and mitochondrial function.32 A study on myectomy samples 
of HCM patients did not fi nd a sex-diff erence in myofi lament calcium sensitivity, but 
the expression of calcium-handling proteins was reduced in female compared to 
male patients.22 Additionally, this study found a higher degree of fi brosis in female 
myectomy samples and observed more compliant titin isoform, which seems to be 
related to increased diastolic dysfunction in women as titin plays a role in regulating 
stiff ness of the cardiomyocytes.33 Overall, the latter study showed more advanced 
cardiac remodeling in female compared to male HCM patients at the time of cardiac 
surgery (Figure 1).
149460_THESIS.indb   153 8-3-2021   14:34:23
154
MECHANISMS BEHIND SEX DIFFERENCES
The mechanisms behind sex-diff erences in HCM are currently not well understood. 
Possible explanations are sought in female interaction with healthcare: a decreased 
awareness and suspicion of disease, leading to under-recognition and delay in 
diagnosis. Reports of sex-diff erences in hypertrophic response, fi brosis and gene 
expression suggest that physiological sex-diff erences may also play a role.22,34 Studies 
in HCM animal models have demonstrated cardio protective eff ects of estrogen and 
estrogen receptor defi cient mice show increased cardiac remodeling by oxidative 
stress.35,36
Figure 3. 
Analysis of echocardiographic measurements showed a higher interventricular septum (IVS) thickness 
(corrected for BSA) in women than in men.22 ** p<0.005. 
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CONCLUSION
Women with HCM are older when they are diagnosed and treated. Additionally, 
women have a higher degree of diastolic dysfunction, lower exercise capacity, are 
more symptomatic and have worse survival. There is a possibility that female HCM 
patients experience a delay in diagnosis and treatment because of a lack of diagnostic 
criteria that account for body size. Women have smaller hearts even after correction 
for BSA, which could mean they are in a more advanced stage of disease at the time 
of HCM diagnosis as they require more hypertrophy to reach the threshold of 15mm 
MWT (Figure 4). Additional studies are warranted to investigate the need for sex-
specifi c diagnostic HCM criteria.
Figure 4. 
Schematic to illustrate that more cardiac hypertrophy is needed in female than in male HCM mutation 
carriers. *In fi rst degree relatives of HCM patients, the diagnostic criterion for HCM is a MWT≥13 mm.  
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ABSTRACT
In 2011 the Netherlands Heart Foundation initiated consortium funding (CVON, 
Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and 
basic (preclinical) researchers on specific areas of research. One of those areas involves 
genetic heart diseases, which are frequently caused by pathogenic variants in genes 
that encode sarcomere proteins. In 2014, the DOSIS (Determinants of susceptibility 
in inherited cardiomyopathy: towards novel therapeutic approaches) consortium was 
initiated, focusing their research on secondary disease hits involved in the initiation 
and progression of cardiomyopathies. Here we highlight several recent observations 
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INTRODUCTION
Inherited cardiomyopathies, caused by pathogenic variants in genes encoding 
proteins that regulate cardiomyocyte contractility, are a major cause of morbidity 
and mortality. In 50-60% of familial hypertrophic (HCM) and 30-40% of dilated (DCM) 
cardiomyopathy, a pathogenic gene variant can be identifi ed. The most common 
genes that are aff ected in HCM are MYH7, MYBPC3 and TNNT2, which encode the thick 
fi lament proteins myosin heavy chain, cardiac myosin-binding protein-C (cMyBP-C), 
and the thin fi lament protein troponin T. In DCM the titin (TTN) gene, which encodes 
the giant myofi lament protein titin, is the most frequently aff ected gene (~15-20% 
of all gene variants);1 in particular gene variants that lead to TTN truncation have 
been shown to be pathogenic.2 In addition, in the Netherlands, a founder mutation 
in the PLN gene, which encodes the calcium-handling protein phospholamban, 
was identifi ed in 2012 as a now well-known cause of DCM and arrhythmogenic 
cardiomyopathy.3,4 Figure 1 depicts a cardiomyocyte to illustrate the aff ected proteins 
involved in cardiomyopathies. Upon activation of a cardiomyocyte, calcium enters the 
cell via the L-type calcium channel, which subsequently releases calcium from the 
intracellular calcium store, the sarcoplasmic reticulum. Calcium binds to the troponin 
complex, which induces a conformational change of troponin-tropomyosin, and 
thereby releases binding sites for myosin heads on the thin actin fi lament. Binding of 
myosin to actin (so-called cross-bridge) results in force development. The kinetics of 
cross-bridge cycling is regulated by cMyBP-C, and the giant protein titin, encoded by 
TTN and linked with DCM, underlies passive stiff ness of sarcomeres.5
In past years the number of genes in genetic diagnostic panels increased with the 
hope to identify a disease-causing variant in a larger group of patients and their 
family members. However, recent studies conclude that the additional benefi t of 
screening large numbers of genes is disappointingly low and of marginal clinical 
utility.6,7 Numerous new TTN gene variants have been identifi ed mainly because of 
its large size. A study in 3 European cardiogenic centers showed that missense and 
non-frameshifting insertions/deletions variants are most likely benign, as reference 
populations showed comparable frequencies of these rare TTN variants.8 The current 
panels thus rather increase the number of variants with unknown signifi cance 
(VUS), which are likely benign, though they may have a modifi er role in disease. 
Cardiomyopathy patients with a suspected genetic etiology should be referred 
for genetic screening. For HCM this includes patients with (usually asymmetric) left 
ventricular hypertrophy, not (fully) explained by abnormal loading conditions, with 
or without a clear family history. For DCM this includes patients with non-ischemic 
DCM, not (fully) explained by other etiological factors. Young age of onset and familial 
occurrence are important parameters that hint towards a genetic etiology. However, 
late onset in seemingly sporadic cases does not exclude a genetic origin due to the 
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Figure 1. 
Activation of a cardiomyocyte triggers calcium entry and release of calcium from the sarcomplasmic 
reticulum, which results in contraction of the cardiac myofibrils. To relax the calcium is pumped back into the 
SR, and out of the cell via the sodium-calcium exchanger (NCX). Myofibrils consist if sarcomeres composed 
of the thin actin and thick myosin filament, and the third filament titin. Sarcomeres consist of sub-regions 
(depicted by the different bands), which underlie the striated pattern of cardiac muscle. Gene variants that 
cause cardiomyopathies are frequently found in myosin heavy chain, troponin T, cardiac myosin-binding 
protein-C (located in the C-zone) and titin. Figure is adapted from Sequeira et al.34
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reduced penetrance and variable disease expression. All HCM and DCM patients in 
whom genetic screening was performed can be added to the biobanks, including 
their relatives (asymptomatic mutation carriers).
Since cardiomyopathies remain to constitute one of the most common causes 
of sudden cardiac death in the young and still represent major causes for 
cardiac transplantation, adequate identifi cation of additional disease triggers 
and understanding the pathomechanisms is of utmost importance. The clinical 
approach is furthermore complicated since inherited cardiomyopathies are clinically 
heterogeneous: age-dependent penetrance and disease-severity diff er greatly 
between patients with the identical genetic variant. The mechanisms that underlie 
the variation in disease expression are still largely unknown. By combining cellular, 
genetic and clinical data from well-phenotyped national patient cohorts, DOSIS 
strived to defi ne disease factors (i.e. secondary hits) that in addition to the pathogenic 
gene variant cause and aggravate cardiac disease in cardiomyopathy patients (Table 
1; Figure 2). Several recent observations are highlighted below.
Figure 2. Disease modifi ers in inherited cardiomyopathies.
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Table 1. Cohorts of DOSIS.
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INDEXATION FOR BODY SIZE TO SET THE 
DIAGNOSTIC THRESHOLD FOR LEFT VENTRICULAR 
THICKENING 
Using a large collection of myectomy samples from patients with obstructive HCM, 
we have shown that there is a sex-specifi c diff erence in diastolic function at the time 
of myectomy in HCM patients carrying pathogenic variants in MYH7 and MYBPC3.9
Women showed more diastolic dysfunction evident from signifi cantly higher E/e’ 
ratios, impaired left ventricular fi lling patterns, and higher tricuspid regurgitation 
velocities. Of the female patients, 50% showed grade III diastolic dysfunction, while 
the majority of male patients (56%) had only mild (grade I) diastolic dysfunction. 
Correction of maximal septal thickness and left atrial diameter for body surface area 
(BSA) resulted in signifi cantly higher values in female compared to male patients. 
Histological and protein analyses revealed more advanced remodeling of the heart 
in female compared to male HCM patients evident from higher levels of fi brosis and 
activation of the cardiac fetal gene program, which is characteristic for heart failure. 
In addition to genetic screening, the current diagnostic criterion of hypertrophy is 
a maximal LV wall thickness of ≥15mm, or ≥13mm in fi rst-degree relatives of HCM 
patients. As the heart of women, and in general relatively small persons, is smaller 
compared to the heart of men, this threshold for the diagnosis of HCM probably 
should be corrected for body size.10 The current diagnostic threshold, which does not 
take into account body size, may likely explain the male predominance in HCM patient 
cohorts, simply because men in general have larger hearts. A recent study in a Dutch 
cohort of 199 genotype-positive subjects, family members of HCM patients, who were 
referred for cardiac screening between 1995 and 2018, indexation of wall thickness 
by BSA decreased the number of HCM diagnoses.11 Moreover, predictive accuracy 
for HCM-related events (mortality, cardiac transplantation, implantable cardioverter-
defi brillator implantation and septal reduction therapy) improved signifi cantly after 
indexation by BSA. These studies indicate that correcting LV thickness for body size 
should be considered for the diagnosis of HCM and longitudinal follow-up studies in 
larger cohorts of preclinical genotype-positive individuals are needed to confi rm this.
ALTERED METABOLISM AS KEY DRIVER OF 
DISEASE IN CARDIOMYOPATHIES
Several studies suggest an important role for secondary disease-modifi ers such as 
additional (epi)genetic variations and environmental disease triggers. Compelling 
data have accumulated that obesity is an overarching risk factor, also for age-of-onset 
and severity of cardiomyopathies. Proof that obesity contributes to disease onset and 
severity comes from cohort studies. The international HCM Share registry showed that 
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patients with a high body mass index have a significantly increased risk of heart failure, 
more advanced left ventricular outflow tract obstruction and arrhythmias (i.e. HCM-
related outcomes).12 Moreover, a prospective study in adolescent men demonstrated 
that even mildly elevated body weight in late adolescence significantly increased the 
risk to develop dilated cardiomyopathy in adulthood.13 At the heart level, a recent 
proteomics study in human HCM tissue samples showed reduced levels of energy 
metabolism proteins.14 This observation is in line with studies in human HCM showing 
energy deficiency of the heart.15,16 Energy deficiency has been proposed as the 
primary variant-induced pathomechanism of HCM,17 which is supported by studies 
showing reduced cardiac efficiency in preclinical asymptomatic carriers of sarcomere 
gene variants in the absence of cardiac hypertrophy.16,18 Accordingly, DCM caused by 
TTN gene variants has been linked with mitochondrial dysfunction and metabolic 
perturbations as cause of disease progression.19 Overall, these studies indicate that 
timely (disease stage-specific) treatment of metabolic perturbations may slow 
down disease progression in cardiomyopathy patients.20 An observational cohort to 
determine the predictive value of metabolic biomarkers (BIO FOr CARe: identification 
of biomarkers for development and progression of HCM in carriers of the Dutch 
MYBPC3 founder carriers) and a clinical trial using metabolic drug therapy aimed to 
improve energetics of the heart at preclinical stage in HCM gene variant carriers are 
currently performed by several DOSIS PIs (ENERGY trial).21
ALTERED PROTEIN QUALITY CONTROL AS 
DISEASE MODIFIER IN CARDIOMYOPATHY
An age-related decline in protein quality control (PQC) has been proposed as 
contributor to disease progression in cardiomyopathy. As sarcomere proteins are 
the most abundant proteins in the heart, maintenance of sarcomere structure and 
function depends on PQC mechanisms. Pathogenic gene variants result in poison 
polypeptides or reduced protein levels (haploinsufficiency) and may trigger PQC and/
or stress cellular protein homeostasis. DCM patients with truncating TTN variants 
show a relatively mild disease course, though with significant excess mortality in 
elderly patients. The latter may be explained by an age-related deterioration of 
the PQC mechanisms. As life expectancy increases, TTN-associated morbidity and 
mortality will likely become more prevalent.22 Also in PLN-associated cardiomyopathy 
protein aggregation and activation of PQC pathways has been observed in end-stage 
disease.23
Terminally misfolded and aggregation-prone (mutant) proteins are cleared by the 
two degradation systems, UPS and autophagy.24 Furthermore, pathways of PQC are 
strongly linked to cell architecture, such as the microtubules network. DOSIS studies 
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in a large set of cardiac tissues from a well-characterized HCM patient group showed 
altered PQC with several specifi c changes in gene-variant positive patients (genotype-
postive) compared to genotype-negative patients and non-failing controls.25 Heat 
shock proteins (HSP) involved in protein stabilization (HSPB1) and refolding (HSPD1, 
HSPA2) were increased in genotype-positive HCM compared to controls. In addition, 
tubulin and acetylated-tubulin levels were signifi cantly higher in HCM compared to 
controls, especially in HCM with truncating variants in MYBPC3, which cause protein 
haploinsuffi  ciency. cMyBP-C protein levels were inversely correlated with α-tubulin 
levels suggesting a compensatory tubulin response to maintain cardiomyocyte 
structure, though this may be at the expense of cardiac function. Our study indicates 
that proliferation of the microtubular network represents a novel pathomechanism 
in cMyBP-C haploinsuffi  ciency-mediated HCM. Recent studies in human heart failure 
identifi ed a central role for detyrosinated microtubules in regulating cardiomyocyte 
function and demonstrated the functional benefi t upon reversal of this 
modifi cation.26,27 This is of clinical importance since it represents a potential treatment 
target to improve cardiac function in HCM.
CELL-TO-CELL MRNA/PROTEIN VARIABILITY AS 
PATHOMECHANISM IN CARDIOMYOPATHY
As familial cardiomyopathies represent an autosomal dominant genetic disorder, 
most patients are heterozygous for the mutation and carry one variant and one 
normal (wild-type) allele. In cardiomyopathy patients, the heart of a genotype-positive 
individual produces the variant protein in addition to the normal protein. As indicated 
above, the homeostasis of cellular proteins is tightly regulated by the PQC system, 
but it is also regulated at the mRNA level by non-sense mediated mRNA decay. Both 
systems are needed to suppress the accumulation of variant protein while keeping 
the normal protein at suffi  cient levels in cardiac muscle cells. It was recently shown 
that transcription of both alleles occurs independently and in a stochastic manner, 
where one cell favors one allele and the next cell favors the other allele.28 This burst-
like, stochastic on/off -switching of allele transcription does not aff ect mRNA and 
protein levels in case of homozygous wild-type alleles. However, heterozygosity of 
alleles as present in genotype-positive individuals may introduce cell-to-cell variation 
with one cardiomyocyte expressing high levels of variant protein, while variant levels 
may be low in another cardiomyocyte.29 Indeed, Kraft and colleagues showed that 
MYH7 gene variants cause a variable variant to wild-type ratio of mRNA expression in 
cardiomyocytes from the same heart.28,30 The DOSIS consortium showed intercellular 
variation of cMyBP-C myofi lament protein expression due to truncating MYBPC3
variants in the myocardium of HCM patients.31 The functional consequences of the 
variable protein expression, which results in a mosaic pattern of cardiomyocytes 
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with low and high variant/wild-type expression remain to be determined. Loss 
of cMyBP-C causes severe dysfunction in mouse studies and engineered heart 
tissue.32,33 We propose that the intercellular variation of cMyBP-C protein levels 
cause inhomogeneous contraction and relaxation and underlies the formation of 
myofibrillar disarray, a currently unexplained disease characteristics of HCM. As aging 
reduces the quality of PQC, an age-dependent progression of the degree of allelic 
imbalance and cell-to-cell variation may contribute to cardiomyopathy development.
CONCLUSION
In conclusion, monogenetic cardiomyopathies have been intensely studied in the last 
three decades, and this has resulted in major progress in understanding what genes 
are involved. On the other hand, the striking heterogeneity, the highly variable age 
of onset, and the presence of gene variant carriers that never develop disease is as 
of yet largely unexplained. Given the profound repercussion for carriers, patients and 
family members we must improve to better understand the individual’s response to 
the presence of a pathogenic gene variant.
DOSIS aims for hitherto unexplored mechanisms that probably will modify the 
pathogenic gene variant (Figure 3). We have set up important initiatives and 
collaborations and have generated preliminary results showing that environmental 
and genetic modifiers indeed are important in our understanding. In the future we 
will step up our initiatives and projects and have identified an agenda, that contains 
- what we feel - important additional factors that when fully understood will guide 
clinicians in proper diagnosis, risk prediction, prognostication and, ultimately, cause-
specific novel treatments.
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Figure 3. 
By combining cellular, genetic and clinical data from well-phenotyped national patient cohorts, DOSIS 
strives to defi ne disease factors that in addition to the pathogenic gene variant cause and aggravate cardiac 
disease in cardiomyopathy patients.
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Summary of thesis and future perspectives
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SUMMARY 
Hypertrophic cardiomyopathy (HCM) is the most prevalent familial heart 
disease occurring in up to 1:200 individuals. The characteristic thickening of the 
interventricular septum leads to obstruction of the left ventricular outflow tract. It is 
often referred to as a disease of the sarcomere with mutations present in 50-70% of 
patients, predominantly in the genes encoding for the thick filament proteins. 
The clinical presentation of HCM is very heterogenous and varies from asymptomatic 
to sudden cardiac death. There are four disease stages described and classified:
1. Patients with a known sarcomere gene mutation without remodeling of the heart 
but with measurable changes in diastolic function
2. HCM patients with left ventricular hypertrophy and diastolic dysfunction (the 
“classic” stage)
3. Adverse remodeling
4. End stage heart failure with myocardial thinning, dilation of the ventricles and 
atria, extensive fibrosis and impaired systolic function
CHAPTER ONE gives a more in depth introduction to hypertrophic cardiomyopathy 
and this thesis in general. We have studied the pathophysiology of secondary cardiac 
remodeling in patients with HCM. Specifically the influences of sex and genotype on 
diastolic dysfunction and cardiac remodeling. Several main cellular pathomechanisms 
which underlie cardiac function are reported in  CHAPTERS TWO through SIX, 
genotype-dependent differences were observed in CHAPTERS TWO and FIVE. 
High-myofilament calcium sensitivity has been proposed as a disease trigger as 
discussed in CHAPTER TWO. We found an increased myofilament calcium sensitivity 
which partly reflects hypophosphorylation of protein kinase A targets. Myofilament 
length-dependent activation is impaired in stage II HCM patients with a missense 
mutation (THIN, MYH7 and missense mutations in MYBPC3), and may be partly 
related to the relatively low phosphorylation of PKA targets and high baseline 
myofilament calcium sensitivity. Restoring phosphorylation resulted in normalization 
of length-dependent activation in SMN and in patients carrying a truncating MYBPC3 
mutation. A blunted response to β-adrenergic receptor stimulation might explain the 
hypophosphorylation in HCM patients and may represent a mechanism underlying 
the development of HCM. 
Sex-differences are present not only in diseased hearts but in healthy hearts as well. 
During puberty these differences become apparent with a higher absolute cardiac 
mass in men compared to women. Women seem to keep their cardiomyocyte number 
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stable during life, while it decreases in men resulting in a compensatory hypertrophy 
of the remaining cardiomyocytes. In both women and men diastolic function 
decreases with age. CHAPTER THREE gives an introduction to sex-diff erences in the 
pathophysiology of the heart.  
Stage II – the “Classic” Stage 
Diastolic dysfunction is one of the fi rst detectable alterations in heart function of 
HCM patients. This is caused by changes in intrinsic properties of the cardiomyocytes 
and the myocardium (as reported in CHAPTER TWO). In addition to hypertrophy, the 
diseased myocardium is characterized by increased interstitial fi brosis (scar tissue), 
cardiomyocyte and myofi lament disarray and vascular abnormalities. In CHAPTER 
FOUR we studied sex-diff erences in diastolic function and included patients with a 
thick fi lament mutation; β-myosin heavy chain (MYH7) and cardiac myosin binding 
protein C (MYBPC3). We found that at the time of myectomy women are older than 
men and show a higher grade of diastolic dysfunction. Cardiac dimensions did not 
diff er between women and men. However, when corrected for body surface area 
diff erences became apparent. Both indexed left atrial and interventricular septum 
diameters were larger in women compared to men. In addition to the diff erences 
in clinical parameters we also found distinct structural and cellular sex-dependent 
changes. A shift was observed from the stiff  titin isoform to the more compliant 
isoform of titin, particularly in female HCM patients. Moreover, there is a signifi cant 
relation between titin compliance and diastolic dysfunction. Furthermore, women 
showed a twofold higher amount of fi brosis compared to HCM men. 
In CHAPTER FIVE we investigated if the observed sex-diff erences apply to all HCM 
patients by including thin fi lament mutations (THIN fi lament) and HCM patients 
without an underlying sarcomere gene mutation (sarcomere mutation-negative, 
SMN). In approximately 40% of HCM patients no sarcomere gene mutations are found. 
These patients share the same phenotype as sarcomere mutation-positive (SMP) 
patients. We found smaller IVS thickness in THIN fi lament and SMN patients compared 
to HCM patients with THICK fi lament mutations. SMN patients are on average 10 years 
older compared to SMP HCM patients, although diastolic dysfunction seems less 
impaired. Cellular changes, such as fi brosis, capillary density and titin ratio are less 
altered in SMN patients. The sex-diff erences reported in previous chapters apply to 
the overall HCM patient group: women are older, show worse diastolic dysfunction 
and show worse cellular changes that might infl uence diastolic dysfunction. Fibrosis 
and titin ratio are increased and capillary density is lower in women compared to HCM 
men. In conclusion, SMN patients are less aff ected in contrast to SMP HCM patients. 
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Stage IV – End Stage HCM 
While most patients show obstructive hypertrophy and a relatively stable clinical 
phenotype (stage II), a small group of patients progresses to end-stage HCM (stage 
IV). The progression from stage II, via adverse remodeling to stage IV shows a relatively 
short clinical course of approximately 6.5 years. It is unclear which factors underlie 
this transition. In CHAPTER SIX we have studied the differences between stage II and 
stage IV HCM. As expected, stage IV HCM patients showed decreased interventricular 
septum thickness and LV outflow tract obstruction, and diameters of left ventricle and 
atrium were increased. Passive tension, titin compliance and amount of fibrosis were 
comparable between the two disease stages, while capillary density was even lower 
in stage IV compared to stage II HCM patients. Our study points to microvascular 
ischemia and fibrosis as main mechanisms of disease progression rather than 
sarcomere dysfunction. 
Stage I – Mutation Carrier
In CHAPTERS FOUR, FIVE and SIX we have found sex differences in secondary 
cardiac remodeling in stage II and IV HCM patients. The absolute thickness of the 
interventricular septum (IVS) is comparable between women and men; however, 
when corrected for body surface area, women show greater IVS thickness compared 
to men. Because women are older at diagnosis and have worse diastolic dysfunction 
we hypothesized that women are in fact in a more advanced disease stage (stage III). 
In CHAPTER SEVEN we studied cardiac dimensions of stage I HCM patients to obtain 
“base-line” parameters via MRI. Even corrected for body surface area female hearts 
were smaller compared to male stage I HCM hearts. This was measured by ventricular 
volumes and cardiac mass. This supports our hypothesis that HCM women are in a 
more advanced disease stage at diagnosis. To reach the diagnostic threshold, a left 
ventricular wall thickness of ≥15mm, they require relatively more hypertrophy.  
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FUTURE PERSPECTIVES
The results described in this thesis could only have been obtained through close 
collaboration between clinical and basic researchers. The majority of chapters in this 
thesis are the result of these collaborations (CHAPTERS FOUR, FIVE, SIX and SEVEN). 
CHAPTER EIGHT highlights several recent observations from the DOSIS consortium 
and collaborators which may ultimately be relevant for clinical practice. The striking 
heterogeneity (e.g. various genetic background and clinical presentation) and the 
fact that not all stage I HCM patients progress to stage II or even III and IV, is as of 
yet largely unexplained. Given the profound repercussions for carriers, patients and 
their relatives, there needs to be a better understanding of the individuals response 
to the presence of a pathogenic gene variant. This is why it is important to stimulate 
collaborations between clinical and fundamental researchers. This will hopefully pay-
off  in multi-disciplinary discussions in order to create new research projects and/or a 
better understanding of this disease in a whole. 
New Diagnostic Criterion for HCM
Our research has shown that women with stage II and IV HCM have worse diastolic 
dysfunction and more severe cardiac remodeling compared to men. We believe 
that this might not be due to the infl uence of sex per se, but could be explained by 
the diagnostic criteria which are currently not sex (body size)-specifi c. As a direct 
consequence of this, the initial diagnosis of HCM in women may occur when they are in 
a more advanced stage of the disease. The current diagnostic criterion of hypertrophy 
is a maximal LV wall thickness of ≥15mm, or ≥13mm in fi rst-degree relatives of HCM 
patients. As the hearts of women are smaller compared to men (CHAPTERS THREE, 
FOUR, FIVE, SIX and SEVEN) they undergo secondary remodeling in a greater 
degree to meet this threshold for diagnosis. The current diagnostic threshold may 
likely explain the male predominance in HCM cohorts simply because, in general, men 
have larger hearts. Which is why we would like to correct maximal wall thickness in 
the diagnostic criterion for HCM. Extensive research should be done to elicit the most 
reliable indexation method (e.g. correct for sex, BSA, total heart mass, etc.).  
Capillary Density
In CHAPTER FIVE we were the fi rst to report a sex-diff erence in stage II HCM patients. 
Capillary density is lower in female compared to male patients. In CHAPTER SIX we 
have shown that capillary density decreases with HCM disease progression. This 
decrease is mainly seen in male HCM patients. It has been known that myocardial 
blood fl ow is decreased in HCM patients, especially in fi brotic areas. Furthermore, 
microvascular dysfunction was associated with a higher incidence of stage IV HCM. 
The decrease in capillary density in our stage IV HCM patients indicates that reduced 
perfusion plays a role in HCM disease progression. A recent study showed a correlation 
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between capillary density and the amount of fibrosis as reported in CHAPTER SIX. 
A decrease in capillary density correlates with an increase in the amount of fibrosis. 
Furthermore, diastolic dysfunction in women has been related to myocardial blood 
flow. Analyses of coronary perfusion and microvascular dysfunction may be warranted 
in HCM patients who show a reduction in left ventricular wall thickness to identify 
patients at risk for disease progression. Future studies are necessary to define the 
cellular components which underlie perturbations in myocardial blood flow during 
HCM disease progression. When the underlying cellular pathologies are elicited it 
might even be possible to intervene therapeutically (e.g. prevention of blood flow 
decline or stimulation of blood flow). 
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CHAPTER TEN 
Nederlandstalige samenvatting
Liefdespad - door Esmee Kranen
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VOOR DE NEDERLANDSTALIGEN ONDER 
ONS DIE ZICH (NOG) NIET BEWKAAM 
VOELEN MET BETREKKING TOT HYPERTROFE 
CARDIOMYOPATHIE (OF HET HART ANSICH)
In dit proefschrift is onderzoek gedaan naar de ziekte hypertrofe cardiomyopathie 
(HCM). Dat is een mond vol he?! Even in het Nederlands vertalen.
Hypertrofie  het groeien van cellen
Cardio   het hart
Myopathie  spierziekte 
Hypertrofische cardiomyopathie: ziekte met een verdikte hartspier. 
Voordat u begint aan de samenvatting, die weliswaar Nederlandstalig is, maar niet 
perse makkelijk te begrijpen, een korte uitleg/introductie.
Functie en Fysiologie van het Hart 
Het hart bestaat uit vier kamers: twee  ventrikels (ook wel de kamers) en twee atria 
(ook wel de boezems). Deze kamers werken samen om zuurstofarm bloed naar de 
longen te pompen en zuurstofrijk bloed naar de rest van het lichaam. Het hart kan 
zich  alleen vullen met bloed als het ontspant (de diastolische fase van de hartcyclus), 
daarna moet het samenknijpen om het bloed weg te pompen (de systolische fase 
van de hartcyclus). De kleinste functionele contractiele eenheid van een hartspiercel 
(cardiomyocyt) is de sarcomeer. Sarcomeren bestaan uit twee hoofdstructuren, de 
dikke en dunne filamenten. 
Hypertrofe Cardiomyopathie 
HCM wordt vaak een ziekte van de sarcomeer genoemd vanwege het grote aantal 
genetische mutaties in de sarcomeer eiwitten die de ziekte veroorzaken. De mutante 
sarcomeer eiwitten veroorzaken waarschijnlijk de eerste defecten in hartfunctie 
voordat het hart zich aanpast (remodellering). Op de korte termijn zorgen deze 
aanpassingen voor een behouden functie van het hart, echter op lange termijn zijn 
ze ongunstig. Diastolische dysfunctie, het niet meer goed kunnen ontspannen van 
de hartspier, is één van de gevolgen van de remodellering van het hart. De hartspier 
is stijver door onder andere de toegenomen dikte (hypertrofie) en het littekenweefsel 
(fibrose).   
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SAMENVATTING
Hypertrofi sche cardiomyopathie (HCM) is de meest voorkomende familiaire 
hartspierziekte en komt voor in ongeveer 1:200 personen. De kenmerkende verdikking 
van het interventriculaire septum (de spierwand tussen de beide ventrikels) leidt tot 
obstructie van het linker ventrikel uitstroomkanaal. Het wordt vaak een sarcomeer 
ziekte genoemd met in 50-70% van de patiënten een mutatie, voornamelijk in de 
genen die coderen voor de dikke fi lament eiwitten. 
De klinische presentatie van HCM is zeer heterogeen en varieert van geen symptomen 
tot plotselinge hartdood. Er zijn vier ziektestadia beschreven en geclassifi ceerd: 
1. Patiënten met een sarcomeer mutatie zonder remodellering van het hart maar 
met achteruitgang in diastolische dysfunctie
2. HCM patiënten met linker ventrikel hypertrofi e en diastolische dysfunctie (het 
“klassieke” ziektebeeld)
3. Ongunstige remodellering
4. Eindstadium hartfalen met verdunning van het myocard, verwijding van de 
ventrikels en atria, uitgebreide fi brose en een verminderde systolische functie. 
HOOFDSTUK EEN geeft een diepgaande introductie tot hypertrofi sche 
cardiomoypathie en dit proefschrift in zijn geheel. We hebben de pathofysiologie 
en secundaire remodellering bestudeerd in patiënten met hypertrofi sche 
cardiomyopathie. Specifi ek de invloeden van geslacht en genotype op diastolische 
dysfunctie en remodellering. Verschillende belangrijke cellulaire pathomechanismen 
die ten grondslag liggen aan de hartfunctie worden beschreven in HOOFDSTUK 
TWEE tot en met ZES, genotype-afhankelijke verschillen zijn gerapporteerd in 
HOOFDSTUKKEN TWEE en VIJF. 
Hoge calcium-gevoeligheid van het myofi lament is een mogelijke ziektetrigger, zoals 
besproken in HOOFDSTUK TWEE. We vonden een verhoogde calcium-gevoeligheid 
van het myofi lament die gedeeltelijk de hypofosforylering van proteïne kinase 
A-targets weerspiegelt. De lengte afhankelijke activering van het myofi lament is 
verstoord in stadium II HCM patiënten met een missense mutatie (THIN, MYH7
en missense mutaties in MYBPC3), en kan gedeeltelijk verband houden met de 
relatief lage fosforylering van de PKA-targets en de hoge baseline myofi lament 
calcium-gevoeligheid. Herstel van fosforylering resulteerde in normalisatie van de 
lengte afhankelijke activering in SMN en bij patiënten met een ‘truncating’ MYBPC3
mutatie. Een zwakke reactie op stimulatie van β-adrenerge receptoren zou de 
hypofosforylering bij HCM patiënten kunnen verklaren en zou een mechanisme 
kunnen zijn dat ten grondslag ligt aan de ontwikkeling van HCM. 
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Sekse verschillen zijn aanwezig in zieke en gezonde harten. Tijdens de pubertijd 
worden deze verschillen zichtbaar met een hogere absolute hartmassa bij mannen 
dan bij vrouwen. Het aantal hartspier cellen bij vrouwen blijft levenslang stabiel 
terwijl het bij mannen afneemt, wat resulteert in een compenserende hypertrofie van 
de resterende hartspiercellen. Bij zowel vrouwen als mannen neemt de diastolische 
functie af met de leeftijd. HOOFDSTUK DRIE geeft een inleiding tot sekse verschillen 
in de pathofysiologie van het hart. 
Stadium II – het ‘Klassieke’ Ziektebeeld
Diastolische dysfunctie is een van de eerste waarneembare veranderingen in 
de hartfunctie van HCM patiënten. Dit wordt veroorzaakt door veranderingen 
in de intrinsieke eigenschappen van de cardiomyocyten en het myocardium 
(zoals gerapporteerd in HOOFDSTUK TWEE). Naast hypertrofie wordt het zieke 
myocardium gekenmerkt door verhoogde interstitiële fibrose (littekenweefsel), 
cardiomyocyt- en myofilament-wanorde en vasculaire afwijkingen. In HOOFDSTUK 
VIER hebben we sekse verschillen in diastolische functie bestudeerd in patiënten met 
dikke filament mutaties; β-myosine zware keten (MYH7) en cardiaal myosine bindend 
eiwit C (MYBPC3). We ontdekten dat vrouwen op het moment van myectomie ouder 
zijn en een hogere graad van diastolische dysfunctie vertonen in vergelijking met 
mannen. Cardiale dimensies verschilden niet tussen vrouwen en mannen, echter bij 
correctie voor lichaamsoppervlakte kwamen de verschillen aan het licht. Zowel de 
geïndexeerde linker atrium en interventriculaire septum diameter waren groter bij 
vrouwen dan bij mannen. Naast de verschillen in klinische parameters vonden we 
ook duidelijke structurele en cellulaire sekse afhankelijke veranderingen. Er werd 
een verschuiving waargenomen van de stijve naar de meer compliante titine isoform 
vooral bij vrouwelijke HCM patiënten. Bovendien is er een significante relatie tussen 
titine compliantie en diastolische dysfunctie. Ook hebben vrouwen twee keer zoveel 
fibrose dan HCM mannen. 
In HOOFDSTUK VIJF hebben we onderzocht of de waargenomen sekse verschillen 
toepasbaar zijn op alle HCM patiënten door dunne filament mutaties (THIN) en HCM 
patiënten zonder onderliggende sarcomeer geen mutaties (SMN) te includeren. 
In ongeveer 40% van de HCM patiënten wordt geen mutatie gevonden in de 
sarcomeer genen. Deze patiënten delen hetzelfde fenotype als de sarcomeer mutatie 
positieve (SMP) patiënten. We vonden een kleinere IVS dikte bij THIN filament en 
SMN patiënten in vergelijking met THICK filament HCM patiënten. SMN patiënten 
zijn gemiddeld 10 jaar ouder dan SMP patiënten hoewel ze minder diastolische 
dysfunctie lijken te hebben. Cellulaire veranderingen zoals fibrose, capillaire 
dichtheid en titine compositie zijn minder veranderd bij SMN patiënten. De sekse 
verschillen die in eerdere hoofdstukken zijn gerapporteerd zijn van toepassing op 
de totale HCM populatie: vrouwen zijn ouder, hebben slechtere diastolische functie 
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en vergevorderde cellulaire veranderingen die de diastolische dysfunctie kunnen 
beïnvloeden. Fibrose en de titine ratio zijn verhoogd en capillaire dichtheid is lager bij 
vrouwen dan bij HCM mannen. Concluderend, SMN patiënten zijn minder aangedaan 
in vergelijking met SMP HCM patiënten. 
Stadium IV – Eindstadium HCM
Terwijl de meeste patiënten obstructieve hypertrofi e en een relatief stabiel klinisch 
fenotype vertonen (stadium II), ontwikkelt een kleine groep patiënten zich tot 
eindstadium HCM (stage IV). De progressie van stadium II, via ongunstige re-
modellering naar stadium IV, vertoont een relatief kort klinisch beloop van ongeveer 
6.5 jaar. Het is onduidelijk welke factoren aan deze transitie ten grondslag liggen. In 
HOOFDSTUK ZES hebben we de verschillen tussen stadium II en IV HCM bestudeerd. 
Zoals verwacht, vertoonden HCM patiënten in stadium IV een dunner interventriculair 
septum en minder LV uitstroomkanaal obstructie en grotere diameters van het linker 
ventrikel en atrium. Passieve stijfheid, titine compliantie en hoeveelheid fi brose waren 
vergelijkbaar tussen de twee ziektestadia, terwijl de capillaire dichtheid nog lager was 
in stadium IV vergeleken met stadium II HCM patiënten. Onze studie wijst op micro 
vasculaire ischemie en fi brose als belangrijkste mechanismen van ziekteprogressie en 
niet sarcomeer dysfunctie. 
Stadium I – Mutatie Drager
In HOOFDSTUK VIER, VIJF en ZES hebben we sekse verschillen gevonden in 
secundaire re-modellering bij stadium II en IV HCM patiënten. De absolute dikte van 
het interventriculaire septum is vergelijkbaar tussen vrouwen en mannen; echter 
gecorrigeerd voor lichaamsoppervlakte, vertonen vrouwen een grotere IVS dikte 
dan mannen. Omdat vrouwen ouder zijn ten tijde van diagnose en een slechtere 
diastolische functie hebben, stelden we de hypothese dat vrouwen zich in een 
verder gevorderd ziektestadium bevinden (stadium III) In HOOFDSTUK ZEVEN
hebben we de cardiale dimensies van stadium I HCM patiënten bestudeerd om via 
MRI “basis” parameters te verkrijgen. Zelfs gecorrigeerd voor lichaamsoppervlakte 
waren vrouwelijke harten kleiner in vergelijking met mannelijke stadium I HCM 
harten. Dit werd gemeten aan de hand van ventriculaire volumes en hartmassa. Deze 
data ondersteunt onze hypothese dat HCM vrouwen zich bij diagnose in een meer 
gevorderd ziektestadium bevinden. Om de diagnostische drempel te bereiken, een 
linkerventrikel wanddikte van ≥ 15mm, hebben ze relatief meer hypertrofi e nodig. 
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TOEKOMST PERSPECTIEVEN
De resultaten die in dit proefschrift worden beschreven konden alleen worden 
verkregen door nauwe samenwerking tussen klinische en fundamentele 
onderzoekers. De meeste hoofdstukken in dit proefschrift zijn het resultaat van deze 
samenwerkingen (HOOFDSTUK VIER, VIJF, ZES en ZEVEN). HOOFDSTUK ACHT 
belicht verschillende recente observaties van het DOSIS-consortium en medewerkers 
die uiteindelijk relevant kunnen zijn voor de klinische praktijk. De opvallende 
heterogeniteit (o.a. verschillende genetische achtergrond en klinische presentatie) 
en het feit dat niet alle stadium I HCM patiënten vorderen tot stadium II of zelfs III 
en IV, is tot dusver grotendeels onverklaard. Gezien de ingrijpende gevolgen voor 
mutatie dragers, patiënten en hun familieleden, moet er een beter begrip komen van 
de individuele respons op de aanwezigheid van een pathogene gen variant. Daarom 
is het belangrijk om samenwerking tussen klinische en fundamentele onderzoekers 
te stimuleren. Dit zal hopelijk zijn vruchten afwerpen in multidisciplinaire discussies 
om nieuwe onderzoekprojecten en/of een beter begrip van deze ziekte als geheel te 
creëren.  
Nieuw Diagnostisch Criterium voor HCM
Ons onderzoek heeft aangetoond dat vrouwen met HCM stadium II en IV een 
slechtere diastolische functie en verder gevorderde re-modellering van het hart 
hebben dan mannen. Wij zijn van mening dat dit misschien niet te wijten is aan de 
invloed van sekse per se, maar kan worden verklaard door de diagnostische criteria 
die momenteel niet sekse (lichaamsoppervlakte) specifiek zijn. Als direct gevolg 
hiervan kan de initiële diagnose van HCM bij vrouwen pas plaatsvinden in een verder 
gevorderd stadium van de ziekte. Eén van de huidige diagnostische criteria voor 
hypertrofe cardiomyopathie is een maximale LV wanddikte van ≥ 15 mm, of ≥ 13 mm 
bij eerstegraads familieleden van HCM patiënten. Aangezien de harten van vrouwen 
kleiner zijn dan die van mannen (HOOFDSTUK DRIE, VIER, VIJF, ZES en ZEVEN), 
ondergaan ze in hogere mate secundaire remodellering om aan deze drempel voor 
diagnose te voldoen. De huidige diagnostische drempel kan mogelijk het mannelijke 
overwicht in HCM cohorten verklaren, simpelweg omdat mannen over het algemeen 
een groter hart hebben. Daarom willen we de maximale wanddikte corrigeren in het 
diagnostische criterium voor HCM. Er moet uitgebreid onderzoek worden gedaan om 
de meest betrouwbare indexatie methode te vinden (bijvoorbeeld corrigeren voor 
geslacht, lichaamsoppervlakte, totale hartmassa, enz.). 
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Capillaire Dichtheid
In HOOFDSTUK VIJF waren we de eerste die een sekse verschil rapporteerden 
bij HCM patiënten in stadium II. De capillaire dichtheid is lager bij vrouwelijke 
dan bij mannelijke HCM patiënten. In HOOFDSTUK ZES hebben we aangetoond 
dat de capillaire dichtheid afneemt tijdens de progressie van HCM. Deze afname 
wordt voornamelijk gezien bij mannelijke HCM patiënten. Het is bekend dat de 
doorbloeding van het myocard verminderd is in HCM patiënten, vooral in de 
fi brotische gebieden. Bovendien wordt micro vasculaire dysfunctie geassocieerd met 
een hogere incidentie van stadium IV HCM. De afname van de capillaire dichtheid in 
onze stadium IV HCM patiënten geeft aan dat verminderde perfusie een rol speelt bij 
de progressie van HCM. Een recente studie toonde een verband aan tussen capillaire 
dichtheid en de hoeveelheid fi brose, zoals gerapporteerd in HOOFDSTUK ZES. 
Afname van de capillaire dichtheid correleert met een toename van de hoeveelheid 
fi brose. Bovendien is diastolische dysfunctie bij vrouwen in verband gebracht met 
de myocardiale doorbloeding. Analyses van coronaire perfusie en micro vasculaire 
dysfunctie zijn mogelijk gerechtvaardigd bij HCM patiënten die een afname van de 
linkerventrikel wand dikte vertonen om patiënten te identifi ceren die risico lopen op 
ziekte progressie. Toekomstige studies zijn nodig om de cellulaire componenten te 
defi niëren die ten grondslag liggen aan verstoringen in de myocardiale bloedstroom 
tijdens de progressie van HCM. Wanneer deze componenten bekent zijn is het 
misschien zelfs mogelijk om therapeutisch in te grijpen (bijv. het voorkomen van 
doorbloedingsproblemen of het stimuleren van doorbloeding). 
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CURRICULUM VITAE
Louise (Lisa Antonia Maria) Nijenkamp werd geboren op 21 januari 1989 in Lelystad-
Haven waar zij ook is opgegroeid. In 2001 heeft zij atheneum met dubbel profiel 
afgerond aan OSG de Rietlanden in Lelystad (Natuur & Techniek en Natuur & 
Gezondheid 2001-2007). Hierna volgde ze één jaar Biomedische wetenschappen 
aan de Vrije Universiteit van Amsterdam, het plan om geneeskunde te studeren 
volgde gelukkig een jaar later. Tijdens haar bachelor Geneeskunde (2008-2011, VUmc 
Amsterdam) liep ze een verzorgingsstage op Curaçao in het St. Elizabeth Hospitaal. 
Na haar bachelor behaald te hebben begon ze haar Master geneeskunde met een 
verlengde onderzoeksstage bij de afdeling fysiologie onder leiding van (toen nog) 
dr. Jolanda van der Velden. Hier werd kennis gemaakt met het ziektebeeld hypertrofe 
cardiomyopathie en ontstond de affiniteit met onderzoek. Na een half jaar stage werd 
het besluit genomen om de rest van de master geneeskunde 2 jaar uit te stellen en 
verder te gaan met het onderzoek, dit keer als PhD student. In 2015, na een jaar co-
schappen in Nederland, werd het tijd voor weer eens een buitenlandse stage. Op 
naar Aruba voor het coschap Heelkunde in het Dr. Horacio E. Oduber Hospitaal. De 
master geneeskunde werd afgesloten met een semi arts stage op de kinder chirurgie 
in 2016 (VUmc, Amsterdam). Inmiddels bij prof. dr. Jolanda van der Velden nog een 
paar maanden het onderzoek een boost geven voor ze als arts aan het werk ging. In 
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cardio-thoracale chirurgie. IN OPLEIDING! In Oktober 2019 krijgt ze de vel begeerde 
opleidingsplek in Nijmegen bij de CTC en verhuist ze naar Nijmegen. 2020 staat in de 
ban van de afronding van haar promotie traject.
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Inmense dankbaarheid uit de meest 
diep gelegen regionen van mijn 
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